
<html lang="en"     class="pb-page"  data-request-id="9c57477d-bae3-4851-acac-f9d31b114946"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";issue:issue:10.1021/jmcmar.2010.53.issue-21;article:article:10.1021/jm100856p;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Novel Spirotetracyclic Zwitterionic Dual H1/5-HT2A Receptor Antagonists for the Treatment of Sleep Disorders" /></meta><meta name="dc.Creator" content="Massimo  Gianotti" /></meta><meta name="dc.Creator" content="Maurizio  Botta" /></meta><meta name="dc.Creator" content="Stephen  Brough" /></meta><meta name="dc.Creator" content="Renzo  Carletti" /></meta><meta name="dc.Creator" content="Emiliano  Castiglioni" /></meta><meta name="dc.Creator" content="Corrado  Corti" /></meta><meta name="dc.Creator" content="Michele  Dal-Cin" /></meta><meta name="dc.Creator" content="Sonia  Delle Fratte" /></meta><meta name="dc.Creator" content="Denana  Korajac" /></meta><meta name="dc.Creator" content="Marija  Lovric" /></meta><meta name="dc.Creator" content="Giancarlo  Merlo" /></meta><meta name="dc.Creator" content="Milan  Mesic" /></meta><meta name="dc.Creator" content="Francesca  Pavone" /></meta><meta name="dc.Creator" content="Laura  Piccoli" /></meta><meta name="dc.Creator" content="Slavko  Rast" /></meta><meta name="dc.Creator" content="Maja  Roscic" /></meta><meta name="dc.Creator" content="Anna  Sava" /></meta><meta name="dc.Creator" content="Mario  Smehil" /></meta><meta name="dc.Creator" content="Luigi  Stasi" /></meta><meta name="dc.Creator" content="Andrea  Togninelli" /></meta><meta name="dc.Creator" content="Mark J.  Wigglesworth" /></meta><meta name="dc.Description" content="Histamine H1 and serotonin 5-HT2A receptors mediate two different mechanisms involved in sleep regulation: H1 antagonists are sleep inducers, while 5-HT2A antagonists are sleep maintainers. Startin..." /></meta><meta name="Description" content="Histamine H1 and serotonin 5-HT2A receptors mediate two different mechanisms involved in sleep regulation: H1 antagonists are sleep inducers, while 5-HT2A antagonists are sleep maintainers. Startin..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="October 13, 2010" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm100856p" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2010 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm100856p" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm100856p" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm100856p" /></link>
        
    
    

<title>Novel Spirotetracyclic Zwitterionic Dual H1/5-HT2A Receptor Antagonists for the Treatment of Sleep Disorders | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm100856p" /></meta><meta property="og:title" content="Novel Spirotetracyclic Zwitterionic Dual H1/5-HT2A Receptor Antagonists for the Treatment of Sleep Disorders" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-21/jm100856p/production/images/large/jm-2010-00856p_0004.jpeg" /></meta><meta property="og:description" content="Histamine H1 and serotonin 5-HT2A receptors mediate two different mechanisms involved in sleep regulation: H1 antagonists are sleep inducers, while 5-HT2A antagonists are sleep maintainers. Starting from 9′a, a novel spirotetracyclic compound endowed with good H1/5-HT2A potency but poor selectivity, very high Cli, and a poor P450 profile, a specific optimization strategy was set up. In particular, we investigated the possibility of introducing appropriate amino acid moieties to optimize the developability profile of the series. Following this zwitterionic approach, we were able to identify several advanced leads (51, 65, and 73) with potent dual H1/5-HT2A activity and appropriate developability profiles. These compounds exhibited efficacy as hypnotic agents in a rat telemetric sleep model with minimal effective doses in the range 3−10 mg/kg po." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm100856p"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm100856p">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm100856p&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm100856p&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm100856p&amp;href=/doi/10.1021/jm100856p" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2010</span><span class="cit-fg-volume">, 53</span><span class="cit-fg-issue">, 21</span><span class="cit-fg-pageRange">, 7778-7795</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/53/21" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm100729b" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jm1009555" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Novel Spirotetracyclic Zwitterionic Dual H<sub>1</sub>/5-HT<sub>2A</sub> Receptor Antagonists for the Treatment of Sleep Disorders</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Massimo++Gianotti">Massimo Gianotti</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Maurizio++Botta">Maurizio Botta</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Stephen++Brough">Stephen Brough</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Renzo++Carletti">Renzo Carletti</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Emiliano++Castiglioni">Emiliano Castiglioni</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Corrado++Corti">Corrado Corti</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Michele++Dal-Cin">Michele Dal-Cin</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sonia++Delle+Fratte">Sonia Delle Fratte</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Denana++Korajac">Denana Korajac</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Marija++Lovric">Marija Lovric</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Giancarlo++Merlo">Giancarlo Merlo</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Milan++Mesic">Milan Mesic</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Francesca++Pavone">Francesca Pavone</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Laura++Piccoli">Laura Piccoli</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Slavko++Rast">Slavko Rast</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Maja++Roscic">Maja Roscic</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Anna++Sava">Anna Sava</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mario++Smehil">Mario Smehil</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Luigi++Stasi">Luigi Stasi</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol "><sup>⊥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Andrea++Togninelli">Andrea Togninelli</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mark+J.++Wigglesworth">Mark J. Wigglesworth</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">Neurosciences CEDD, GlaxoSmithKline, Medicines Research Centre, Via A. Fleming 4, 37135 Verona, Italy</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">GlaxoSmithKline, New Frontiers Science Park, Third Avenue, Harlow, Essex, CM19 5AW, U.K.</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">§</span> <span class="aff-text">Integrated Research Unit, IRU Chemistry, Prilaz Baruna Filipovica 29, 10000 Zagreb, Croatia</span></div><div class="aff-info" id="aff4"><span class="aff-symbol">∥</span> <span class="aff-text">Dipartimento Farmaco Chimico Tecnologico, Universitá degli Studi di Siena, Via Aldo Moro 2, I-53100 Siena, Italy</span></div><div class="corresp-info"><strong>*</strong>To whom correspondence should be addressed. Phone: +39-045-8219524. Fax: +39-045-8218196. E-mail: <a href="/cdn-cgi/l/email-protection#89e4e8faeee0e8e7c9e5e0ebecfbe6a7e0fd"><span class="__cf_email__" data-cfemail="8fe2eefce8e6eee1cfe3e6edeafde0a1e6fb">[email protected]</span></a></div><div class="corresp-fn" id="fn1">⊥Present address: Rottapharm Madaus, R&D Division, Via Valosa di Sopra 9, 20052 Monza, Italy.</div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm100856p&amp;href=/doi/10.1021%2Fjm100856p" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2010</span></span><span class="cit-volume">, 53</span><span class="cit-issue">, 21</span><span class="cit-pageRange">, 7778–7795</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">October 13, 2010</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>9 July 2010</li><li><span class="item_label"><b>Published</b> online</span>13 October 2010</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 11 November 2010</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm100856p" title="DOI URL">https://doi.org/10.1021/jm100856p</a></div><div class="article_header-article-copyright"><strong>Copyright © 2010 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D7778%26pageCount%3D18%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DMassimo%2BGianotti%252C%2BMaurizio%2BBotta%252C%2BStephen%2BBrough%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D53%26issueNum%3D21%26contentID%3Djm100856p%26title%3DNovel%2BSpirotetracyclic%2BZwitterionic%2BDual%2BH1%252F5-HT2A%2BReceptor%2BAntagonists%2Bfor%2Bthe%2BTreatment%2Bof%2BSleep%2BDisorders%26numPages%3D18%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D7795%26publicationDate%3DNovember%2B2010">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm100856p"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1758</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">18</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm100856p" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Novel Spirotetracyclic Zwitterionic Dual H1/5-HT2A Receptor Antagonists for the Treatment of Sleep Disorders&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Massimo&quot;,&quot;last_name&quot;:&quot;Gianotti&quot;},{&quot;first_name&quot;:&quot;Maurizio&quot;,&quot;last_name&quot;:&quot;Botta&quot;},{&quot;first_name&quot;:&quot;Stephen&quot;,&quot;last_name&quot;:&quot;Brough&quot;},{&quot;first_name&quot;:&quot;Renzo&quot;,&quot;last_name&quot;:&quot;Carletti&quot;},{&quot;first_name&quot;:&quot;Emiliano&quot;,&quot;last_name&quot;:&quot;Castiglioni&quot;},{&quot;first_name&quot;:&quot;Corrado&quot;,&quot;last_name&quot;:&quot;Corti&quot;},{&quot;first_name&quot;:&quot;Michele&quot;,&quot;last_name&quot;:&quot;Dal-Cin&quot;},{&quot;first_name&quot;:&quot;Sonia&quot;,&quot;last_name&quot;:&quot;Delle Fratte&quot;},{&quot;first_name&quot;:&quot;Denana&quot;,&quot;last_name&quot;:&quot;Korajac&quot;},{&quot;first_name&quot;:&quot;Marija&quot;,&quot;last_name&quot;:&quot;Lovric&quot;},{&quot;first_name&quot;:&quot;Giancarlo&quot;,&quot;last_name&quot;:&quot;Merlo&quot;},{&quot;first_name&quot;:&quot;Milan&quot;,&quot;last_name&quot;:&quot;Mesic&quot;},{&quot;first_name&quot;:&quot;Francesca&quot;,&quot;last_name&quot;:&quot;Pavone&quot;},{&quot;first_name&quot;:&quot;Laura&quot;,&quot;last_name&quot;:&quot;Piccoli&quot;},{&quot;first_name&quot;:&quot;Slavko&quot;,&quot;last_name&quot;:&quot;Rast&quot;},{&quot;first_name&quot;:&quot;Maja&quot;,&quot;last_name&quot;:&quot;Roscic&quot;},{&quot;first_name&quot;:&quot;Anna&quot;,&quot;last_name&quot;:&quot;Sava&quot;},{&quot;first_name&quot;:&quot;Mario&quot;,&quot;last_name&quot;:&quot;Smehil&quot;},{&quot;first_name&quot;:&quot;Luigi&quot;,&quot;last_name&quot;:&quot;Stasi&quot;},{&quot;first_name&quot;:&quot;Andrea&quot;,&quot;last_name&quot;:&quot;Togninelli&quot;},{&quot;first_name&quot;:&quot;Mark&quot;,&quot;last_name&quot;:&quot;J. Wigglesworth&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2010&quot;,&quot;month&quot;:&quot;10&quot;,&quot;day&quot;:&quot;13&quot;,&quot;issue&quot;:&quot;21&quot;,&quot;volume&quot;:&quot;53&quot;,&quot;pages&quot;:&quot;7778-7795&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm100856p&quot;},&quot;abstract&quot;:&quot;Histamine H1 and serotonin 5-HT2A receptors mediate two different mechanisms involved in sleep regulation: H1 antagonists are sleep inducers, while 5-HT2A antagonists are sleep maintainers. Starting from 9′a, a novel spirotetracyclic compound endowed with good H1/5-HT2A potency but poor selectivity, very high Cli, and a poor P450 profile, a specific optimization strategy was set up. In particular, we investigated the possibility of introducing appropriate amino acid moieties to optimize the developability profile of the series. Following this zwitterionic approach, we were able to identify several advanced leads (51, 65, and 73) with potent dual H1/5-HT2A activity and appropriate developability profiles. These compounds exhibited efficacy as hypnotic agents in a rat telemetric sleep model with minimal effective doses in the range 3−10 mg/kg po.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm100856p&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm100856p" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm100856p&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm100856p" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm100856p&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm100856p" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm100856p&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm100856p&amp;href=/doi/10.1021/jm100856p" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm100856p" /></input><a href="/doi/pdf/10.1021/jm100856p" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (1 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm100856p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm100856p%26sid%3Dliteratum%253Aachs%26pmid%3D20942472%26genre%3Darticle%26aulast%3DGianotti%26date%3D2010%26atitle%3DNovel%2BSpirotetracyclic%2BZwitterionic%2BDual%2BH1%252F5-HT2A%2BReceptor%2BAntagonists%2Bfor%2Bthe%2BTreatment%2Bof%2BSleep%2BDisorders%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D53%26issue%3D21%26spage%3D7778%26epage%3D7795%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291171" title="Antagonists">Antagonists</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292444" title="Molecular structure">Molecular structure</a>,</li><li><a href="/action/doSearch?ConceptID=291711" title="Selectivity">Selectivity</a>,</li><li><a href="/action/doSearch?ConceptID=292186" title="Receptors">Receptors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/53/21" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-21/jmcmar.2010.53.issue-21/production/jmcmar.2010.53.issue-21.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-21/jm100856p/production/images/medium/jm-2010-00856p_0004.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-21/jm100856p/production/images/large/jm-2010-00856p_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100856p&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Histamine H<sub>1</sub> and serotonin 5-HT<sub>2A</sub> receptors mediate two different mechanisms involved in sleep regulation: H<sub>1</sub> antagonists are sleep inducers, while 5-HT<sub>2A</sub> antagonists are sleep maintainers. Starting from <b>9′a</b>, a novel spirotetracyclic compound endowed with good H<sub>1</sub>/5-HT<sub>2A</sub> potency but poor selectivity, very high Cli, and a poor P450 profile, a specific optimization strategy was set up. In particular, we investigated the possibility of introducing appropriate amino acid moieties to optimize the developability profile of the series. Following this zwitterionic approach, we were able to identify several advanced leads (<b>51</b>, <b>65</b>, and <b>73</b>) with potent dual H<sub>1</sub>/5-HT<sub>2A</sub> activity and appropriate developability profiles. These compounds exhibited efficacy as hypnotic agents in a rat telemetric sleep model with minimal effective doses in the range 3−10 mg/kg po.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_85806" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_85806" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Insomnia, defined as difficulty in initiating and/or maintaining sleep, is one of the most common central nervous system (CNS<a class="ref internalNav" href="#fnabbrev" aria-label="a">a</a>) <div class="NLM_fn" id="fnabbrev">a<p class="last">Abbreviations: CNS, central nervous system; hERG, human ether-a-go-go-related gene K<sup>+</sup> channel; PK, pharmacokinetic; P450, cytochrome P450; Cli, intrinsic clearance; fu, fraction unbound; MW, molecular weight; clogD, calculated log <i>D</i>; PSA, polar surface area; CHO, Chinese hamster ovary; HEK, human embryonic kidney; Fpo, oral bioavailability; Br:Bl, brain−blood; Clb, blood clearance; Vss, distribution volume; FLIPR, fluorescent imaging plate reader; SWS, slow wave sleep; TST, total sleep time; ECG, electrocardiogram; EMG, electromiogram; CT18, circadian time 18; REM, rapid eye movement; NREM, nonrapid eye movement; RO, receptor occupancy; EWG, electron withdrawing group; RCM, ring closing metathesis; TFA, trifluoroacetic acid; DMP, Dess−Martin periodinane; HPLC, high performance liquid chromatography; NT, not tested.</p></div> disorders. According to the National Sleep Foundation’s 2010 Sleep in America Poll, the majority of those surveyed report that they only get a good night’s sleep a few nights per week or less, with some ethnic groups doing more poorly than others.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> The incidence of insomnia in the general population is between 10−30%, and approximately 50% of cases complain of serious daytime consequences, such as inability to concentrate, reduced energy, and memory problems. When this persists for more than 1 month, without an associated mental disorder or physical problem, it is classified as primary insomnia.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a></div><div class="NLM_p">Common symptoms of those suffering with a sleep disorder include abnormal sleep behavior and difficulties in one or more of falling asleep, remaining asleep, sleeping for adequate lengths of time, and achieving restorative sleep.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Available treatments for sleep disorders include the use of prescription hypnotics, such as benzodiazepines. However, these drugs may be habit-forming, lose their effectiveness after extended use, and metabolize more slowly for certain designated groups, resulting in persisting medicative effects.</div><div class="NLM_p">Other treatments include over-the-counter antihistamines, e.g., diphenhydramine and dimenhydrinate. These medicines are not designed to be strictly sedative in their activity, and as such, this method of treatment has been associated with a number of adverse side effects, e.g., persistence of the sedating medication after the prescribed time of treatment or the so-called “hangover effect”. Many of these side effects result from nonspecific activity in the periphery as well as in the CNS during this period of extended medication.</div><div class="NLM_p">It has been suggested that brain histamine is involved in the regulation of the sleep−wake cycle, arousal, cognition, and memory primarily through action at the H<sub>1</sub> receptors, producing a reduction of sleep latency in both preclinical<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> and clinical studies.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> On the other hand, selective blockade of the 5-HT<sub>2A</sub> receptor has been proven in both preclinical<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> and clinical<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> studies to be efficacious in reducing wake after sleep onset (WASO) and increasing slow wave sleep (SWS) and total sleep time (TST), therefore providing consolidation of sleep. It can be hypothesized that the combination of these two mechanisms may provide an improved hypnotic profile versus the marketed gold standard benzodiazepine-like drugs.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a></div><div class="NLM_p">As part of a broad drug discovery strategy aimed at the identification of novel hypnotic agents,<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> we reasoned on the possibility of optimizing (1<i>S</i>,3<i>R</i>)-5′,11′-dihydrospiro[cyclopentane-1,10′-dibenzo[<i>a</i>,<i>d</i>]cyclohepten]-3-yl(dimethyl)amine (<b>9′a</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>), a novel spirotetracyclic compound endowed with promising dual H<sub>1</sub>/5-HT<sub>2A</sub> in vitro activity.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Compound <b>9′a</b> represents a low molecular weight lead, although it is characterized by poor selectivity toward human adrenergic α<sub>1</sub> receptors and the human ether-a-go-go-related gene (hERG) potassium channel as well as by suboptimal physiochemical parameters. When preliminary pharmacokinetic data were gathered, a very high rat in vitro intrinsic clearance (Cli), a low free fraction measured in vitro in homogenized brain tissue (Br-fu), and a strong inhibition of the 2D6 isoform of the human CYP450 were also observed. An additional trait of <b>9′a</b> is its antagonism of the 5-HT<sub>2B</sub> and 5-HT<sub>2C</sub> receptors. While there is some evidence of slight increases in wakefulness and motor activity after blockade of the 5-HT<sub>2B</sub> receptor,<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> no significant alteration in the percentage distribution of any sleep stage, arousal and light SWS (SWS1), was observed with the inhibition of the 5-HT<sub>2C</sub> receptor.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Therefore, it appears that the presence of 5-HT<sub>2B</sub> and 5-HT<sub>2C</sub> activity in <b>9′a</b> and in general in our compounds may not represent a potential issue for their hypnotic profile.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-21/jm100856p/production/images/medium/jm-2010-00856p_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-21/jm100856p/production/images/large/jm-2010-00856p_0005.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. In vitro and physicochemical data of compound <b>9′a</b>. Superscript letters indicate the following: (a) functional p<i>K</i><sub>i</sub> measured in FLIPR (fluorescent imaging plate reader) assay;<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> (b) pharmacokinetics; (c) intrinsic clearance in human (h) and rat (r) liver microsomes (mL/min/g liver); (d) CYPEX (see experimental for details); (e) fraction unbound in rat brain; (f) ACD logD 7.4, version 11; (g) Å<sup>2</sup>; (h) dofetilide binding. See <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a> for details.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-21/jm100856p/production/images/large/jm-2010-00856p_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100856p&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">It is well-known that the structure of H<sub>1</sub> receptor antagonists can tolerate zwitterion moieties,<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> as they have been intentionally introduced to reduce the sedating properties of centrally acting first generation antihistamines by reducing their brain penetrating capacities. Furthermore, in the second generation H<sub>1</sub> antagonists (e.g., cetirizine and fexofenadine), the introduction of the zwitterion group was responsible for a reduction of the drug−drug interactions and enhanced receptor selectivity profiles with respect to first generation drugs.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Despite the fact that zwitterions were initially introduced to limit brain penetration of the first generation antihistamines, scientists at Hypnion, now Lilly, recently demonstrated that zwitterionic structures can penetrate the brain and induce hypnotic activity. In fact, they shaped their sleep program strategy by incorporating zwitterion moieties into known H<sub>1</sub>/5-HT<sub>2A</sub> antagonist scaffolds.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> This approach led Hypnion to quickly progress several compounds into the clinical phase, one of which, HY-10275 (LY-2624803) whose structure has not yet been disclosed, successfully achieved its proof of concept as a sleep drug.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a></div><div class="NLM_p">On the basis of this information, we considered introducing a series of constrained/hindered amino acid derivatives to the top region of this novel template with the aim of optimizing compound <b>9′a</b> by eradicating the observed developability issues.</div><div class="NLM_p last">In this article the optimization process of the initial lead <b>9′a</b>, which resulted in the identification of compounds <b>51</b>, <b>65</b>, and <b>73</b>, will be described in detail. These compounds demonstrated suitable overall profiles for a hypnotic with in vivo activity in an animal model of sleep disorders.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_65352" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_65352" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The spirocyclic skeleton of our lead is an unexplored scaffold in organic chemistry; therefore, it was necessary to identify a novel synthetic route to successfully prepare compounds <b>43</b>−<b>73</b> and <b>74</b>−<b>77</b> (Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>). The synthesis of compound <b>9′a</b> has already been reported in a previous communication,<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> while herein we illustrate an optimized synthesis, which has been adapted for the purpose of introducing substituents on the scaffold (such as R = Cl or F) and different heteroatoms (such as X = O and S) in place of the carbon in the benzhydrylic position in the lower part of the compound. Thus, starting from the appropriately substituted ketone <b>1</b>,<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> the first step of the synthesis was a potassium <i>tert</i>-butoxide promoted bis-alkylation with allyl bromide.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> In the case of <b>1c</b> and <b>1d</b> the reaction led directly to the <i>C</i>-diallyl compounds <b>3c</b> and <b>3d</b>, respectively, whereas a mixture of the corresponding compounds <b>3</b> and <i>C</i>-allyl/<i>O</i>-allyl compound <b>2</b> was observed, when starting from <b>1a</b>, <b>1b</b>, and <b>1e</b>. Nevertheless, the mixture of <b>2</b> and <b>3</b> was readily converted into the single compound <b>3</b> by Claisen rearrangement.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> The diallylation reaction is a crucial step because it permits the construction of the quaternary center. As reported, the intermediates <b>3</b> were then converted via ring-closing metathesis (RCM), in good yields, into intermediates <b>4</b>, which underwent hydroboration/oxidation to afford a mixture of compounds <b>5</b> and <b>6</b>, which in turn was oxidize using Dess−Martin periodinane (DMP) to provide <b>7</b> in excellent yields. The bis-ketone <b>7</b> could be either transformed into the key intermediate <b>8</b> via a regioselective hydrogenation reaction or processed through a reductive amination reaction with an amino acid ester and hydrolysis of the ensuing ester to give the final compounds <b>74</b>−<b>77</b>.</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-21/jm100856p/production/images/medium/jm-2010-00856p_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-21/jm100856p/production/images/large/jm-2010-00856p_0006.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. General Synthetic Procedure for the Preparation of Compounds <b>9</b> and <b>43</b>−<b>77</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-21/jm100856p/production/images/large/jm-2010-00856p_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100856p&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(i) <i>tert</i>-Butanol, potassium <i>tert</i>-butoxide, allyl bromide, 35 °C (starting from <b>1c</b> and <b>1d</b>, the reaction led directly to <b>3</b>); (ii) Claisen rearrangement; (iii) degassed CH<sub>2</sub>Cl<sub>2</sub>, Grubbs second generation catalyst, room temp; (iv) BH<sub>3</sub> in THF, room temp, H<sub>2</sub>O, then NaOH 3 M, H<sub>2</sub>O<sub>2</sub>, room temp; (v) DMP, dry CH<sub>2</sub>Cl<sub>2</sub>, room temp; (vi) THF/acetic acid, Pd/C, H<sub>2</sub>, room temp; (vii) dimethylamine or appropriate amino esters (R<sup>1</sup>; see Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>−<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>), DCE, NaBH(OAc)<sub>3</sub>, room temp; (viii) KOH, MeOH/H<sub>2</sub>O. (ix) To obtain <b>8b</b>: (a) H-Cube hydrogenation (30 atm at 60 °C); (b) DMP, dry CH<sub>2</sub>Cl<sub>2</sub>, room temp.</p></p></figure><div class="NLM_p">The reduction of the benzylic ketone by hydrogenation is probably the step of the synthesis that would most warrant improvement, as the reaction usually necessitates harsh conditions to proceed, such as a large excess of palladium on carbon, high pressure and lengthy reaction times; nonetheless, the recovery of desired product is good. Many alternative reaction conditions were assessed to reduce this ketone, for instance, a Wolf−Kishner reaction or triethylsilane in trifluoroacetic acid (TFA), but a lack of reactivity or degradation was typically observed. In general, the removal of the benzylic keto group has proven to be difficult from oxygen and carbon-bridged scaffolds (X = O, C) and impossible from sulfur-bridged compounds (X = S) and in some cases when the aromatic ring is substituted (R ≠ H).</div><div class="NLM_p">Compounds <b>8</b> are racemic mixtures that can be resolved by preparative chiral HPLC. For example, intermediates <b>8a</b>, <b>8b</b>, and <b>8c</b> have been resolved and the two enantiomers have been named <b>8a</b> (ent 1), <b>8a</b> (ent 2), <b>8b</b> (ent 1), <b>8b</b> (ent 2), and <b>8c</b> (ent 1), <b>8c</b> (ent 2) depending on their respective retention times in the corresponding HPLC separation. For compounds <b>8a</b> (ent 1) and <b>8a</b> (ent 2) the absolute stereochemistry was determined by means of ab initio vibrational circular dichroism (VCD) analysis;<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> hence, <b>8a</b> (ent 1) was assigned as the (1<i>R</i>)-enantiomer and <b>8a</b> (<b>ent 2</b>) as the (1<i>S</i>)-enantiomer. Henceforth, compound <b>8a</b> (ent 1) is named <b>8a</b>(<i>R</i>) and <b>8a</b> (ent 2) is named <b>8a</b>(<i>S</i>).</div><div class="NLM_p">The reductive amination reaction that leads to the formation of the second stereogenic center gave good diastereomeric excess; in fact, the amine <b>9′a</b> and the amino esters <b>10</b>−<b>38</b> and <b>39</b>−<b>42</b> were obtained with a diastereomeric ratio between 70/30 and 90/10. The major diastereoisomer is identified with the prime symbol (′) while the minor with the double prime (′′). The separation of the two diastereoisomers was carried out at this stage by using, also in this case, a preparative chiral HPLC because of the difficulty of the separation by conventional silica gel chromatography. The last step of the synthesis was the hydrolysis of the esters <b>10</b>−<b>38</b> and <b>39</b>−<b>42</b> to give the final amino acids <b>43</b>−<b>73</b> and <b>74</b>−<b>77</b> that were habitually purified by chromatography on a C18 column.</div><div class="NLM_p">Considering that in the final compounds there are two stereogenic centers and consequentially four stereoisomers, it was imperative to identify the most active isomer in order to simplify the exploration. This analysis was carried out using guvacine as amino ester and both the single known enantiomers of the spiroketone <b>8a</b>, <b>8a</b>(<i>R</i>) and <b>8a</b>(<i>S</i>) (see Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>). The amino acid products obtained, <b>45</b> and <b>46</b>, were tested as a mixture of diastereoisomers, and it was clear that the mixture <b>46</b>, obtained from <b>8a</b>(<i>S</i>) via amino ester <b>13</b>, was the most active. The two diastereoisomers of <b>13</b> were then separated to give the major <b>13′</b> and the minor <b>13′′</b> isomers. In this case we observed that the major diastereoisomer (<b>13′</b>) gave the best compound in terms of a mixed H<sub>1</sub>/5-HT<sub>2A</sub> profile (<b>47</b>), while the minor diastereoisomer (<b>13′′</b>) gave <b>48</b>, which is potent at H<sub>1</sub> but inactive at 5-HT<sub>2A</sub>. Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>−<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a> illustrate the structures of compounds (<b>43</b>−<b>73</b> and <b>74</b>−<b>77</b>) prepared according to the procedures described in Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>, along with corresponding data from primary assays. In order to better identify the stereochemistry of the reported compounds, Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>−<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a> also contain details of the parent amino esters from which they were derived and the parent spiroketone used in the reductive amination step (Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>, step vii).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Functional Activity (<i>f</i>-p<i>K</i><sub>i</sub><a class="ref internalNav" href="#t1fn1" aria-label="a">a</a>) at the Human H<sub>1</sub><a class="ref internalNav" href="#t1fn2" aria-label="b">b</a>, 5-HT<sub>2A</sub><a class="ref internalNav" href="#t1fn3" aria-label="c">c</a>, 5-HT<sub>2B</sub>,<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a> and 5-HT<sub>2C</sub><a class="ref internalNav" href="#t1fn2" aria-label="b">b</a> Receptors, PSA<a class="ref internalNav" href="#t1fn4" aria-label="d">d</a> and clogD<a class="ref internalNav" href="#t1fn5" aria-label="e">e</a> for Compounds <b>43</b>−<b>67</b><a class="ref internalNav" href="#tbl1-fn1" aria-label="j">j</a><sup>,</sup><a class="ref internalNav" href="#tbl1-fn2" aria-label="k">k</a></div><p class="last"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-21/jm100856p/production/images/medium/jm-2010-00856p_0007.gif" alt="" id="fx1" /></img></p></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="center" /></col></colgroup><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-21/jm100856p/production/images/medium/jm-2010-00856p_0008.gif" alt="" id="fx2" /></img></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center" valign="top"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-21/jm100856p/production/images/medium/jm-2010-00856p_0009.gif" alt="" id="_i5" /></img></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>a</sup><p class="last"><i>f</i>-p<i>K</i><sub>i</sub> = functional p<i>K</i><sub>i</sub> obtained from the FLIPR and aequorin assays. SEM for H<sub>1</sub>, 5-HT<sub>2A</sub>, 5-HT<sub>2B</sub>, and 5-HT<sub>2C</sub> data sets is <0.1 with a minimum of two replicates.</p></div><div class="footnote" id="t1fn2"><sup>b</sup><p class="last">FLIPR = fluorescent imaging plate reader. See <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a> for assay details.</p></div><div class="footnote" id="t1fn3"><sup>c</sup><p class="last">Aequorin assay (intracellular Ca luminescence). See <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a> for assay details.</p></div><div class="footnote" id="t1fn4"><sup>d</sup><p class="last">Å<sup>2</sup>.</p></div><div class="footnote" id="t1fn5"><sup>e</sup><p class="last">ACD logD 7.4, version 11.</p></div><div class="footnote" id="t1fn6"><sup>f</sup><p class="last">Not isolated.</p></div><div class="footnote" id="t1fn7"><sup>g</sup><p class="last">When the reductive amination is performed with a racemic amine (R<sup>1</sup> in Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>) and the chiral ketone <b>8a</b>(<i>S</i>), the term “isomer 1” is used for the single stereoisomer with the shorter retention time in the conditions of the chiral separation. Conversely the term “isomer 2” is used for the single stereoisomer with the longer retention time in the conditions of the chiral separation. See <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a> for details.</p></div><div class="footnote" id="t1fn8"><sup>h</sup><p class="last">When the reductive amination is performed with a chiral or achiral amine (R<sup>1</sup> in the Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>) and the racemic ketone <b>8a</b>, the term “isomer 1” is used for the single stereoisomer with the shorter retention time in the conditions of the chiral separation. Conversely the term “isomer 2” is used for the single stereoisomer with the longer retention time in the conditions of the chiral separation. See <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a> for details.</p></div><div class="footnote" id="t1fn9"><sup>i</sup><p class="last">H<sub>1</sub> antagonist positive control.</p></div><div class="footnote" id="tbl1-fn1"><sup>j</sup><p class="last">Symbol ∗ represents the following: single unknown enantiomer.</p></div><div class="footnote" id="tbl1-fn2"><sup>k</sup><p class="last">Symbols ′ and ′′ represent the following: The major diastereoisomer after reductive amination reaction was identified with the prime symbol (′) while the minor with the double prime (′′).</p></div><div class="footnote" id="t1fn10"><sup>l</sup><p class="last">5-HT<sub>2A</sub> antagonist positive control.</p></div></div></div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Functional Activity (<i>f</i>-p<i>K</i><sub>i</sub><sup><i>a</i></sup>) at the Human H<sub>1</sub>,<i><sup>b</sup></i> 5-HT<sub>2A</sub>,<i><sup>c</sup></i> 5-HT<sub>2B</sub>,<i><sup>b</sup></i> and 5-HT<sub>2C</sub><i><sup>b</sup></i> Receptors, PSA,<i><sup>d</sup></i> and clogD<i><sup>e</sup></i> for Compounds <b>68</b>−<b>73</b> (See Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a> for Footnotes)</div><p class="last"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-21/jm100856p/production/images/medium/jm-2010-00856p_0012.gif" alt="" id="fx3" /></img></p></div></div><div class="scrollable-table-wrap"><table class="table single-image" border="0"><colgroup><col align="center" /></col></colgroup><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-21/jm100856p/production/images/medium/jm-2010-00856p_0013.gif" alt="" id="fx4" /></img></td></tr></tbody></table></div></div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Functional Activity (<i>f</i>-p<i>K</i><sub>i</sub><i><sup>a</sup></i>) at the Human H<sub>1</sub>,<i><sup>b</sup></i> 5-HT<sub>2A</sub>,<i><sup>c</sup></i> 5-HT<sub>2B</sub>,<i><sup>b</sup></i> and 5-HT<sub>2C</sub><i><sup>b</sup></i> Receptors, PSA,<i><sup>d</sup></i> and clogD<i><sup>e</sup></i> for Compounds <b>74</b>−<b>77</b> (See Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a> for Footnotes)</div><p class="last"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-21/jm100856p/production/images/medium/jm-2010-00856p_0010.gif" alt="" id="_i8" /></img></p></div></div><div class="scrollable-table-wrap"><table class="table single-image" border="0"><colgroup><col align="center" /></col></colgroup><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-21/jm100856p/production/images/medium/jm-2010-00856p_0001.gif" alt="" id="_i9" /></img></td></tr></tbody></table></div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i10">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_01588" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_01588" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">All the newly prepared compounds were assayed for their agonist and antagonist activities using two kinds of functional assays: a FLIPR (fluorescent imaging plate reader) assay, using stably transfected Chinese hamster ovary (CHO) cells expressing the human H<sub>1</sub> receptor and stably transfected SHSY5Y cells expressing the human 5-HT<sub>2A</sub>, 5-HT<sub>2B</sub>, and 5-HT<sub>2C</sub> receptors; a luminescence (Aequorin) assay using frozen human embryonic kidney (HEK) cells stably expressing the human 5-HT<sub>2A</sub> receptor. Most of the 5-HT<sub>2A</sub> data reported in Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>−<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a> were generated using the aequorin assay, and those generated with the FLIPR assay are indicated with a footnote. The well-known ketotifen<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> and MDL-100,907<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> were used as positive controls for H<sub>1</sub> and 5-HT<sub>2A</sub> receptor antagonists; data obtained were consistent with the corresponding affinities reported in the literature.</div><div class="NLM_p">Before entering into a detailed discussion of the results obtained, a few general observations can be made. In order to combine the effect on sleep latency of a H<sub>1</sub> antagonist with the effect on sleep maintenance of a 5-HT<sub>2A</sub> antagonist, we considered, in the first instance, balanced dual H<sub>1</sub>/5-HT<sub>2A</sub> antagonist compounds to achieve comparable receptor occupancy for the two targets. No agonist activity was observed for any of the amino acids considered. High selectivity vs 5-HT<sub>2B</sub> and 5-HT<sub>2C</sub> receptors proved elusive; however, this was not considered a criterion to preclude compound progression because of the minor role of these two receptors in sleep regulation, as stated previously. With regards to selectivity versus adrenergic α<sub>1</sub> receptors and the hERG potassium channel, which was a concern for our initial hit <b>9′a</b> (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>), we never observed significant activity for any of the zwitterionic compounds synthesized and tested in these assays (<i>f-</i>p<i>K</i><sub>i</sub>(hα<sub>1A/B</sub>) < 6 in the FLIPR assay, hERG is discussed in detail below). In terms of activity versus the primary targets we noticed that the zwitterionic modification almost always retained the H<sub>1</sub> activity but reduced the 5-HT<sub>2A</sub> potency; thus, in light of these preliminary results, it was clear that the challenge for the exploration was to find balanced dual antagonist zwitterionic compounds.</div><div class="NLM_p">As highlighted above, the objective of this optimization strategy was to identify suitable zwitterionic moieties able to maximize the in vitro affinity versus both the H<sub>1</sub> and 5-HT<sub>2A</sub> receptors and the selectivity toward undesired biological targets enhancing the druglike characteristics of compound <b>9′a</b>. Thus, the β-alanine derivative <b>43</b><a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> and the <i>N</i>-methyl analogue <b>44</b>, characterized by a reduced lipophilicity and increased polar surface area (PSA) with respect to <b>9′a</b>, were readily prepared and tested as a mixture of diastereoisomers. Both of them showed good potency at the H<sub>1</sub> receptor (<i>f</i>-p<i>K</i><sub>i</sub> = 7.6 and 8.0 for <b>43</b> and <b>44</b>, respectively), whereas the tertiary amine <b>44</b> exhibited higher in vitro activity at the 5-HT<sub>2A</sub> receptor (<i>f</i>-p<i>K</i><sub>i</sub> = 5.7 and 6.8 for <b>43</b> and <b>44</b>, respectively), although it proved to be less potent than the reference compound <b>9′a</b> (<i>f</i>-p<i>K</i><sub>i</sub> = 7.9). Compound <b>43</b> was found to be more selective than parent compound <b>9′a</b>, whereas <b>44</b> retained some in vitro activity at the 5-HT<sub>2C</sub> receptor (<i>f</i>-p<i>K</i><sub>i</sub> = 7.0). Notably both compounds were found to be clean in terms of CYP450 inhibition (IC<sub>50</sub> > 10 μM against all isoforms tested) and affinity for the hERG ion channel (pIC<sub>50</sub> < 4.2 and pIC<sub>50</sub> = 4.2 for <b>43</b> and <b>44</b>, respectively). Further to these promising initial results it was decided to concentrate the exploration on the amino acid moiety with the aim of maximizing the in vitro affinity for the 5-HT<sub>2A</sub> receptor while maintaining the improved developability properties observed. To this end, a series of modified/constrained β, γ and δ-amino acid derivatives shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a> was synthesized.</div><div class="NLM_p">The results obtained for <b>43</b> and <b>44</b> suggested that the exploration should be biased toward tertiary amines and, in particular, attention was focused on cyclic amines. Thus, compound <b>47</b> emerged with good H<sub>1</sub> activity (<i>f</i>-p<i>K</i><sub>i</sub> = 7.6), a satisfactory level of 5-HT<sub>2A</sub> potency (<i>f</i>-p<i>K</i><sub>i</sub> = 6.9), good selectivity versus 5-HT<sub>2B</sub>, and no selectivity over 5-HT<sub>2C</sub> (<i>f</i>-p<i>K</i><sub>i</sub> = 6.8). Compound <b>47</b> was also found to be clean in terms of CYP450 inhibition (IC<sub>50</sub> > 10 μM against all isoforms tested) and affinity for the hERG ion channel (pIC<sub>50</sub> < 4.4). The substitution of the tetracyclic scaffold was also investigated, but the scope of the exploration was limited to a specific position, following some indications from the literature,<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> due to synthetic feasibility. Therefore, compound <b>49</b> was synthesized and it was found to show high potency on H<sub>1</sub> (<i>f</i>-p<i>K</i><sub>i</sub> = 7.4), but unlike the unsubstituted analogue <b>47</b>, it was inactive as a 5-HT<sub>2A</sub> receptor antagonist. The exploration continued on the tetrahydropyridine substructure and the isoguvacine derivative <b>50</b> came out with suitable H<sub>1</sub>/5-HT<sub>2A</sub> potencies (<i>f</i>-p<i>K</i><sub>i</sub> = 7.4 and <i>f</i>-p<i>K</i><sub>i</sub> = 7.1, respectively) and 5-HT<sub>2B</sub> selectivity. Some isonipecotic acid derivatives were also taken into consideration, and the reference compound for this subclass, compound <b>51</b>, maintained a good overall target profile (<i>f</i>-p<i>K</i><sub>i</sub> = 7.3/<i>f</i>-p<i>K</i><sub>i</sub> = 7.1, on H<sub>1</sub>/5-HT<sub>2A</sub>, respectively) without any selectivity versus 5-HT<sub>2B</sub> and 5-HT<sub>2C</sub> as well as resulting to be clean in terms of CYP450 (IC<sub>50</sub> > 10 μM against all isoforms tested) and hERG ion channel inhibition (pIC<sub>50</sub> < 4.2). Substitution in the α-position of the acidic moiety of <b>51</b> led to compounds <b>52</b>, <b>53</b>, and <b>54</b> characterized by good H<sub>1</sub>/5-HT<sub>2A</sub> antagonist potencies and increasing selectivity versus 5-HT<sub>2B</sub> and 5-HT<sub>2C</sub> passing from methyl to fluorine substitution, suggesting that electron withdrawing groups (EWG) in this position successfully improve selectivity. Compound <b>54</b> also shows a clean CYP450 profile (IC<sub>50</sub> > 10 μM against all isoforms tested) and selectivity over the hERG ion channel (pIC<sub>50</sub> < 4.4). Homologation of compound <b>51</b> was not tolerated for 5-HT<sub>2A</sub> receptor antagonist activity (compound <b>55</b>). Moving to the nipecotic acid derivatives, compound <b>56</b> showed potent primary assay activity and 5-HT<sub>2B</sub> selectivity, while its fluorine substituted analogue, compound <b>57</b>, is selective versus both 5-HT<sub>2B</sub> and 5-HT<sub>2C</sub> receptors, confirming that an EWG in the α-position enhances selectivity but is poorly active on H<sub>1</sub>. The morpholine and piperazine derivatives were also considered and synthesized; both of them are selective over 5-HT<sub>2B</sub>, but while compound <b>58</b> has well balanced target potencies, a slight drop in the 5-HT<sub>2A</sub> activity was observed for <b>59</b>.</div><div class="NLM_p">A group of pyrrolidines was also studied, and in general, all the compounds synthesized showed increased potency compared to the piperidine derivatives previously described. Compounds <b>60</b> and <b>61</b> have similar pharmacological profiles, characterized by very high potency on the primary targets and no selectivity at all versus 5-HT<sub>2B</sub> and 5-HT<sub>2C</sub> receptors, while the homologated compound <b>62</b> retains potency on H<sub>1</sub>/5-HT<sub>2A</sub> with a significantly reduced 5-HT<sub>2B</sub> activity, displaying a different behavior with respect to the homologated compound <b>55</b>. Two [3.1.0] amino acidic fragments were also investigated and the corresponding final compounds <b>63</b> and <b>64</b> synthesized; they show very interesting profiles with high H<sub>1</sub> antagonist potency. In particular <b>64</b> is characterized by a well balanced profile (<i>f</i>-p<i>K</i><sub>i</sub> = 7.5/<i>f</i>-p<i>K</i><sub>i</sub> = 7.5, on H<sub>1</sub>/5-HT<sub>2A</sub>, respectively), with selectivity versus 5-HT<sub>2B</sub> (<i>f</i>-p<i>K</i><sub>i</sub> = 6.4), the hERG ion channel (pIC<sub>50</sub> < 4.4), and a clean CYP450 profile (IC<sub>50</sub> > 10 μM against all isoforms tested).</div><div class="NLM_p">The analysis of different cyclic secondary amines, which started with piperidine, passing through pyrrolidines and arriving at azetidine derivatives, is now close to completion. Three compounds were prepared belonging to the latter class. The first, compound <b>65</b>, is the most active and balanced derivative found (<i>f</i>-p<i>K</i><sub>i</sub> = 8.2/<i>f</i>-p<i>K</i><sub>i</sub> = 7.8, H<sub>1</sub>/5-HT<sub>2A</sub>, respectively), even if it is not selective versus 5-HT<sub>2C</sub> (<i>f</i>-p<i>K</i><sub>i</sub> = 8.2). Compound <b>65</b> also shows a clean CYP450 profile (IC<sub>50</sub> > 10 μM against all isoforms tested) and selectivity over the hERG ion channel (pIC<sub>50</sub> < 4.3). The other two azetidine derivatives, <b>66</b> and <b>67</b>, are characterized by an unbalanced profile versus 5-HT<sub>2A</sub>, and the former is also characterized by inactivity versus 5-HT<sub>2C</sub>.</div><div class="NLM_p">With the aim of increasing PSA and further reducing lipophilicity, we decided to introduce heteroatoms in the scaffold and a number of oxepine derivatives were synthesized (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>). Learnings from the previous exploration were transferred to the new oxepine scaffold, and the first two compounds prepared, guvacine derivative <b>68</b> and isoguvacine derivative <b>69</b>, displayed some very interesting features. In particular, a trend of selectivity versus 5-HT<sub>2B</sub> and 5-HT<sub>2C</sub>, driven by the oxepine scaffold, is evident, even if there is also a trend toward reduced potency on the primary targets. In fact <b>69</b>, besides compound <b>54</b> mentioned above, was the only compound synthesized that combines selectivity (<i>f</i>-p<i>K</i><sub>i</sub> ≤ 5.7/<i>f</i>-p<i>K</i><sub>i</sub> = 6.0, on 5-HT<sub>2B</sub>/5-HT<sub>2C</sub>, respectively) with appropriate potencies on the desired targets (<i>f</i>-p<i>K</i><sub>i</sub> = 7.3/<i>f</i>-p<i>K</i><sub>i</sub> = 7.6, on H<sub>1</sub>/5-HT<sub>2A</sub>, respectively). Some piperidine derivatives were also considered in this case, and three compounds, <b>70</b>, <b>71</b>, and <b>72</b>, were prepared. Unfortunately, they did not withstand the reduction of potency derived from the oxepine scaffold, showing moderate activities on the target receptors. On the other hand, the azepine derivative <b>73</b> was very well tolerated (<i>f</i>-p<i>K</i><sub>i</sub> = 7.3/<i>f</i>-p<i>K</i><sub>i</sub> = 7.5, on H<sub>1</sub>/5-HT<sub>2A</sub>, respectively) and displayed low activity for the 5-HT<sub>2B</sub> receptor (<i>f</i>-p<i>K</i><sub>i</sub> = 6.1) and no selectivity versus the 5-HT<sub>2C</sub> receptor (<i>f</i>-p<i>K</i><sub>i</sub> = 7.5). Compound <b>73</b> showed a clean CYP450 profile (IC<sub>50</sub> > 10 μM against all isoforms tested) and selectivity over the hERG ion channel (pIC<sub>50</sub> < 4.3).</div><div class="NLM_p">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a> reports some efforts of structural diversification. Fixing the carbonyl group next to the spiro system, substitution on the phenyl ring on the right-hand side (RHS), and different heteroatoms in the benzhydrylic position in the lower part of the compound (X = C, O, and S) were considered. A comparison between compounds <b>47</b>, <b>68</b>, and <b>74</b>, representative examples from the three scaffolds considered in this exploration, showed how, starting from the carbocyclotetraspiro, then considering the oxepine, and finally moving to the last scaffold described with a carbonyl group, the H<sub>1</sub> activity was basically maintained but the 5-HT<sub>2A</sub> affinity dropped in the last case. The only compound, in this last subseries, able to maintain a balanced overall target profile, albeit with moderate potency, was <b>76</b>, characterized by a fluorine on the RHS phenyl ring and a sulfur on the lower part.</div><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> H<sub>1</sub> and 5-HT<sub>2A</sub> Receptor Binding in Rat Cortex</h3><div class="NLM_p">Competition studies were performed to determine test compound affinity at both H<sub>1</sub> and 5-HT<sub>2A</sub> receptors in membranes from rat cortex by using [<sup>3</sup>H]pyrilamine and [<sup>3</sup>H]ketanserin as radioligands, respectively. Data obtained for the most advanced compounds, <b>47</b>, <b>51</b>, <b>54</b>, <b>64</b>, <b>65</b>, <b>69</b>, and <b>73</b>, are reported in Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>. In general, the p<i>K</i><sub>i</sub> values obtained in binding studies for 5-HT<sub>2A</sub> were in good agreement with the <i>f</i>-p<i>K</i><sub>i</sub> values found in the functional assay in human recombinant cells (Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a> and <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>), whereas the affinity values for the H<sub>1</sub> receptor were higher than functional potencies. This difference could depend on the species (rat versus human) and/or different conditions of the assays, such as the ionic composition of the incubation media or the incubation time.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Summary of the Affinity (p<i>K</i><sub>i</sub>) of Compounds at the Rat Native H<sub>1</sub>/5-HT<sub>2A</sub> Receptors Determined Using Radioligand Binding</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" colspan="2" align="center" char=".">p<i>K</i><sub>i</sub><a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center" char=".">r-H<sub>1</sub><a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char=".">r-5-HT<sub>2A</sub><a class="ref internalNav" href="#t4fn3" aria-label="c">c</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>47</b></td><td class="colsep0 rowsep0" align="char" char=".">8.06</td><td class="colsep0 rowsep0" align="char" char=".">6.93</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>51</b></td><td class="colsep0 rowsep0" align="char" char=".">8.33</td><td class="colsep0 rowsep0" align="char" char=".">7.47</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>54</b></td><td class="colsep0 rowsep0" align="char" char=".">7.91</td><td class="colsep0 rowsep0" align="char" char=".">6.45</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>64</b></td><td class="colsep0 rowsep0" align="char" char=".">8.27</td><td class="colsep0 rowsep0" align="char" char=".">7.16</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>65</b></td><td class="colsep0 rowsep0" align="char" char=".">8.25</td><td class="colsep0 rowsep0" align="char" char=".">7.48</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>69</b></td><td class="colsep0 rowsep0" align="char" char=".">7.70</td><td class="colsep0 rowsep0" align="char" char=".">6.98</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>73</b></td><td class="colsep0 rowsep0" align="char" char=".">7.85</td><td class="colsep0 rowsep0" align="char" char=".">7.47</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>a</sup><p class="last">p<i>K</i><sub>i</sub> values are the mean of two independent experiments performed in duplicate. The difference between the averaged p<i>K</i><sub>i</sub> values was lower than 0.35.</p></div><div class="footnote" id="t4fn2"><sup>b</sup><p class="last">[<sup>3</sup>H]Pyrilamine binding to rat cortical membranes.</p></div><div class="footnote" id="t4fn3"><sup>c</sup><p class="last">[<sup>3</sup>H]Ketanserin binding to rat cortical membranes.</p></div></div></div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Pharmacokinetic Studies</h3><div class="NLM_p">Compounds with favorable in vitro profiles, able to combine H<sub>1</sub> and 5-HT<sub>2A</sub> potencies and exhibit selectivity versus 5-HT<sub>2B</sub> and/or 5-HT<sub>2C</sub>, were progressed through the screening cascade and evaluated in rat pharmacokinetic studies, both in vitro and in vivo (Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>). All the amino acids considered for progression displayed very low values of intrinsic clearance in rat and human microsomes, low CYP450 inhibitory potencies, thus minimizing the possibility of drug−drug interactions, and increased fraction unbound in brain with respect to the starting lead amine <b>9′a</b>. The in vivo pharmacokinetics were investigated in male rat following intravenous (iv) and oral (po) administration, in a cassette dosing experimental design. Brain penetration was determined, in almost all the experiments, after po administration through measurement of the brain to blood AUC<sub>0−8h</sub> ratio. For <b>47</b> brain penetration was measured at 1 h following iv dosing. After iv administration, all the compounds showed low clearance, in agreement with the in vitro results except for <b>54</b>. The volume of distribution (Vss) was low for <b>47</b> and moderate for the other compounds, and the half-life (<i>t</i><sub>1/2</sub>) was between 1 and 3 h except for compound <b>64</b> where it was longer (<i>t</i><sub>1/2</sub> = 5.3 h). After oral administration, all the compounds displayed moderate to high bioavailability (Fpo) with the exception of <b>54</b> (Fpo = 22%), and the brain penetration generally ranged from 0.1 to 0.5. Only compounds <b>64</b> and <b>69</b> showed higher brain penetration of 2.2 and 1.8, respectively. Progression of some compounds was determined on the basis of these results: Compound <b>54</b> was stopped because of its inferior in vivo profile, characterized by low bioavailability combined with high blood clearance and also low brain penetration. Compound <b>64</b> was stopped as well, although it did not present any major PK issues, as the half-life of 5.3 h did not reflect the hypnotic profile required.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Rat Pharmacokinetic Profile for Compounds</div><p class="last"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-21/jm100856p/production/images/medium/jm-2010-00856p_0002.gif" alt="" id="fx7" /></img></p></div></div><div class="scrollable-table-wrap"><table class="table single-image" border="0"><colgroup><col align="center" /></col></colgroup><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-21/jm100856p/production/images/medium/jm-2010-00856p_0003.gif" alt="" id="fx8" /></img></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>a</sup><p class="last">Intrinsic clearance in liver microsomes, rat and human.</p></div><div class="footnote" id="t5fn2"><sup>b</sup><p class="last">CYPEX assay.</p></div><div class="footnote" id="t5fn3"><sup>c</sup><p class="last">fu = fraction unbound in brain−blood rat.</p></div><div class="footnote" id="t5fn4"><sup>d</sup><p class="last">In vivo data determined by 0.5 mg/kg iv and 1 mg/kg po administration in rat for compounds <b>51</b>, <b>64</b>, <b>73</b> and by 1 mg/kg iv and 3 mg/kg po administration in rat for compounds <b>47</b>, <b>54</b>, <b>65</b> and <b>69</b>. Br:Bl measured by brain to blood AUC<sub>0−8h</sub> ratio following po dosing for <b>47</b> at 1 h following iv dosing.</p></div></div></div><div class="NLM_p last">Despite their promising profile, compounds <b>47</b> and <b>69</b> were put on hold because of a developability concern related to the potential toxicity associated with their tetrahydropyridine substructures.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a></div></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> In Vivo Pharmacodynamic Profile</h3><div class="NLM_p">The hypnotic effects of the remaining compounds (<b>51</b>, <b>65</b>, and <b>73</b>) were assessed using telemetric recording of electroencephalogram (EEG) and electromiogram (EMG) in the rat. Simultaneous recording of EEG and EMG allows the accurate derivation of the following sleep parameters: awake, nonrapid eye movement (NREM) sleep, and REM sleep. The test compound’s effects were assessed for 5 h immediately after treatment in the active phase, starting at circadian time [CT] 18 (lights off at circadian time 12) of the rat light−dark cycle. CT18 was chosen to allow a maximal window to assess the hypnotic effects of the compound.</div><div class="NLM_p">The three compounds were tested orally in this paradigm at 1, 3, and 10 mg/kg. All of them showed dose related increases in total sleep time (TST) during the 5 h of observation, reaching a statistically significant effect at 3 mg/kg for compound <b>65</b> (<i>p</i> < 0.01) and at 10 mg/kg for compounds <b>51</b> (<i>p</i> < 0.01) and <b>73</b> (<i>p</i> < 0.01). No effect was observed on the sleep latency (Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a>). An effect of H<sub>1</sub> antagonists on sleep latency has been reported in the literature<a onclick="showRef(event, 'ref4 ref25'); return false;" href="javascript:void(0);" class="ref ref4 ref25">(4, 25)</a> where compounds were tested in a disturbed sleep model; taken together with our results, these data suggest that H<sub>1</sub>/5HT<sub>2A</sub> antagonists may act on sleep onset in disturbed sleep conditions.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Sleep Promoting Effects of Compounds <b>51</b>, <b>65</b>, and <b>73</b> Administered Orally at 1, 3, and 10 mg/kg in Rat during Active Phase (Starting CT18)<a class="ref internalNav" href="#tbl6-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">dose</th><th class="colsep0 rowsep0" align="center">TST (min)</th><th class="colsep0 rowsep0" align="center">NREM sleep latency (min)</th><th class="colsep0 rowsep0" align="center">NREM sleep over 5 h (min)</th><th class="colsep0 rowsep0" align="center">REM sleep latency (min)</th><th class="colsep0 rowsep0" align="center">REM sleep over 5 h (min)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>51</b></td><td class="colsep0 rowsep0" align="left">veh</td><td class="colsep0 rowsep0" align="left">90.2 ± 10.7</td><td class="colsep0 rowsep0" align="left">54.2 ± 13.9</td><td class="colsep0 rowsep0" align="left">80.9 ± 8.5</td><td class="colsep0 rowsep0" align="left">70.3 ± 12.8</td><td class="colsep0 rowsep0" align="left">9.3 ± 3.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">1 mg/kg</td><td class="colsep0 rowsep0" align="left">94.4 ± 7.4</td><td class="colsep0 rowsep0" align="left">69.8 ± 20.3</td><td class="colsep0 rowsep0" align="left">84.7 ± 6.4</td><td class="colsep0 rowsep0" align="left">83.6 ± 21.0</td><td class="colsep0 rowsep0" align="left">9.7 ± 1.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">3 mg/kg</td><td class="colsep0 rowsep0" align="left">105.2 ± 9.1</td><td class="colsep0 rowsep0" align="left">51.4 ± 11.5</td><td class="colsep0 rowsep0" align="left">94.2 ± 8.1</td><td class="colsep0 rowsep0" align="left">77.9 ± 13.6</td><td class="colsep0 rowsep0" align="left">11.0 ± 2.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">10 mg/kg</td><td class="colsep0 rowsep0" align="left">105.2 ± 9.1*</td><td class="colsep0 rowsep0" align="left">34.6 ± 6.8</td><td class="colsep0 rowsep0" align="left">103.7 ± 9.8*</td><td class="colsep0 rowsep0" align="left">83.8 ± 18.0</td><td class="colsep0 rowsep0" align="left">12.6 ± 2.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>65</b></td><td class="colsep0 rowsep0" align="left">veh</td><td class="colsep0 rowsep0" align="left">92.1 ± 5.8</td><td class="colsep0 rowsep0" align="left">39.8 ± 7.1</td><td class="colsep0 rowsep0" align="left">79.4 ± 5.6</td><td class="colsep0 rowsep0" align="left">75.3 ± 13.9</td><td class="colsep0 rowsep0" align="left">12.7 ± 3.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">1 mg/kg</td><td class="colsep0 rowsep0" align="left">98.1 ± 10.9</td><td class="colsep0 rowsep0" align="left">58.1 ± 11.7</td><td class="colsep0 rowsep0" align="left">87.4 ± 9.3</td><td class="colsep0 rowsep0" align="left">77.8 ± 23.9</td><td class="colsep0 rowsep0" align="left">10.7 ± 2.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">3 mg/kg</td><td class="colsep0 rowsep0" align="left">134.7 ± 9.8**</td><td class="colsep0 rowsep0" align="left">51.6 ± 6.0</td><td class="colsep0 rowsep0" align="left">118.6 ± 9.1**</td><td class="colsep0 rowsep0" align="left">81.6 ± 9.8</td><td class="colsep0 rowsep0" align="left">16.1 ± 1.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">10 mg/kg</td><td class="colsep0 rowsep0" align="left">145.2 ± 11.5**</td><td class="colsep0 rowsep0" align="left">33.5 ± 7.2</td><td class="colsep0 rowsep0" align="left">130.5 ± 10.1**</td><td class="colsep0 rowsep0" align="left">64.5 ± 8.9</td><td class="colsep0 rowsep0" align="left">14.6 ± 2.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>73</b></td><td class="colsep0 rowsep0" align="left">veh</td><td class="colsep0 rowsep0" align="left">116.1 ± 7.6</td><td class="colsep0 rowsep0" align="left">40.4 ± 6.3</td><td class="colsep0 rowsep0" align="left">105.6 ± 21</td><td class="colsep0 rowsep0" align="left">57.0 ± 18</td><td class="colsep0 rowsep0" align="left">10.5 ± 1.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">1 mg/kg</td><td class="colsep0 rowsep0" align="left">120.7 ± 7.8</td><td class="colsep0 rowsep0" align="left">37.8 ± 7.1</td><td class="colsep0 rowsep0" align="left">107.3 ± 6.6</td><td class="colsep0 rowsep0" align="left">67.0 ± 12.3</td><td class="colsep0 rowsep0" align="left">13.3 ± 2.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">3 mg/kg</td><td class="colsep0 rowsep0" align="left">138.3 ± 12.9</td><td class="colsep0 rowsep0" align="left">37.9 ± 7.5</td><td class="colsep0 rowsep0" align="left">123.2 ± 12</td><td class="colsep0 rowsep0" align="left">77.7 ± 12.1</td><td class="colsep0 rowsep0" align="left">15.1 ± 2.7*</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">10 mg/kg</td><td class="colsep0 rowsep0" align="left">155.7 ± 11.6**</td><td class="colsep0 rowsep0" align="left">31.5 ± 5.7</td><td class="colsep0 rowsep0" align="left">139.5 ± 10.5**</td><td class="colsep0 rowsep0" align="left">63.4 ± 8.2</td><td class="colsep0 rowsep0" align="left">16.2 ± 1.7*</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl6-fn1"><div class="footnote" id="tbl6-fn1"><sup>a</sup><p class="last">(∗) <i>p</i> < 0.05 and (∗∗) <i>p</i> < 0.01 for each dose versus corresponding vehicle as determined by one-way ANOVA followed by Dunnett’s test. Values are expressed as the mean ± SEM; <i>n</i> = 8. See <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a> for assay details.</p></div></div></div></div><div id="sec3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Ex Vivo Receptor Occupancy Study</h3><div class="NLM_p">Two compounds, <b>51</b> and <b>65</b>, were characterized for their receptor occupancy (RO) in rats in order to understand the level of occupancy achieved at both target receptors at doses where <b>51</b> and <b>65</b> have been shown to produce a hypnotic effect in rats (CT18 model). Three doses were tested (1, 3, and 10 mg/kg, po, 2 h pretreatment). A time point of 2 h after treatment was chosen on the basis of preliminary PK data indicating <i>T</i><sub>max</sub> occurred at 2 h for both compounds with plasma exposures <i>C</i><sub>max</sub> = 216 ng/mL for compound <b>51</b> (at 1 mg/kg po) and <i>C</i><sub>max</sub> = 626 ng/mL for compound <b>65</b> (at 3 mg/kg po). At this time point the maximal RO values are expected. In the RO study, both compounds showed a linear plasma exposure at <i>T</i><sub>max</sub> across the three doses tested (compound <b>51</b> showing 119, 303, and 755 ng/mL at 1, 3, and 10 mg/kg, respectively; compound <b>65</b> showing 127, 417, and 1217 ng/mL at 1, 3, and 10 mg/kg, respectively).</div><div class="NLM_p last">[<sup>3</sup>H]Ketanserin was used as ligand for the 5-HT<sub>2A</sub> receptor, whereas [<sup>3</sup>H]pyrilamine was used for the H<sub>1</sub> receptor. Compound <b>51</b> showed receptor occupancy levels of 0%, 5.6%, and 18% for the 5-HT<sub>2A</sub> receptor and 30%, 35%, and 55% for the H<sub>1</sub> receptor. Similarly, compound <b>65</b> showed levels of 0.9%, 24%, and 47% for the 5-HT<sub>2A</sub> receptor and 16%, 45%, and 66% for the H<sub>1</sub> receptor. The two compounds <b>51</b> and <b>65</b> showed efficacy in the rat sleep model (CT18) at 10 mg/kg po and at 3 mg/kg po, respectively (Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a>), thus suggesting that in order to reach a hypnotic profile, a combination of a low RO of both H<sub>1</sub> and 5-HT<sub>2A</sub> receptors is needed; in particular a 5-HT<sub>2A</sub> receptor occupancy of ∼20% is sufficient to observe the in vivo readout.</div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i18">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_64142" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_64142" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">A new spirotetracyclic class of dual H<sub>1</sub>/5-HT<sub>2A</sub> antagonists, together with the lead optimization process, has been presented. Starting from an unselective and poorly developable lead (<b>9′a</b>), a zwitterionic approach successfully delivered high quality leads characterized by low risk of CYP450 inhibition and low affinity vs the hERG potassium channel and adrenergic receptors. On the basis of their favorable overall profile, several leads (<b>51</b>, <b>65</b>, and <b>73</b>), with equivalent in vitro potencies and in vivo profiles, were identified and progressed in the screening cascade toward a pharmacodynamic model of sleep disorders (rat CT18 sleep model), where they exhibited a robust effect, thus confirming a possible application as an alternative therapy to currently available hypnotic drugs with the potential for a reduced side effect burden.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i19">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_71617" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_71617" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Biological Test Methods</h3><div class="NLM_p last">FLIPR screening assays for H<sub>1</sub>, 5-HT<sub>2A</sub>, 5-HT<sub>2B</sub>, and 5-HT<sub>2C</sub> were all run essentially as described in Wigglesworth et al.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a></div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> 5-HT<sub>2A</sub> Aequorin Assay<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a></h3><div class="NLM_p last">Frozen human embryonic kidney (HEK) cells stably expressing the human 5-HT<sub>2A</sub> serotonin receptor and aequorin apoprotein were thawed and added dropwise to an appropriate volume of warm DMEM media (Gibco Invitrogen 41965-039) containing 10% dialyzed fetal bovine serum (FBS) (Invitrogen, 05-4011DK). Cells were then spun down at 1000 rpm for 5 min at room temperature. The supernatant was poured off and the pellet resuspended in HBSS buffer (Sigma kit H1387) supplemented with HEPES (Sigma H0887), NaHCO<sub>3</sub> (Sigma S8761), 0.1% pluronic acid F68 solution (Gibco Invitrogen 24040-032), and 0.1% bovine serum albumin (CalBiochem 126609). A sample was taken and a cell count performed. Cells were diluted down to 2.5 × 10<sup>6</sup> cells/mL in loading buffer. Coelenterazine [5 μM] (Invitrogen C6780) was added to the cell suspension and the cell vessel wrapped in foil. The cell vessel was put on a windmill rotator (Bibby Stuart) and left overnight at room temperature. Before assay, a sample was taken and a cell count performed. Cells were diluted to an appropriate final density immediately prior to assay. Plates containing compounds (0.5 μL) were placed in a Lumilux, where they were diluted in buffer (20 μL), before additions of cells (20 μL) and a predetermined submaximal concentration of 5-HT (20 μL), while luminescence was monitored. Data were analyzed using area under curve for the entire time course, normalized to in-plate nominal high and low controls, and fitted to a four-parameter logistic equation.</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> hERG <sup>3</sup>H-Dofetilide Binding Assay</h3><div class="NLM_p last">hERG activity was measured using <sup>3</sup>H-dofetilide binding in a scintillation proximity assay (SPA) format. The activity was measured with a Perkin-Elmer Viewlux imager.</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> Receptor Binding Assays</h3><div class="NLM_p">The in vitro binding assays of H<sub>1</sub> and 5-HT<sub>2A</sub> receptors were performed using the rat cerebral cortex. Male Spagrue−Dawley rats (200−250 g) were decapitated, and the cerebral cortex was rapidly removed and homogenized in 20 volumes of ice-cold 50 mM Tris-hydrochloride buffer, pH 7.4. The homogenate was centrifuged at 41000<i>g</i> for 15 min at 4 °C. The pellet was resuspended in buffer, incubated at 37 °C for 15 min, and washed twice by the same procedure. The final pellet was resuspended in 4 volumes of ice-cold buffer. The final suspension was distributed into aliquots and stored at −80 °C. Protein content in the membrane preparations was evaluated using the Bradford method (BCA protein assay, PIERCE).</div><div class="NLM_p">The receptor−ligand binding assays were performed using [ethylene-3<i>H</i>]ketanserin hydrochloride (NET-791, 2.22−3.33 TBq/mmol, Perkin-Elmer) for 5-HT<sub>2A</sub> receptor binding and [pyridinyl-5-3<i>H</i>]pyrilamine (TRK608, 1.1 TBq/moml, Amersham) for H<sub>1</sub> receptor binding. Binding experiments were carried out in deep-well 96-well plates in a total volume of 0.5 mL/well containing the radioligand (final concentration of 1 nM [<sup>3</sup>H]ketanserin or 0.6 nM [<sup>3</sup>H]pyrilamine), tissue suspension (50 μg/well for 5-HT<sub>2A</sub> receptor or 150 μg/well for H<sub>1</sub> receptor), various concentrations of test compound, and the appropriate buffer (50 mM Tris-HCl, 10 mM MgCl<sub>2</sub>, pH7.4, for 5-HT<sub>2A</sub> receptor or 50 mM HEPES, pH 7.4, for H<sub>1</sub> receptor). The mixture was incubated with shaking at 37 °C for 1 h for 5-HT<sub>2A</sub> receptor binding or at room temperature for 2 h for H<sub>1</sub> receptor binding.</div><div class="NLM_p">Samples were rapidly filtered through Whatman GF/B glass-fiber filters presoaked with 0.3% PEI using a cell harvester and then washed 4 times with 4 mL of ice-cold 0.9% NaCl buffer. The filters were dried and counted in a liquid scintillation counter (Tri-Carb 2900TR, Perkin-Elmer). Nonspecific binding was determined by the presence of 10 μM mianserin or cetirizine for 5-HT<sub>2A</sub> or H<sub>1</sub> receptor, respectively.</div><div class="NLM_p last">Radioligand binding data were analyzed by nonlinear regression analysis using GraphPad Prism 4.0 (GraphPad Software, CA). Curve fitting from competition binding experiments was determined by using a one site competition equation after checking that the Hill slope in the four-parameter logistic equation was not different from 1.0. In this condition, p<i>K</i><sub>i</sub> values of test drugs were calculated according to the Cheng−Prusoff equation from the IC<sub>50</sub>, and the <i>K</i><sub>D</sub> (equilibrium dissociation constant of the radioligand) was determined at each receptor type (5-HT<sub>2A</sub>, H<sub>1</sub>) through saturation experiments. Results are expressed as mean values of two separate experiments performed in duplicate.</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> P450 CYPEX Assay</h3><div class="NLM_p last">Inhibition (IC<sub>50</sub>) of human CYP1A2, 2C9, 2C19, 2D6, and 3A4 was determined using Cypex Bactosomes expressing the major human P450s. A range of concentrations (0.1, 0.2, 0.4, 1, 2, 4, and 10 μM) of test compound were prepared in methanol and preincubated at 37 °C for 10 min in 50 mM potassium phosphate buffer (pH 7.4) containing recombinant human CYP450 microsomal protein (0.1 mg/mL; Cypex Limited, Dundee, U.K.) and probe-fluorescent substrate. The final concentration of solvent was between 3% and 4.5% of the final volume. Following preincubation, NADPH regenerating system (7.8 mg of glucose 6-phosphate, 1.7 mg of NADP, and 6 units of glucose 6-phosphate dehydrogenase/mL of 2% (w/v) NaHCO<sub>3</sub>; 25 μL) was added to each well to start the reaction. Production of fluorescent metabolite was then measured over a 10 min time course using a Spectrafluor Plus plate reader. The rate of metabolite production (AFU/min) was determined at each concentration of compound and converted to a percentage of the mean control rate using Magellan (Tecan software). The inhibition (IC<sub>50</sub>) of each compound was determined from the slope of the plot using Grafit, version 5 (Erithacus software, U.K.). Miconazole was added as a positive control to each plate. CYP450 isoform substrates used were ethoxyresorufin (ER; 1A2; 0.5 μM), 7-methoxy-4-triflouromethylcoumarin-3-acetic acid (FCA, 2C9, 50 μM), 3-butyryl-7-methoxycoumarin (BMC, 2C19, 10 μM), 4-methylaminomethyl-7-methoxycoumarin (MMC, 2D6, 10 μM), diethoxyfluorescein (DEF, 3A4, 1 μM), and 7-benzyloxyquinoline (7-BQ, 3A4, 25 μM). The test was performed in three replicates.</div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> Intrinsic Clearance (Cli) Assay</h3><div class="NLM_p last">Intrinsic clearance (Cli) values were determined in rat and human liver microsomes. Test compounds (0.5 μM) were incubated at 37 °C for 30 min in 50 mM potassium phosphate buffer (pH 7.4) containing 0.5 mg of microsomal protein/mL. The reaction was started by addition of cofactor (NADPH, 8 mg/mL). The final concentration of solvent was 1% of the final volume. At 0, 3, 6, 9, 15, and 30 min, an aliquot (50 μL) was taken, quenched with acetonitrile containing an appropriate internal standard, and analyzed by HPLC−MS/MS. The intrinsic clearance (Cli) was determined from the first-order elimination constant by nonlinear regression using Grafit, version 5 (Erithacus software, U.K.), corrected for the volume of the incubation and assuming 52.5 mg of microsomal protein/g liver for all species. Values for Cli were expressed as (mL/min)/g liver. The lower limit of quantification of clearance was determined to be when <15% of the compound had been metabolized by 30 min, and this corresponded to a Cli value of 0.5 (mL/min)/g liver. The upper limit was 50 (mL/min)/g liver.</div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> In Vivo Studies</h3><div class="NLM_p last">All experiments were prereviewed and approved by a local animal care committee in accordance with the guidelines of the “Principles of Laboratory Animal Care” (NIH Publication No. 86-23, revised 1985) and with a project license that was obtained according to Italian law (Art. 7, Legislative Decree No. 116, January 27, 1992), which acknowledges European Directive 86/609/EEC on the care and welfare of laboratory animals.</div></div><div id="sec5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> In Vivo Pharmacokinetics</h3><div class="NLM_p last">The pharmacokinetics and oral bioavailability of test compounds were determined following iv (bolus) and po (suspension) administration to male Sprague−Dawley rats at 0.5−1 and 1−3 mg free base/kg, respectively. Blood and brain samples were collected at intervals up to 24 h after dosing. Blood and brain samples were subsequently assayed for test compound concentration using a method based on protein precipitation followed by HPLC−MS/MS analysis.</div></div><div id="sec5_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> Rat Sleep Study</h3><div class="NLM_p">Male Sprague−Dawley rats (275−300 g, Charles River Italy) were housed singly on a light−dark cycle (15:00−03:00 h light) 1 week prior to surgery. Access to food and water was allowed ad libitum.</div><div class="NLM_p">In order to collect the biopotential signals, a miniature multichannel telemetric transmitter (TL10M3-F40-EET, Data Sciences Int.) was implanted intraperitoneally into the animals.</div><div class="NLM_p">To allow recording of cortical electroencephalogram (EEG), two electrodes were fixed permanently, with dental cement, to the skull. They were directly in contact with the dura mater through two drilled holes on the fronto-parietal region. Two electrodes were fixed to the skeletal muscles of the neck for recording electromyogram (EMG).</div><div class="NLM_p">After recovery from surgery, animals were maintained in their home cage in a temperature controlled environment (21 ± 1 °C) with access to food and water ad libitum. Implanted animals demonstrated a normal behavioral repertoire immediately after recovery from surgery, but to allow normal sleep patterns to be re-established, animals were utilized after 3 weeks. The environmental conditions described above were maintained throughout the sleep studies.</div><div class="NLM_p">For the duration of the test period freely moving animals remained in their home cages on individual receivers. EEG and EMG signals were recorded continuously using DSI Dataquest A.R.T.</div><div class="NLM_p">The EEG trace, divided into 10 s epochs, was digitally transformed (FFT transformation) to provide the power spectra of δ, θ, α, and β bands in order to distinguish three different activity patterns in the rat (awake, NREM sleep, and REM sleep). The markers assigned by the automated scoring system (sleep stage, DSI) were transferred to the EEG digital signal and subsequently confirmed by visual examination of the EEG and EMG traces by trained operators, blind to the drug treatment.</div><div class="NLM_p">Analysis of sleep parameters included latency to NREM sleep (time interval to the first six consecutive NREM sleep epochs after injection), latency to REM sleep (time interval to the first REM sleep epoch after injection), and time spent wake, NREM sleep, REM sleep, and total sleep time (TST).</div><div class="NLM_p">Drug studies were carried out according to a randomized paired crossover design where, in separate experimental sessions, each animal received control and drug treatments. Compounds were administered orally in a volume of 2 mL/kg in doses of 1, 3, and 10 mg/kg. Animals were treated with compound or respective vehicle 6 h after switch off of the light (circadian time (CT) 18). Recordings were made for the subsequent 5 h test period.</div><div class="NLM_p last">Results were expressed as mean value ± SEM. Statistical analysis was performed by a one-way analysis of variance followed by Dunnett’s test.</div></div><div id="sec5_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> Ex Vivo Receptor Occupancy by Autoradiography</h3><div class="NLM_p last">Sprague−Dawley rats were acutely administered with vehicle (0.5% HPMC po) or test compounds (1, 3, or 10 mg/kg po), and after 2 h they were sacrificed and brains were quickly removed and frozen in precooled isopentane at −20 °C.</div></div><div id="sec5_10_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> H<sub>1</sub> ex Vivo Receptor Occupancy</h3><div class="NLM_p last">Coronal brain sections were cut at 14 μm, mounted onto microscope slides, and incubated with 1nM [<sup>3</sup>H]pyrilamine (TRK608, Amersham) in 50 mM Tris-HCl, pH 7.5, buffer for 10 min at room temperature. Nonspecific binding was determined in the presence of 10 μM pyrilamine. Sections were subsequently washed 4 × 2 min in ice-cold incubation buffer and exposed to imaging plates for 7 days and analyzed with a phosphoimager scanner (Fuji BAS-5000). Receptor occupancy was measured in cerebral cortex.</div></div><div id="sec5_10_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> 5-HT<sub>2A</sub> ex Vivo Receptor Occupancy</h3><div class="NLM_p last">Coronal brain sections were cut at 14 μm, mounted onto microscope slides and incubated with 1 nM [<sup>3</sup>H]ketanserine (NET791, Perkin-Elmer) in 50 mM Tris-HCl + 10 mM MgCl<sub>2</sub>, pH 7.5, buffer for 10 min at room temperature. Nonspecific binding was determined in the presence of 10 μM mianserin. Sections were subsequently washed 4 × 2 min in ice-cold incubation buffer and exposed to imaging plates for 7 days and analyzed with a phosphoimager scanner (Fuji BAS-5000). Receptor occupancy was measured in cerebral cortex.</div></div><div id="sec5_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> Chemistry. General Methods</h3><div class="NLM_p">Proton nuclear magnetic resonance (<sup>1</sup>H NMR) spectra were recorded either on Varian instruments at 300, 400, or 500 MHz or on Bruker instruments at 300, 400, or 500 MHz. Chemical shifts are reported in ppm (δ) using the residual solvent line as internal standard. Splitting patterns are designated as follows: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; b, broad. The NMR spectra were recorded at a temperature ranging from 25 to 90 °C. When more than one conformer was detected, the chemical shifts for the most abundant one is reported.</div><div class="NLM_p">Mass spectra (MS) were run on a 4 II triple quadrupole Agilent MSD 1100 mass spectrometer, operating in ES(+) and ES(−) ionization mode. The usage of this methodology is indicated by “MS”.</div><div class="NLM_p">Optical rotations were measured by using a Jasco DIP-360 digital polarimeter with a path length of 10 cm recorded at the sodium D line.</div><div class="NLM_p">HPLC−mass spectra were run on an Agilent LC/MSD 1100 mass spectrometer, operating in ES(+) and ES(−) ionization mode coupled with HPLC instrument Agilent 1100 series. LC/MS ES(+) was performed on a Supelcosil ABZ + Plus (33 mm × 4.6 mm, 3 m) (mobile phase, 100% [water + 0.1% formic acid] for 1 min, then from 100% [water + 0.1% formic acid] to 5% [water + 0.1% formic acid] and 95% acetonitrile in 5 min, finally under these conditions for 2 min; <i>T</i> = 40 °C; flow = 1 mL/min. LC/MS ES(−) was performed on a Supelcosil ABZ + Plus (33 mm × 4.6 mm, 3 m) (mobile phase, 100% [water + 0.05% ammonia] for 1 min, then from 100% [water + 0.05% ammonia] to 5% [water + 0.05% ammonia] and 95% acetonitrile in 5 min, finally under these conditions for 2 min; <i>T</i> = 40 °C; flow = 1 mL/min. In the mass spectra only one peak in the molecular ion cluster is reported. The usage of this methodology is indicated by “HPLC−MS” in the analytical characterization of the described compounds.</div><div class="NLM_p">Alternatively mass directed analytical HPLC (Agilent technology HP1100) was carried out using a 19 mm ×100 mm or 30 mm ×100 mm, 5 μm, reversed phase Waters Atlantis column as the stationary phase and a gradient from water + 0.1% formic acid to acetonitrile + 0.1% formic acid as the eluent. The HPLC system was monitored by DAD array detector and an Agilent 110MSD mass spectrometer. The LC elution method (using Zorbax Eclipse XDB, 4.6 mm × 150 mm, 5 μm C8 column) was the following: 15 min method at 25 °C, mobile phase composed of different CH<sub>3</sub>CN/H<sub>2</sub>O−HCOOH 0.1% mixtures at a flow rate of 1 mL/min (all solvents were HPLC grade, Fluka).</div><div class="NLM_p">Alternatively HPLC spectra were performed using a reversed-phase liquid chromatography (ProStar 210/215 PrepStar218) and UV−vis detector (ProStar 325). The LC elution method (using Varian Polaris 5 C-18, 150 mm × 4.6 mm) was the following: 15 min method at 25 °C, mobile phase composed of different CH<sub>3</sub>CN/H<sub>2</sub>O−HCOOH 0.1% mixtures at a flow rate of 1 mL/min (all solvent were HPLC grade, Fluka).</div><div class="NLM_p">Alternatively HPLC spectra were performed using a Waters 2690 apparatus at 25 °C using a 3 mm ×100 mm, 3.5 μm, reversed phase X-Terra C-18 column as the stationary phase and a gradient from 5% [water + 0.1% formic acid] to 90% [acetonitrile + 0.1% formic acid] during 19.5 min or 20% [water + 0.1% formic acid] to 95% [acetonitrile + 0.1% formic] during 19 min as the eluent. Flow rate was 0.5 mL/min (all solvents were HPLC grade, Merck). The HPLC system was monitored by DAD array detector at 254 nm and a Micromass Quattromicro mass spectrometer.</div><div class="NLM_p">Total ion current (TIC) and DAD UV chromatographic traces together with MS and UV spectra associated with the peaks were taken on a UPLC/MS Acquity system equipped with 2996 PDA detector and coupled to a Waters Micromass ZQTM mass spectrometer operating in positive or negative electrospray ionization mode. LC/MS ES(±) was performed using an Acquity UPLC BEH C18 column (50 mm × 21 mm, 1.7 μm particle size) and column temperature of 40 °C (mobile phase A, (water + 0.1% formic acid); mobile phase B, (acetonitrile + 0.075% formic acid); flow rate of 1.0 mL/min; gradient, <i>t</i> = 0 min 3% B, <i>t</i> = 0.05 min 6% B, <i>t</i> = 0.57 min 70% B, <i>t</i> = 1.4 min 99% B, <i>t</i> = 1.45 min 3% B). The usage of this methodology is indicated by “UPLC/MS” in the analytic characterization of the described compounds.</div><div class="NLM_p">GC−MS (Varian Saturn 2000) was carried out using a Varian Chrompack CP-Sil low bleed/MS 30 m × 0.25 mm, 0.5 μm column as the stationary phase and helium (2 mL/min) as the carrier gas. Injector temperature was 270 °C, and column temperature was increased from 200 to 300 °C at a rate of 10 °C/min and then held at 300 °C for 5 min. Mass detection was performed using chemical ionization (CH<sub>3</sub>CN) in the range from 200 <i>m</i>/<i>z</i> to 450 <i>m</i>/<i>z</i>.</div><div class="NLM_p">For reactions involving microwave irradiation, a Personal Chemistry Emrys optimizer was used.</div><div class="NLM_p">For hydrogenation reactions, H-Cube continuous-flow hydrogenation reactor occasionally was used.</div><div class="NLM_p">Flash silica gel chromatography was carried out on silica gel 230−400 mesh (supplied by Merck AG Darmstadt, Germany) or over Varian Mega Be−Si prepacked cartridges or over prepacked Biotage or Isolute Flas silica cartridges. Alternatively chromatographic purifications were performed on columns packed with Merck 60 silica gel, 23−400 mesh, for flash technique. Thin-layer chromatography was carried out using Merck TLC plates Kieselgel 60F-254 and visualized with UV light, 5% phosphomolybdic acid, and aqueous potassium permanganate. SPE-SCX cartridges are ion exchange solid phase extraction columns by supplied by Varian. The eluent used with SPE-SCX cartridges is methanol followed by 2 N ammonia solution in methanol. Oasis HLB extraction cartridges are ion exchange solid phase extraction columns supplied by Waters. The eluent used with HLB cartridges is water followed by methanol.</div><div class="NLM_p">In a number of preparations, purification was performed using either Biotage manual flash chromatography (Flash+) or automatic flash chromatography (Horizon) systems. All these instruments work with standard Biotage Silica cartridges.</div><div class="NLM_p">In a number of preparations, purification was performed on a mass-directed autopurification (MDAP) system Fraction Lynx equipped with Waters 2996 PDA detector and coupled with a ZQTM mass spectrometer (Waters) operating in positive and negative electrospray ionization modes ES(+) and ES(−) (mass range 100−1000).</div><div class="NLM_p">A set of acidic and basic semipreparative gradients have been used.</div><div class="NLM_p">Method A consisted of the following chromatographic acidic conditions for up to 30 mg of crude: column, 100 mm × 21.2 mm SupelcosilTM ABZ + Plus (5 μm particle size); mobile phase, A [water + 0.1% formic acid]/B [acetonitrile + 0.1% formic acid]; flow rate, 20 mL/min; gradient, 5% B for 1 min, 95% B in 9 min, 100% B in 3.5 min.</div><div class="NLM_p">Method B consisted of the following chromatographic acidic conditions for up to 100 mg of crude: column, 150 mm × 30 mm XTerra Prep MS C18 (10 μm particle size); mobile phase, A [water + 0.1% formic acid]/B [acetonitrile + 0.1% formic acid]; flow rate, 40 mL/min; gradient, 1% B to 100% B in 7 min lasting for 7.5 min.</div><div class="NLM_p">Method C consisted of the following chromatographic basic conditions for up to 100 mg of crude: column, 150 mm × 30 mm XTerra Prep MS C18 (10 μm particle size); mobile phase, A [water + 10 mM ammonium carbonate (adjusted to pH 10 with ammonia)]/B [acetonitrile]; flow rate, 40 mL/min; gradient, 10% B for 0.5 min, 95% B in 12.5 min.</div><div class="NLM_p last">General procedures for the preparation of compounds <b>9</b> and <b>43</b>−<b>77</b> are shown in Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>. The purity of the compounds reported in the manuscript was established through HPLC and/or <sup>1</sup>H NMR methodologies. All final compounds reported in the manuscript have a purity of >95%.</div></div><div id="sec5_11_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> 11,11-Di-2-propen-1-yl-5,11-dihydro-10<i>H</i>-dibenzo[<i>a</i>,<i>d</i>]cyclohepten-10-one (<b>3a</b>)</h3><div class="NLM_p last">The starting ketone 5,11-dihydro-10<i>H</i>-dibenzo[<i>a</i>,<i>d</i>]cyclohepten-10-one (<b>1a</b>, 10 g, 48 mmol, whose preparation has been described in  <cite>J. Med. Chem.</cite> <span class="NLM_year">2004</span>, <em>47</em>, 4202−4212) was suspended in <i>tert</i>-butanol (100 mL) and heated to 35 °C. Potassium <i>tert</i>-butoxide (13.5 g, 120 mmol) and allyl bromide (16.6 mL, 192 mmol) were added at this temperature, and the pink suspension was stirred for 1 h. The suspension was cooled to room temperature and quenched with NH<sub>4</sub>Cl (saturated solution). The mixture was partitioned between diethyl ether and water. The organic phase was separated, dried over N<sub>2</sub>SO<sub>4</sub>, and evaporated in vacuum to give the crude material (13 g) as an orange oil as a mixture of <i>C</i>-diallyl (<b>3a</b>) and <i>C</i>-allyl/<i>O</i>-allyl (<b>2a</b>), which was progressed to the Claisen rearrangement without any further purification/characterization. The neat mixture (13 g) was heated at 185 °C for 15 min to give the desired product (<b>3a</b>, 13 g) that was used in the next step without any further purification. MS (ESI) <i>m</i>/<i>z</i>: 311 [M + Na]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ: 2.75−2.96 (m, 4H), 3.94 (s, 2H), 4.92−5.04 (m, 4H), 5.42−5.55 (m, 2H), 7.10−7.35 (m, 8H).</div></div><div id="sec5_11_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> 8-Chloro-11,11-di-2-propen-1-yldibenzo[<i>b</i>,<i>f</i>]oxepin-10(11<i>H</i>)-one (<b>3d</b>)</h3><div class="NLM_p last">The solution of KO<sup><i>t</i></sup>Bu (2.47 g,22 mmol) in 100 mL of the <sup><i>t</i></sup>BuOH was stirred for 10 min under a stream of argon at room temperature. Then 8-chlorodibenzo[<i>b</i>,<i>f</i>]oxepin-10(11<i>H</i>)-one (1 g, 4.1 mmol; for preparation see  <cite>J. Med. Chem.</cite> <span class="NLM_year">1980</span>, <em>23</em> (5), 494−501) and allyl bromide (9.31 mL,21,8 mmol) were added. The mixture was then heated at 60 °C for 3 h. After the mixture was cooled to room temperature, a saturated solution of NaHCO<sub>3</sub> (150 mL) was added in one portion. The mixture was left under magnetic stirring for an additional 15 min. The precipitate was filtered off, and the aqueous phase was then extracted using ethyl acetate (3 × 50 mL). Collected organic layers were washed with saturated NaHCO<sub>3</sub> solution, dried with anhydrous Na<sub>2</sub>SO<sub>4</sub>, and evaporated, giving a crude product (<b>3d</b>, 1.8 g) as an oil. GC−MS <i>m</i>/<i>z</i>: 325 [M + 1] <sup>+</sup>. <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ: 2.85−3.01 (m, 4H), 5.04−5.12 (m, 4H), 5.62−5.76 (m, 2H), 7.14−7.30 (m, 7H).</div></div><div id="sec5_11_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> Spiro[cyclopent-3-ene-1,10′-dibenzo[<i>a</i>,<i>d</i>]cyclohepten]-11′(5′<i>H</i>)-one (<b>4a</b>)</h3><div class="NLM_p last">To a solution of 11,11-di-2-propen-1-yl-5,11-dihydro-10<i>H</i>-dibenzo[<i>a</i>,<i>d</i>]cyclohepten-10-one (<b>3a</b>, 1.00 g, 3.47 mmol) in degassed DCM (1 L) was added Grubbs second generation catalyst (15 mol %, 0.44 g) under argon atmosphere at room temperature. The reaction mixture was stirred at room temperature overnight. The dark solution was then adsorbed on silica gel (10 equiv wt relative to catalyst) and passed through a pad of silica gel (petroleum ether/diethyl ether 1/1). The filtered solution was stirred with activated charcoal (50 equiv wt relative to product) for 12 h. After the carbon was filtered, the filtrate was concentrated in vacuum and purified by silica gel column chromatography (petroleum ether/diethyl ether = 9/1) to give the title compound (<b>4a</b>, 748 mg) as a white solid. MS (ESI) <i>m</i>/<i>z</i>: 283 [M + Na]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ: 2.92−2.99 (m, 2H), 3.56−3.63 (m, 2H), 4.36 (m, 2H), 5.71−5.74 (m, 2H), 7.09−7.51 (m, 7H), 7.78−7.88 (m, 1H).</div></div><div id="sec5_11_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> 2′-Chloro-11′<i>H</i>-spiro[cyclopent-3-ene-1,10′-dibenzo[<i>b</i>,<i>f</i>]oxepin]-11′-one (<b>4d</b>)</h3><div class="NLM_p last">An amount of 3 L of dry DCM was degassed with argon, and 8-chloro-11,11-di-2-propen-1-yldibenzo[<i>b</i>,<i>f</i>]oxepin-10(11<i>H</i>)-one (<b>3d</b>, 6.78 g, 20.8 mmol) and Grubbs second generation catalyst (15.5 mol %, 1.275 g) were added. The solution was stirred under argon atmosphere for 8 h, and then it was passed through a prepacked silica gel column and evaporated. The crude oil obtained (6.5 g) was purified by silica gel column chromatography (<i>n</i>-hexane/ethyl acetate = 9:0.2), and the fraction of the product that was obtained gave a precipitate after suspension in hexane to give the title compound (<b>4d</b>, 3.5 g). GC−MS <i>m</i>/<i>z</i>: 297 [M + 1] <sup>+</sup>. <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ: 2.92−3.95 (d, 2H), 3.42−3.46 (d, 2H), 5.72 (s, 2H), 7.20−7.35 (m, 6H), 7.45−7.47 (m, 1H).</div></div><div id="sec5_11_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> Mixture of 3-Hydroxyspiro[cyclopentane-1,10′-dibenzo[<i>a</i>,<i>d</i>]cyclohepten]-11′(5′<i>H</i>)-one (<b>5a</b>) and 5′,11′-Dihydrospiro[cyclopentane-1,10′-dibenzo[<i>a</i>,<i>d</i>]cycloheptene]-3,11′-diol (<b>6a</b>)</h3><div class="NLM_p last">1 M borane solution in THF (0.77 mL, 0.77 mmol) was added dropwise to a stirred solution of spiro[cyclopent-3-ene-1,10′-dibenzo[<i>a</i>,<i>d</i>]cyclohepten]-11′(5′<i>H</i>)-one (<b>4a</b>, 0.200 g, 0.77 mmol) in anhydrous THF (1.6 mL) at room temperature under an N<sub>2</sub> atmosphere, and the mixture was stirred at room temperature for 2.5 h. Water (0.08 mL) was then added dropwise, followed by 3 M sodium hydroxide (0.10 mL). Hydrogen peroxide (0.12 mL, 35%) was then added at a rate to maintain the temperature between 30 and 50 °C, and the reaction mixture was stirred for 16 h at room temperature. Diethyl ether (1.6 mL) was added to the reaction mixture, and the organic phase was washed with brine and water. The organic solvent was evaporated to give a residue which, for analytical purposes, was purified by silica gel column chromatography (5/1 petroleum ether/diethyl ether), affording 3-hydroxyspiro[cyclopentane-1,10′-dibenzo[<i>a</i>,<i>d</i>]cyclohepten]-11′(5′<i>H</i>)-one (<b>5a</b>, 0.091 g) and 5′,11′-dihydrospiro[cyclopentane-1,10′-dibenzo[<i>a</i>,<i>d</i>]cycloheptene]-3,11′-diol (<b>6a</b>, 0.079 g).</div></div><div id="sec5_11_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> 3-Hydroxyspiro[cyclopentane-1,10′-dibenzo[<i>a</i>,<i>d</i>]cyclohepten]-11′(5′<i>H</i>)-one (<b>5a</b>)</h3><div class="NLM_p last">MS (ESI) <i>m</i>/<i>z</i>: 279 [M + 1]<sup>+</sup>, 301 [M + Na]<sup>+</sup>, 261 [M − H<sub>2</sub>O]<sup>+</sup>, 579 [2M + Na]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ: 1.66−1.92 (m, 2H), 2.12−2.21 (m, 1H), 2.32−2.48 (m, 1H), 2.85−2.95 (m, 1H), 3.21−3.30 (m, 1H), 4.35−4.44 (m, 3H), 7.10−7.46 (m, 7H), 7.91−7.95 (m, 1H).</div></div><div id="sec5_11_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> 5′,11′-Dihydrospiro[cyclopentane-1,10′-dibenzo[<i>a</i>,<i>d</i>]cycloheptene]-3,11′-diol (<b>6a</b>)</h3><div class="NLM_p last">MS (ESI) <i>m</i>/<i>z</i>: 303 [M + Na]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ: 1.83−2.43 (m, 5H), 2.61−2.71 (m, 1H), 3.81−3.89 (m, 1H), 4.47−4.61 (m, 2H), 5.03 (s, 1H), 7.03−7.61 (m, 8H).</div></div><div id="sec5_11_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> 3<i>H</i>-Spiro[cyclopentane-1,10′-dibenzo[<i>a</i>,<i>d</i>]cycloheptene]-3,11′(5′<i>H</i>)-dione (<b>7a</b>)</h3><div class="NLM_p last">To a solution of Dess−Martin triacetoxyperiodinane (0.38 g, 0.9 mmol) a mixture of 3-hydroxyspiro[cyclopentane-1,10′-dibenzo[<i>a</i>,<i>d</i>]cyclohepten]-11′(5′<i>H</i>)-one and 5′,11′-dihydrospiro[cyclopentane-1,10′-dibenzo[<i>a</i>,<i>d</i>]cycloheptene]-3,11′-diol (<b>5a</b> and <b>6a</b>, 0.100 g, 0.36 mmol) was added in dry DCM (8 mL). The reaction mixture was left at 25 °C for 3.5 h. The mixture was diluted with DCM (10 mL) and washed with NaOH (1 N) and then brine. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub> and after solvent evaporation gave the title compound (<b>7a</b>, 92 mg). MS (ESI) <i>m</i>/<i>z</i>: 299 [M + Na]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ: 2.26−2.49 (m, 3H), 2.76−2.84 (m, 1H), 3.26−3.46 (m, 2H), 4.32−4.51 (m, 2H), 7.16−7.48 (m, 7H), 7.92−7.96 (m, 1H).</div></div><div id="sec5_11_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> 2′-Chloro-3<i>H</i>,11′<i>H</i>-spiro[cyclopentane-1,10′-dibenzo[<i>b</i>,<i>f</i>]oxepin]-3,11′-dione (<b>7d</b>)</h3><div class="NLM_p last">2′-Chloro-11′<i>H</i>-spiro[cyclopent-3-ene-1,10′-dibenzo[<i>b</i>,<i>f</i>]oxepin]-11′-one (<b>4d</b>, 2.1 g, 7.08 mmol) was melted in anhydrous THF (100 mL) under argon atmosphere, and 1 M solution of BH<sub>3</sub>−THF (8 mL, 8 mmol) was added dropwise. The mixture was left for 4 h under stirring at room temperature. After 4 h, H<sub>2</sub>O (20 mL) and 10% NaOH (10 mL) were added followed by 30% H<sub>2</sub>O<sub>2</sub> (5 mL). The mixture was stirred overnight and then diluted with H<sub>2</sub>O (40 mL) and extracted with diethyl ether. Organic layer was washed with brine, dried, and evaporated, giving a crude product as a mixture of <b>5d</b> and <b>6d</b> (2 g). The mixture was dissolved in dry DCM (100 mL), and Dess−Martin (triacetoxyperiodinane) (9 g, 21.31 mmol) was added. The mixture was stirred overnight under argon atmosphere. The reaction was worked up by washing three times with NaOH (10% aqueous solution). Water layers were washed with DCM and combined organic layers were dried (Na<sub>2</sub>SO<sub>4</sub>/MgSO<sub>4</sub>) and evaporated to give the crude title compound (<b>7d</b>, 2.13 g), which was used in the next step without any further purification. HPLC−MS <i>m</i>/<i>z</i>: 312.89 [M + 1]<sup>+</sup>; <i>t</i><sub>R</sub> = 8.44 min. GC−MS <i>m</i>/<i>z</i>: 313 [M + 1]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ: 2.18−2.39 (m, 2H), 2.41−2.47 (m, 1H), 2.76−2.79 (d, 1H), 3.07−3.12 (m, 1H), 7.25−7.38 (m, 5H), 7.50−7.52 (m, 1H), 8.01−8.02 (d, 1H).</div></div><div id="sec5_11_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> 5′,11′-Dihydro-3<i>H</i>-spiro[cyclopentane-1,10′-dibenzo[<i>a</i>,<i>d</i>]cyclohepten]-3-one (<b>8a</b>)</h3><div class="NLM_p">In a Parr apparatus, 3<i>H</i>-spiro[cyclopentane-1,10′-dibenzo[<i>a</i>,<i>d</i>]cycloheptene]-3,11′(5′<i>H</i>)-dione (<b>7a</b>, 2.200 g, 7.96 mmol) was dissolved in THF (40 mL). AcOH (10.00 mL) and wet Pd/C (10% (w/w), 50% w/w of water content) (4.24 g, 3.98 mmol) were added, and the mixture was hydrogenated (0.016 g, 7.96 mmol) under 5 atm pressure for 5 days. During this time three portions of Pd/C (2.5 g, 10% (w/w), 50% w/w of water content) were added. The palladium was then filtered over Celite and the solvent evaporated to afford the title compound (<b>8a</b>, 2.2 g) as a racemic mixture. MS (ESI) <i>m</i>/<i>z</i>: 285 [M + Na]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ: 2.24−2.32 (m, 2H), 2.51−2.62 (m, 4H), 3.09−3.16 (m, 2H), 4.11−4.21 (m, 2H), 7.04−7.35 (m, 8H).</div><div class="NLM_p last">The racemic mixture of 5′,11′-dihydro-3<i>H</i>-spiro[cyclopentane-1,10′-dibenzo[<i>a</i>,<i>d</i>]cyclohepten]-3-one (<b>8a</b>) was submitted for preparative chiral HPLC (column, Chiralpak IA (25 cm × 2.0 cm), 5 μm; bobile phase, <i>n</i>-hexane/(ethanol/methanol 50/50) 96/4% v/v; flow rate, 14 mL/min; UV, 225 nm; 19 mg/inj in CH<sub>2</sub>Cl<sub>2</sub>/ethanol/methanol/hexane) and gave two enantiomers:</div></div><div id="sec5_11_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> (−)-(1<i>R</i>)-5′,11′-Dihydro-3<i>H</i>-spiro[cyclopentane-1,10′-dibenzo[<i>a</i>,<i>d</i>]cyclohepten]-3-one (<b>8a</b>(<i>R</i>) (ent 1))</h3><div class="NLM_p last">[α]<sub class="stack">D</sub><sup class="stack">20</sup> −83° (<i>c</i> 0.88, CHCl<sub>3</sub>) (optical rotation was measured on a different batch); retention time = 12.5 min (683 mg).</div></div><div id="sec5_11_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> (+)-(1<i>S</i>)-5′,11′-Dihydro-3<i>H</i>-spiro[cyclopentane-1,10′-dibenzo[<i>a</i>,<i>d</i>]cyclohepten]-3-one (<b>8a</b>(<i>S</i>) (ent 2))</h3><div class="NLM_p last">[α]<sub class="stack">D</sub><sup class="stack">20</sup> +83° (<i>c</i> 0.93, CHCl<sub>3</sub>) (optical rotation was measured on a different batch); retention time = 14.0 min (655 mg).</div></div><div id="sec5_11_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> 3<i>H</i>,11′<i>H</i>-Spiro[cyclopentane-1,10′-dibenzo[<i>b</i>,<i>f</i>]oxepin]-3-one (<b>8c</b>)</h3><div class="NLM_p">THF (10 mL) and glacial acetic acid (5 mL) were mixed in a Paar bottle, and 2′-chloro-3<i>H</i>,11′<i>H</i>-spiro[cyclopentane-1,10′-dibenzo[b,f]oxepin]-3,11′-one (<b>7d</b>, 100 mg, 0.319 mmol) and Pd/C (100 mg) were added. The mixture was shaken in the Paar apparatus under H<sub>2</sub> atmosphere (6 bar) at room temperature for 2 days. Then the mixture was filtered through a membrane filter and evaporated. The residue was dissolved in ethyl acetate (10 mL) and washed with NaHCO<sub>3</sub> (saturated solution 3 × 15 mL). Organic layer was dried (Na<sub>2</sub>SO<sub>4</sub>/MgSO<sub>4</sub>) and evaporated to give an oil that crystallized from MeOH to give the title compound (<b>8c</b>, 91.2 mg) as a racemic mixture. GC−MS <i>m</i>/<i>z</i>: 265 [M + 1]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ: 2.33−2.49 (m, 4H), 2.62−2.66 (d, 1H), 2.74−2.78 (d, 1H), 3.07−3.18 (m, 2H), 7.02−7.27 (m, 8H).</div><div class="NLM_p last">The racemic mixture of 3<i>H</i>,11′<i>H</i>-spiro[cyclopentane-1,10′-dibenzo[<i>b</i>,<i>f</i>]oxepin]-3-one (<b>8c</b>, 550 mg) was submitted for preparative chiral HPLC (column = Chiralcel OJ-H; mobile phase = <i>n</i>-hexane/isopropanol 88/12; flow rate =14 mL/min; UV, 225 nm; 25 mg/inj) and gave two enantiomers:</div></div><div id="sec5_11_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> 3<i>H</i>,11′<i>H</i>-Spiro[cyclopentane-1,10′-dibenzo[<i>b</i>,<i>f</i>]oxepin]-3-one (<b>8c</b> (ent 1))</h3><div class="NLM_p last">Retention time = 17.1 min (171 mg).</div></div><div id="sec5_11_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> 3<i>H</i>,11′<i>H</i>-Spiro[cyclopentane-1,10′-dibenzo[<i>b</i>,<i>f</i>]oxepin]-3-one (<b>8c</b> (ent 2))</h3><div class="NLM_p last">Retention time = 19.7 min (180 mg).</div></div><div id="sec5_11_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> (1<i>S</i>)-<i>N</i>,<i>N</i>-Dimethyl-5′,11′-dihydrospiro[cyclopentane-1,10′-dibenzo[<i>a</i>,<i>d</i>]cyclohepten]-3-amine (<b>9a</b>)</h3><div class="NLM_p">Dimethylamine (2.0 M in THF, 0.09 mL, 0.172 mmol, 1.5 equiv) and (+)-(1<i>S</i>)-5′,11′-dihydro-3<i>H</i>-spiro[cyclopentane-1,10′-dibenzo[<i>a</i>,<i>d</i>]cyclohepten]-3-one (<b>8a</b>(<i>S</i>), 30 mg, 0.115) were mixed in DCE and glacial acetic acid (2 drops). After 20 min at room temperature NaBH(OAc)<sub>3</sub> (29 mg, 0.137 mmol, 1.2 equiv) was added and the resulting reaction mixture was stirred at room temperature from 6 h. The workup was done by adding NaHCO<sub>3</sub> (saturated solution) and then by extracting with DCM. Products were purified by silica gel column chromatography.</div><div class="NLM_p">The reaction mixture was quenched with NaHCO<sub>3</sub> (saturated aqueous solution) and extracted with dichloromethane. The organic layers were combined, dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated in vacuo. The crude product was purified by SCX, affording the title compound (<b>9</b>, 21 mg) as a mixture of diastereoisomers (∼85/15).</div><div class="NLM_p last">This diastereomeric mixture was submitted for chiral HPLC purification (preparative SFC chromatographic conditions: column, Chiralcel OD-H, 25 cm × 2.0 cm; pressure, 172 bar; flow rate, 22 mL/min; UV detection, CD 220 nm; modifier, ethanol + 0.1% isopropylamine 10%) to give two diastereoisomers:</div></div><div id="sec5_11_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> (1<i>S</i>,3<i>R</i>)-<i>N</i>,<i>N</i>-Dimethyl-5′,11′-dihydrospiro[cyclopentane-1,10′-dibenzo[<i>a</i>,<i>d</i>]cyclohepten]-3-amine (<b>9′a</b>)</h3><div class="NLM_p last">Retention time = 14.05 min (5.1 mg). <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ: 1.87−2.22 (m, 6H), 2.33 (s, 6H), 2.84 (m, 1H), 3.15 (d, 1H), 3.27 (d, 1H), 4.04 (d, 1H), 4.25 (d, 1H), 7.01−7.32 (m, 8H).</div></div><div id="sec5_11_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> (1<i>S</i>,3<i>S</i>)-<i>N</i>,<i>N</i>-Dimethyl-5′,11′-dihydrospiro[cyclopentane-1,10′-dibenzo[<i>a</i>,<i>d</i>]cyclohepten]-3-amine (<b>9′′a</b>)</h3><div class="NLM_p last">Retention time = 17.39 min (1.9 mg). <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ: 1.85−2.27 (m, 6H), 2.36 (s, 6H), 2.89 (m, 1H), 3.07 (d, 1H), 3.19 (d, 1H), 4.07 (d, 1H), 4.23 (d, 1H), 7.03−7.25 (m, 7H), 7.43−7.49 (m, 1H).</div></div><div id="sec5_11_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> Methyl 1-((1<i>R</i>)-5′,11′-Dihydrospiro[cyclopentane-1,10′-dibenzo[<i>a</i>,<i>d</i>]cyclohepten]-3-yl)-1,2,5,6-tetrahydro-3-pyridinecarboxylate (<b>12</b>)</h3><div class="NLM_p last">To a solution of (−)-(1<i>R</i>)-5′,11′-dihydro-3<i>H</i>-spiro[cyclopentane-1,10′-dibenzo[<i>a</i>,<i>d</i>]cyclohepten]-3-one (<b>8a</b>(<i>R</i>), 60 mg, 0.229 mmol) in 1,2-DCE (2 mL) were added methyl 1,2,5,6-tetrahydro-3-pyridinecarboxylate (40.6 mg, 0.229 mmol) and DIPEA (0.044 mL, 0.252 mmol). After the mixture was stirred for 10 min at room temperature, AcOH (2 drops) and NaBH(OAc)<sub>3</sub> (72.7 mg, 0.343 mmol) were added. The reaction mixture was stirred at room temperature overnight. The mixture was washed with saturated aqueous NaHCO<sub>3</sub> solution and then brine. The layers were separated and the organic layer was evaporated under vacuum to afford a yellow oil, which was dissolved in methanol and purified using a 1 g SCX cartridge (eluting first with MeOH and then 2 M NH<sub>3</sub> in MeOH). Evaporation of the solvent gave the title product (<b>12</b>, 55 mg) as a mixture of diastereoisomers as yellow foam. UPLC/MS <i>R<sub>f</sub></i> = 0.63; <i>m</i>/<i>z</i> (ES) 388.1 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ: 6.95−7.37 (m, 9H), 4.15−4.31 (m, 1H), 3.92−4.13 (m, 1H), 3.65−3.85 (m, 3H), 2.99−3.47 (m, 5H), 2.52−2.75 (m, 2H), 1.79−2.51 (m, 8H).</div></div><div id="sec5_11_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> Methyl 1-((1<i>S</i>)-5′,11′-Dihydrospiro[cyclopentane-1,10′-dibenzo[<i>a</i>,<i>d</i>]cyclohepten]-3-yl)-1,2,5,6-tetrahydro-3-pyridinecarboxylate (<b>13</b>)</h3><div class="NLM_p">To a solution of (+)-(1<i>S</i>)-5′,11′-dihydro-3<i>H</i>-spiro[cyclopentane-1,10′-dibenzo[<i>a</i>,<i>d</i>]cyclohepten]-3-one, (<b>8a</b>(<i>S</i>),100 mg, 0.38 mmol) in 1,2-dichloroethane (5 mL) were added methyl 1,2,5,6-tetrahydro-3-pyridinecarboxylate hydrochloride (67.7 mg, 0.381 mmol) and DIPEA (0.073 mL, 0.419 mmol). After the mixture was stirred for 10 min at room temperature, AcOH (0.044 mL, 0.762 mmol) and NaBH(OAC)<sub>3</sub> (121 mg, 0.572 mmol) were added. The reaction mixture was stirred at room temperature overnight. Further guvacine methyl esther hydrocloride (0.3 equiv) and NaBH(OAC)<sub>3</sub> (0.5 equiv) were added, and the mixture was stirred for an additional 4 h. The mixture was washed with saturated aqueous NaHCO<sub>3</sub> solution, then brine, and the organic phase was separated and concentrated under vacuum. The crude product was purified using a SCX cartridge, eluting first with DCM, second with MeOH, and third with NH<sub>3</sub> in MeOH (2 M). After solvent evaporation the desired compound (<b>13</b>, 94 mg) was obtained as mixture of diastereoisomers (∼85/15). UPLC/MS <i>R<sub>f</sub></i> = 0.66; <i>m</i>/<i>z</i> (ES) 388.2 [M + H]<sup>+</sup>.</div><div class="NLM_p last">The diastereomeric mixture of methyl 1-(5′,11′-dihydrospiro[cyclopentane-1,10′-dibenzo[<i>a</i>,<i>d</i>]cyclohepten]-3-yl)-1,2,5,6-tetrahydro-3-pyridinecarboxylate (<b>13</b>, 94 mg) was submitted for chiral HPLC purification (preparative chromatographic conditions: column = Chiralcel OD-H; mobile phase = <i>n</i>-hexane/ethanol 75/25% v/v; flow rate = 0.8 mL/min; DAD = 210−340 nm; CD = 225 nm) to give <b>13′</b> and <b>13′′</b>.</div></div><div id="sec5_11_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> Methyl 1-((1<i>S</i>)-5′,11′-Dihydrospiro[cyclopentane-1,10′-dibenzo[<i>a</i>,<i>d</i>]cyclohepten]-3-yl)-1,2,5,6-tetrahydro-3-pyridinecarboxylate (<b>13′</b>)</h3><div class="NLM_p last">Retention time = 8 min (70 mg). <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ: 6.98−7.37 (m, 9H), 4.27 (d, 2H), 4.02 (d, 2H), 3.72−3.79 (m, 3H), 3.36−3.45 (m, 1H), 3.21−3.34 (m, 2H), 3.05−3.19 (m, 2H), 2.55−2.73 (m, 2H), 2.34−2.50 (m, 2H), 2.20−2.33 (m, 2H), 2.08−2.19 (m, 1H), 1.80−2.05 (m, 3H).</div></div><div id="sec5_11_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> Methyl 1-((1<i>S</i>)-5′,11′-Dihydrospiro[cyclopentane-1,10′-dibenzo[<i>a</i>,<i>d</i>]cyclohepten]-3-yl)-1,2,5,6-tetrahydro-3-pyridinecarboxylate (<b>13′′</b>)</h3><div class="NLM_p last">Retention time = 10 min (11 mg). <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ: 7.39−7.52 (m, 1H), 7.09−7.27 (m, 6H), 6.99−7.09 (m, 2H), 4.24 (d, 1H), 4.06 (d, 1H), 3.75 (s, 3H), 3.01−3.40 (m, 5H), 2.54−2.74 (m, 2H), 2.25−2.46 (m, 2H), 1.87−2.19 (m, 4H).</div></div><div id="sec5_11_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> Ethyl 1-((1<i>S</i>)-5′,11′-Dihydrospiro[cyclopentane-1,10′-dibenzo[<i>a</i>,<i>d</i>]cyclohepten]-3-yl)-4-piperidinecarboxylate (<b>16</b>)</h3><div class="NLM_p">To a solution of (+)-(1<i>S</i>)-5′,11′-dihydro-3<i>H</i>-spiro[cyclopentane-1,10′-dibenzo[<i>a</i>,<i>d</i>]cyclohepten]-3-one (<b>8a</b>(<i>S</i>), 74 mg, 0.27 mmol) and ethyl isonipecotate (0.082 mL, 0.534 mmol) in 1,2-dichloroethane (4 mL) was added AcOH (2 drops). The reaction mixture was stirred at room temperature for 1 h, and then NaBH(OAC)<sub>3</sub> (85 mg, 0.400 mmol) was added. The resulting mixture was stirred overnight. The mixture was diluted with DCM and washed with a saturated solution of NaHCO<sub>3</sub>, brine. The phases were separated, and the organic layer was concentrated under vacuum. The crude mixture was purified by passing through a 12 g Si-redisep cartridge (eluting with cHex/EtOAc, from 100:0 to 80:20) to afford the title compound (<b>16</b>, 82 mg) as mixture of two diastereoisomers. UPLC/MS <i>R<sub>f</sub></i> = 0.63; <i>m</i>/<i>z</i> (ES) 404.2 [M + H]<sup>+</sup>.</div><div class="NLM_p last">This diastereomeric mixture of ethyl 1-(5′,11′-dihydrospiro[cyclopentane-1,10′-dibenzo[<i>a</i>,<i>d</i>]cyclohepten]-3-yl)-4-piperidinecarboxylate (<b>16</b>) was submitted for chiral chromatography purification (preparative chromatographic conditions: column = Chiralcel OD-H; mobile phase = <i>n</i>-hexane/isopropanol 85/15% v/v; flow rate = 1 mL/min; DAD = 210−340 nm; CD = 225 nm) to give <b>16′</b>.</div></div><div id="sec5_11_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> Ethyl 1-((1<i>S</i>)-5′,11′-Dihydrospiro[cyclopentane-1,10′-dibenzo[<i>a</i>,<i>d</i>]cyclohepten]-3-yl)-4-piperidinecarboxylate (<b>16′</b>)</h3><div class="NLM_p last">Only the major diastereoisomer was isolated: retention time = 7 min (60 mg). <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ: 6.84−7.48 (m, 8H), 3.86−4.40 (m, 3H), 2.74−3.44 (m, 4H), 1.62−2.48 (m, 15H), 1.16−1.39 (m, 3H).</div></div><div id="sec5_11_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> Ethyl 1-((1<i>S</i>)-5′,11′-Dihydrospiro[cyclopentane-1,10′-dibenzo[<i>a</i>,<i>d</i>]cyclohepten]-3-yl)-4-fluoro-4-piperidinecarboxylate (<b>19</b>)</h3><div class="NLM_p">To a solution of (+)-(1<i>S</i>)-5′,11′-dihydro-3<i>H</i>-spiro[cyclopentane-1,10′-dibenzo[<i>a</i>,<i>d</i>]cyclohepten]-3-one (<b>8a</b>(<i>S</i>), 58 mg, 0.221 mmol) and ethyl 4-fluoro-4-piperidinecarboxylate (prepared as described in WO/2002/032893<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a>) (58.1 mg, 0.332 mmol) in 1,2-dichloroethane (3 mL) was added a drop of AcOH. The reaction mixture was stirred at room temperature for 0.5 h, and then NaBH(OAC)<sub>3</sub> (70.3 mg, 0.332 mmol) was added. The resulting reaction mixture was stirred for 3 h, quenched with NaHCO<sub>3</sub> (saturated aqueous solution), and extracted with dichloromethane. The organic layers were combined, dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated in vacuo. The crude product was purified by flash chromatography on silica gel (20 g), eluting with a gradient of dichloromethane/methanol 99.5/0.5 to 99/1 to afford the title compound (<b>19</b>, 30 mg) as a mixture of diastereoisomers (∼10/90).</div><div class="NLM_p last">This diastereomeric mixture was submitted for chiral HPLC purification (preparative chromatographic conditions: column = Chiralcel OJ-H; mobile phase = <i>n</i>-hexane/EtOH 85/15% v/v; flow rate = 0.8 mL/min; DAD = 210−340 nm; CD = 225 nm) to give <b>19′</b>.</div></div><div id="sec5_11_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> Ethyl 1-((1<i>S</i>)-5′,11′-Dihydrospiro[cyclopentane-1,10′-dibenzo[<i>a</i>,<i>d</i>]cyclohepten]-3-yl)-4-fluoro-4-piperidinecarboxylate (<b>19′</b>)</h3><div class="NLM_p last">Only the major diastereoisomer was isolated: retention time = 21.9 min (21 mg). UPLC/MS <i>R<sub>f</sub></i> = 0.70; <i>m</i>/<i>z</i> (ES) 422.2 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ: 7.31−7.32 (m, 1H), 7.14−7.21 (m, 6H), 7.00−7.08 (m, 1H), 4.20−4.35 (m, 3H), 4.02 (d, 1H), 3.31 (d, 1H), 3.12 (d, 1H), 2.97−3.08 (m, 2H), 2.74−2.90 (m, 1H), 1.78−2.49 (m, 12H), 1.34 (t, 3H).</div></div><div id="sec5_11_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> Ethyl 3-((1<i>S</i>)-5′,11′-Dihydrospiro[cyclopentane-1,10′-dibenzo[<i>a</i>,<i>d</i>]cyclohepten]-3-yl)-3-azabicyclo[3.1.0]hexane-1-carboxylate (<b>29</b>)</h3><div class="NLM_p">To a solution of (+)-(1<i>S</i>)-5′,11′-dihydro-3<i>H</i>-spiro[cyclopentane-1,10′-dibenzo[<i>a</i>,<i>d</i>]cyclohepten]-3-one (<b>8a</b>(<i>S</i>), 70 mg, 0.267 mmol) and ethyl 3-azabicyclo[3.1.0]hexane-1-carboxylate (83 mg, 0.534 mmol, for preparation see WO/2007/055093<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a>) in 1,2-dichloroethane (5 mL) under nitrogen was added AcOH (2 drops). The reaction mixture was stirred at room temperature for 1 h 30 min, and then NaBH(OAC)<sub>3</sub> (85 mg, 0.400 mmol) was added. The resulting mixture was stirred overnight. The mixture was diluted with DCM. The organic phase was then washed with saturated solution of NaHCO<sub>3</sub>, then brine and concentrated under vacuum. The crude product was purified through Si-redisep cartridge (12 g), eluting with cHex/EtOAc (from 100:0 to 80:20) to afford the title compound (<b>29</b>, 82 mg) as a mixture of two diastereoisomeric racemates. UPLC/MS <i>R<sub>f</sub></i> = 0.67; <i>m</i>/<i>z</i> (ES) 402.2 [M + H]<sup>+</sup>.</div><div class="NLM_p last">This mixture was submitted for chiral HPLC separation (preparative chromatographic conditions: column = Chiralcel OJ-H; mobile phase = <i>n</i>-hexane/ethanol/isopropanol 96/2/2% v/v′; flow rate = 1 mL/min; DAD = 210−340 nm; CD = 225 nm) to obtain <b>29′′</b> isomer 1 and <b>29′′</b> isomer 2; minor isomers were not characterized.</div></div><div id="sec5_11_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60"> Ethyl 3-((1<i>S</i>)-5′,11′-Dihydrospiro[cyclopentane-1,10′-dibenzo[<i>a</i>,<i>d</i>]cyclohepten]-3-yl)-3-azabicyclo[3.1.0]hexane-1-carboxylate (<b>29′</b> Isomer 1)</h3><div class="NLM_p last">Retention time = 13.62 min (28 mg). <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ: 7.29−7.34 (m, 1 H), 7.08−7.24 (m, 6 H), 7.00−7.07 (m, 1 H), 4.22 (d, 1 H), 4.14 (q, 2 H), 4.04 (d, 1 H), 3.21−3.29 (m, 1 H), 3.08−3.16 (m, 3 H), 2.96−3.06 (m, 1 H), 2.68 (d, 1 H), 2.41−2.51 (m, 1 H), 1.77−2.15 (m, 7 H), 1.44−1.51 (m, 1 H), 1.29−1.37 (m, 1 H), 1.25 (t, 3 H).</div></div><div id="sec5_11_29" class="NLM_sec NLM_sec_level_2"><div id="ac_i61" class="anchor-spacer"></div><h3 class="article-section__title" id="_i61"> Ethyl 3-((1<i>S</i>)-5′,11′-Dihydrospiro[cyclopentane-1,10′-dibenzo[<i>a</i>,<i>d</i>]cyclohepten]-3-yl)-3-azabicyclo[3.1.0]hexane-1-carboxylate (<b>29′</b> Isomer 2)</h3><div class="NLM_p last">Retention time = 17.76 min (26 mg). <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ: 7.26−7.32 (m, 1 H), 7.08−7.25 (m, 6 H), 6.98−7.07 (m, 1 H), 4.12−4.26 (m, 3 H), 4.05 (d, 1 H), 3.21−3.29 (m, 2 H), 3.14 (d, 1 H), 2.97−3.07 (m, 2 H), 2.78 (d, 1 H), 2.33−2.42 (m, 1 H), 1.80−2.13 (m, 7 H), 1.43−1.54 (m, 1 H), 1.33−1.39 (m, 1 H), 1.28 (t, 3 H).</div></div><div id="sec5_11_30" class="NLM_sec NLM_sec_level_2"><div id="ac_i62" class="anchor-spacer"></div><h3 class="article-section__title" id="_i62"> Methyl 1-((1<i>S</i>)-5′,11′-Dihydrospiro[cyclopentane-1,10′-dibenzo[<i>a</i>,<i>d</i>]cyclohepten]-3-yl)-3-azetidinecarboxylate (<b>30</b>)</h3><div class="NLM_p">A mixture of (+)-(1<i>S</i>)-5′,11′-dihydro-3<i>H</i>-spiro[cyclopentane-1,10′-dibenzo[<i>a</i>,<i>d</i>]cyclohepten]-3-one (<b>8a</b>(<i>S</i>), 5.45 g, 20.77 mmol) and methyl 3-azetidinecarboxylate hydrochloride (3.78 g, 24.9 mmol) in dry DCM (25 mL) was stirred for 15 min. NaBH(OAC)<sub>3</sub> (8.81 g, 41.5 mmol) was then added and the reaction mixture stirred overnight, quenched with NaHCO<sub>3</sub> (saturated aqueous solution), and extracted with dichloromethane. The organic layers were combined, dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated in vacuo. The crude product was purified by flash chromatography on silica gel, eluting with a gradient of MeOH in dichloromethane (from 0% to 3%) to afford the title compound (<b>30</b>, 6.7 g) as a mixture of two diastereoisomers. UPLC/MS <i>R<sub>f</sub></i> = 0.61; <i>m</i>/<i>z</i> (ES) 362.11 [M + H]<sup>+</sup>.</div><div class="NLM_p last">The diastereomeric mixture (<b>30</b>, 4.5 g) was submitted for chiral HPLC purification (semipreparative SFC conditions: column = Chiralcel OD-H; modifier = ethanol 15%; flow rate = 2.5 mL/min; pressure = 120 bar; temperature = 38 °C; detector = 220 nm) to give two single diastereoisomers, but only the major distereoisomer was characterized:</div></div><div id="sec5_11_31" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63"> Methyl 1-((1<i>S</i>)-5′,11′-Dihydrospiro[cyclopentane-1,10′-dibenzo[<i>a</i>,<i>d</i>]cyclohepten]-3-yl)-3-azetidinecarboxylate (<b>30′</b>)</h3><div class="NLM_p last">Retention time = 4.9 min (2.62 g). <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ: 7.30−7.02 (m, 8 H), 4.13 (q, 2 H), 3.75 (s, 3 H), 3.63−3.57 (m, 2 H), 3.39−3.08 (m, 6 H), 2.15−1.65 (m, 6 H).</div></div><div id="sec5_11_32" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> Methyl 1-(11′<i>H</i>-Spiro[cyclopentane-1,10′-dibenzo[<i>b</i>,<i>f</i>]oxepin]-3-yl)-1,2,3,6-tetrahydro-4-pyridinecarboxylate (<b>34</b>)</h3><div class="NLM_p">To 3<i>H</i>,11′<i>H</i>-spiro[cyclopentane-1,10′-dibenzo[<i>b</i>,<i>f</i>]oxepin]-3-one (<b>8c</b>,100 mg, 0.378 mmol) in DCE (5 mL) were added methyl 1,2,3,6-tetrahydro-4-pyridinecarboxylate (81 mg, 0.574 mmol) HCl salt and DIPEA (0.066 mL, 0.378 mmol). After the mixture was stirred for 10 min, sodium triacetoxyborohydride (120 mg, 0.567 mmol) and acetic acid (2 drops) were added. The mixture was left stirring overnight. The reaction was quenched with NaHCO<sub>3</sub>. The organic layer was separated and the water phase extracted with DCM. The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub> and the solvent was evaporated to give the title compound (<b>34</b>, 150 mg) as a mixture of two diastereoisomeric racemates. <i>m</i>/<i>z</i> (ES): 390.2 [M + H]<sup>+</sup>.</div><div class="NLM_p last">This mixture was submitted for chiral HPLC separation (preparative chromatographic conditions: column = Chiralcel OJ-H; mobile phase = <i>n</i>-hexane/(ethanol + 0.1% isopropylamine) 93/7% v/v; flow rate = 14 mL/min; DAD = 225 nm) to give <b>34′</b> isomer 1 and <b>34′</b> isomer 2 (the minor isomers were not characterized).</div></div><div id="sec5_11_33" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65"> Methyl 1-(11′<i>H</i>-Spiro[cyclopentane-1,10′-dibenzo[<i>b</i>,<i>f</i>]oxepin]-3-yl)-1,2,3,6-tetrahydro-4-pyridinecarboxylate (<b>34′</b>, Isomer 1)</h3><div class="NLM_p last">Retention time = 17.23 min (28 mg). <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ: 7.26−7.32 (m, 1 H), 7.00−7.25 (m, 7 H), 6.87−6.94 (m, 1 H), 3.76 (s, 3 H), 3.05−3.32 (m, 4 H), 2.85−2.99 (m, 1 H), 2.59−2.71 (m, 2 H), 2.38−2.52 (m, 3 H), 2.14 (d, 5 H).</div></div><div id="sec5_11_34" class="NLM_sec NLM_sec_level_2"><div id="ac_i66" class="anchor-spacer"></div><h3 class="article-section__title" id="_i66"> Methyl 1-(11′<i>H</i>-Spiro[cyclopentane-1,10′-dibenzo[<i>b</i>,<i>f</i>]oxepin]-3-yl)-1,2,3,6-tetrahydro-4-pyridinecarboxylate (<b>34′</b>, Isomer 2)</h3><div class="NLM_p last">Retention time = 26.42 min (27 mg). <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ: 7.27−7.33 (m, 1 H), 7.01−7.24 (m, 7 H), 6.87−6.95 (m, 1 H), 3.76 (s, 3 H), 3.06−3.31 (m, 4 H), 2.83−2.99 (m, 1 H), 2.60−2.70 (m, 2 H), 2.38−2.51 (m, 3 H), 2.14 (s, 5 H).</div></div><div id="sec5_11_35" class="NLM_sec NLM_sec_level_2"><div id="ac_i67" class="anchor-spacer"></div><h3 class="article-section__title" id="_i67"> Methyl 1-(11′<i>H</i>-Spiro[cyclopentane-1,10′-dibenzo[<i>b</i>,<i>f</i>]oxepin]-3-yl)-3-azetidinecarboxylate (<b>38</b>)</h3><div class="NLM_p">3<i>H</i>,11′<i>H</i>-Spiro[cyclopentane-1,10′-dibenzo[b,f]oxepin]-3-one (<b>8c</b> (ent 2), 70 mg, 0.265 mmol) and methyl 3-azetidinecarboxylate hydrochloride (48.2 mg, 0.318 mmol) in acetonitrile (4 mL) were stirred under nitrogen to give a colorless solution. After the mixture was stirred for 30 min at room temperature, NaBH(OAC)<sub>3</sub> (84 mg, 0.397 mmol) was added. The mixture was stirred overnight. Water was added. The solution was concentrated under reduced pressure and the aqueous layer extracted with DCM. The phases were separated on a hydrophobic frit, and the combined organic solvent was evaporated. The product was purified using a NH<sub>2</sub> 5 g column, eluting with EtOAc/cyclohexane 1:9 to give the title compound (<b>38</b>, 85 mg) as a mixture of two diastereoisomers. UPLC/MS <i>R<sub>f</sub></i> = 0.65; <i>m</i>/<i>z</i> (ES) 364.06 [M + H]<sup>+</sup>.</div><div class="NLM_p last">The diastereomeric mixture (<b>38</b>) was submitted for chiral HPLC purification (semipreparative chiral SFC conditions: column = Chiralpak AD-H; modifier = ethanol + 0.1% isopropylamine, 10%; flow rate = 52 mL/min; pressure = 120 bar; temperature = 38 °C; DAD = 220 nm) to give <b>38′</b> (only the major diastereoisomer was characterized).</div></div><div id="sec5_11_36" class="NLM_sec NLM_sec_level_2"><div id="ac_i68" class="anchor-spacer"></div><h3 class="article-section__title" id="_i68"> Methyl 1-(11′<i>H</i>-Spiro[cyclopentane-1,10′-dibenzo[<i>b</i>,<i>f</i>]oxepin]-3-yl)-3-azetidinecarboxylate (<b>38′</b>)</h3><div class="NLM_p last">Retention time = 7.0 min (19 mg). <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ: 7.29−7.00 (m, 8 H), 3.73 (s, 3 H), 3.58−2.94 (m, 8 H), 2.21−1.58 (m, 6 H).</div></div><div id="sec5_11_37" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69"> 1-((1<i>R</i>)-5′,11′-Dihydrospiro[cyclopentane-1,10′-dibenzo[<i>a</i>,<i>d</i>]cyclohepten]-3-yl)-1,2,5,6-tetrahydro-3-pyridinecarboxylic Acid Hydrochloride Salt (<b>45</b>)</h3><div class="NLM_p last">To a solution of methyl 1-((1<i>R</i>)-5′,11′-dihydrospiro[cyclopentane-1,10′-dibenzo[<i>a</i>,<i>d</i>]cyclohepten]-3-yl)-1,2,5,6-tetrahydro-3-pyridinecarboxylate (<b>12</b>, 55 mg, 0.142 mmol) in methanol/water 3:1 (2.4 mL) was added LiOH (16.99 mg, 0.710 mmol), and the reaction mixture was left to stir for 4 h. Further LiOH (17 mg, 0.71 mmol) was added, and the mixture was left to stir overnight. The organic solvent was evaporated under vacuum and the aqueous phase washed with DCM. The reaction mixture was slowly acidified with 3 N HCl, checking the pH of the solution. A white precipitate formed at pH 1. The solid was filtered and dried under vacuum. The solid was triturated from EtOAc to give the title compound (<b>45</b>, 41 mg). UPLC/MS <i>R<sub>f</sub></i> = 0.62; <i>m</i>/<i>z</i> (ES) 374.3 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ: 6.95−7.37 (m, 9H), 4.15−4.31 (m, 1H), 3.92−4.13 (m, 1H), 3.65−3.85 (m, 3H), 2.99−3.47 (m, 5H), 2.52−2.75 (m, 2H), 1.79−2.51 (m, 8H).</div></div><div id="sec5_11_38" class="NLM_sec NLM_sec_level_2"><div id="ac_i70" class="anchor-spacer"></div><h3 class="article-section__title" id="_i70"> Methyl 1-((1<i>S</i>)-5′,11′-Dihydrospiro[cyclopentane-1,10′-dibenzo[<i>a</i>,<i>d</i>]cyclohepten]-3-yl)-1,2,5,6-tetrahydro-3-pyridinecarboxylate (<b>46</b>)</h3><div class="NLM_p last">Methyl 1-((1<i>S</i>)-5′,11′-dihydrospiro[cyclopentane-1,10′-dibenzo[<i>a</i>,<i>d</i>]cyclohepten]-3-yl)-1,2,5,6-tetrahydro-3-pyridinecarboxylate (<b>13</b>, 66 mg, 0.17 mmol) was dissolved in methanol (1.8 mL)/water (0.6 mL), and LiOH (20.39 mg, 0.852 mmol) was added. The reaction mixture was left under stirring overnight. Methanol was evaporated under vacuum and the aqueous phase washed with DCM. The aqueous phase was acidified with 3 N HCl, checking the pH of the solution (until pH 1), but only a few milligrams of the desired compound precipitated. The compound was retained by the organic phase (DCM). Solvent was removed to give the title compound (<b>46</b>, 25 mg) as free base. UPLC/MS <i>R<sub>f</sub></i> = 0.63; <i>m</i>/<i>z</i> (ES) 374.17 [M + H]<sup>+</sup>. Data reported for the major diastereoisomer: <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ 7.30−7.40 (m, 1H), 7.09−7.22 (m, 5H), 6.96−7.07 (m, 2H), 3.97−4.24 (m, 2H), 3.59−3.85 (m, 2H), 3.44−3.56 (m, 1H), 3.14−3.37 (m, 2H), 2.92−3.09 (m, 2H), 1.84−2.75 (m, 5H).</div></div><div id="sec5_11_39" class="NLM_sec NLM_sec_level_2"><div id="ac_i71" class="anchor-spacer"></div><h3 class="article-section__title" id="_i71"> 1-((1<i>S</i>)-5′,11′-Dihydrospiro[cyclopentane-1,10′-dibenzo[<i>a</i>,<i>d</i>]cyclohepten]-3-yl)-1,2,5,6-tetrahydro-3-pyridinecarboxylic Acid (<b>47</b>)</h3><div class="NLM_p last">To a solution of methyl 1-((1<i>S</i>)-5′,11′-dihydrospiro[cyclopentane-1,10′-dibenzo[<i>a</i>,<i>d</i>]cyclohepten]-3-yl)-1,2,5,6-tetrahydro-3-pyridinecarboxylate (<b>13′</b>, 70 mg, 0.181 mmol) in methanol (6 mL) and water (1 mL) was added LiOH (21.63 mg, 0.903 mmol). The reaction mixture was left to stir at room temperature overnight. Further LiOH (1.2 equiv) and water (0.5 mL) were added, and the resulting mixture was stirred at 40 °C for 6 h. The methanol was then evaporated under vacuum, and the reaction mixture was acidified with 3 N HCl (until pH ∼ 1). This solution was purified using an HLB cartridge (5 g) by eluting first with water and then MeOH to give the title compound (<b>47</b>, 56 mg). UPLC/MS <i>R<sub>f</sub></i> = 0.61; <i>m</i>/<i>z</i> (ES) 374.2 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ: 7.30−7.40 (m, 1H), 7.09−7.22 (m, 5H), 6.96−7.07 (m, 2H), 3.97−4.24 (m, 2H), 3.59−3.85 (m, 2H), 3.44−3.56 (m, 1H), 3.14−3.37 (m, 2H), 2.92−3.09 (m, 2H), 1.84−2.75 (m, 5H).</div></div><div id="sec5_11_40" class="NLM_sec NLM_sec_level_2"><div id="ac_i72" class="anchor-spacer"></div><h3 class="article-section__title" id="_i72"> 1-((1<i>S</i>)-5′,11′-Dihydrospiro[cyclopentane-1,10′-dibenzo[<i>a</i>,<i>d</i>]cyclohepten]-3-yl)-1,2,5,6-tetrahydro-3-pyridinecarboxylic Acid (<b>48</b>)</h3><div class="NLM_p last">To a solution of methyl 1-((1<i>S</i>)-5′,11′-dihydrospiro[cyclopentane-1,10′-dibenzo[<i>a</i>,<i>d</i>]cyclohepten]-3-yl)-1,2,5,6-tetrahydro-3-pyridinecarboxylate (<b>13′′</b>, 11 mg, 0.028 mmol) in methanol (1.5 mL) and water (0.15 mL) was added LiOH (3.40 mg, 0.142 mmol). The reaction mixture was left to stir overnight at room temperature and then at 40 °C for 4 h. The methanol was evaporated under vacuum, and the reaction mixture was acidified with 3 N HCl, checking the pH of the solution (until pH 1). This solution was purified using an HLB cartridge (2 g) by eluting first with water and then MeOH to give the title compound (<b>48</b>, 5.8 mg). UPLC/MS <i>R<sub>f</sub></i> = 0.61; <i>m</i>/<i>z</i> (ES) 374.2 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ: 7.47−7.73 (m, 1 H), 6.86−7.33 (m, 8 H), 3.98−4.28 (m, 2 H), 3.60−3.96 (m, 3 H), 2.85−3.36 (m, 4 H), 1.86−2.74 (m, 7 H), 1.10−1.39 (m, 2 H).</div></div><div id="sec5_11_41" class="NLM_sec NLM_sec_level_2"><div id="ac_i73" class="anchor-spacer"></div><h3 class="article-section__title" id="_i73"> (−)-1-((1<i>S</i>)-5′,11′-Dihydrospiro[cyclopentane-1,10′-dibenzo[<i>a</i>,<i>d</i>]cyclohepten]-3-yl)-4-piperidinecarboxylic Acid (<b>51</b>)</h3><div class="NLM_p last">LiOH (17.80 mg, 0.743 mmol) was added to a solution of ethyl 1-((1<i>S</i>)-5′,11′-dihydrospiro[cyclopentane-1,10′-dibenzo[<i>a</i>,<i>d</i>]cyclohepten]-3-yl)-4-piperidinecarboxylate (<b>16′</b>, 60 mg, 0.149 mmol) in ethanol (5 mL) and water (1 mL). The reaction mixture was left to stir at 70 °C for 4 h, overnight at room temperature, and then at 70 °C for further for 3 h. The ethanol was evaporated under vacuum, and the mixture was acidified with 3 N HCl (until pH 1 was reached). The solution was purified using an HLB cartridge (6 g) by eluting first with water and then MeOH to afford the title compound (<b>51</b>, 55 mg). [α]<sub class="stack">D</sub><sup class="stack">20</sup> −18.6° (<i>c</i> 0.63, MeOH) (optical rotation was measured on a different batch and for the HCl salt). UPLC/MS <i>R<sub>f</sub></i> = 0.62; <i>m</i>/<i>z</i> (ES) 376.2 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ: 7.30−7.44 (m, 1 H), 6.99−7.23 (m, 7 H), 3.95−4.25 (m, 2 H), 3.14−3.71 (m, 6 H), 1.80−2.70 (m, 12 H).</div></div><div id="sec5_11_42" class="NLM_sec NLM_sec_level_2"><div id="ac_i74" class="anchor-spacer"></div><h3 class="article-section__title" id="_i74"> 1-((1<i>S</i>)-5′,11′-Dihydrospiro[cyclopentane-1,10′-dibenzo[<i>a</i>,<i>d</i>]cyclohepten]-3-yl)-4-fluoro-4-piperidinecarboxylic Acid (<b>54</b>)</h3><div class="NLM_p last">To a solution of ethyl 1-((1<i>S</i>)-5′,11′-dihydrospiro[cyclopentane-1,10′-dibenzo[<i>a</i>,<i>d</i>]cyclohepten]-3-yl)-4-fluoro-4-piperidinecarboxylate (<b>19′</b>, 21 mg, 0.050 mmol) in THF (1.5 mL) and water (0.5 mL) was added LiOH (4.77 mg, 0.199 mmol), and the mixture was heated under reflux for 4 h. The solvent was concentrated at reduced pressure, and the residue was dissolved in water and then neutralized with HCl (1 M). This mixture was purified by C18 column (10 g) to give the title compound (<b>54</b>, 14 mg) as a white solid. UPLC/MS <i>R<sub>f</sub></i> = 0.64; <i>m</i>/<i>z</i> (ES) 394.2 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (500 MHz, chloroform-<i>d</i>) δ: 7.00−7.40 (m, 8 H), 4.15 (d, 1 H), 4.06 (d, 1 H), 3.71−3.85 (m, 1 H), 3.51−3.70 (m, 1 H), 3.29−3.44 (m, 1 H), 3.31 (d, 1 H), 3.17 (d, 1 H), 2.84−3.03 (m, 2 H), 2.49−2.83 (m, 4 H), 2.11−2.36 (m, 5 H), 1.79−2.00 (m, 1 H).</div></div><div id="sec5_11_43" class="NLM_sec NLM_sec_level_2"><div id="ac_i75" class="anchor-spacer"></div><h3 class="article-section__title" id="_i75"> 3-((1<i>S</i>)-5′,11′-Dihydrospiro[cyclopentane-1,10′-dibenzo[<i>a</i>,<i>d</i>]cyclohepten]-3-yl)-3-azabicyclo[3.1.0]hexane-1-carboxylic Acid (<b>64</b>)</h3><div class="NLM_p last">To a mixture of ethyl 3-((1<i>S</i>)-5′,11′-dihydrospiro[cyclopentane-1,10′-dibenzo[<i>a</i>,<i>d</i>]cyclohepten]-3-yl)-3-azabicyclo[3.1.0]hexane-1-carboxylate (<b>29′</b> isomer 2, 26 mg, 0.065 mmol) in ethanol (5 mL) and water (1 mL) was added KOH (14.53 mg, 0.259 mmol). The resulting mixture was heated at 100 °C in a microwave reactor (Personal Chemistry Emrys optimizer) for 30 min. The solvent was then evaporated under vacuum and the mixture acidified with 3 N HCl (until pH 1 was reached). The solution was purified with a HLB cartridge (6 g), eluting first with water and then MeOH to afford the title compound (<b>64</b>, 18.8 mg). UPLC/MS <i>R<sub>f</sub></i> = 0.63; <i>m</i>/<i>z</i> (ES) 374.2 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ: 7.40−7.57 (m, 1 H), 7.08−7.25 (m, 5 H), 6.97−7.08 (m, 2 H), 4.02−4.19 (m, 2 H), 3.88−4.02 (m, 1 H), 3.52−3.84 (m, 3 H), 3.21−3.37 (m, 2 H), 3.05−3.18 (m, 1 H), 2.53−2.72 (m, 1 H), 2.34−2.53 (m, 1 H), 2.03−2.28 (m, 4 H), 1.73−1.97 (m, 2 H), 1.58−1.71 (m, 1 H).</div></div><div id="sec5_11_44" class="NLM_sec NLM_sec_level_2"><div id="ac_i76" class="anchor-spacer"></div><h3 class="article-section__title" id="_i76"> 1-((1<i>S</i>)-5′,11′-Dihydrospiro[cyclopentane-1,10′-dibenzo[<i>a</i>,<i>d</i>]cyclohepten]-3-yl)-3-azetidinecarboxylic Acid Formate Salt (<b>65</b>)</h3><div class="NLM_p last">In a 50 mL round-bottomed flask was dissolved methyl 1-((1<i>S</i>)-5′,11′-dihydrospiro[cyclopentane-1,10′-dibenzo[<i>a</i>,<i>d</i>]cyclohepten]-3-yl)-3-azetidinecarboxylate (<b>30′</b>, 66 mg, 0.183 mmol) in methanol (5 mL) and water (2.5 mL) to give a colorless solution. KOH (41.0 mg, 0.730 mmol) was added, and the mixture was stirred at room temperature overnight. MS monitoring showed that the reaction was complete. Solvent was removed and the residue taken up with HCl 1 M and passed through an HLB 6 g column (water and MeOH to elute). Then a second purification was done by Fraction Lynx acid method to give the title compound as a yellow solid (<b>65</b>, 57.9 mg). UPLC/MS <i>t</i><sub>R</sub> = 0.58; <i>m</i>/<i>z</i> (ES) 348.08 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 7.33−6.94 (m, 8 H), 4.17−3.99 (m, 2 H), 3.48−3.37 (m, 2 H), 3.26−3.15 (m, 5 H), 3.14−3.06 (m, 1 H), 2.01−1.90 (m, 2 H), 1.85−1.61 (m, 4 H).</div></div><div id="sec5_11_45" class="NLM_sec NLM_sec_level_2"><div id="ac_i77" class="anchor-spacer"></div><h3 class="article-section__title" id="_i77"> 1-(11′<i>H</i>-Spiro[cyclopentane-1,10′-dibenzo[<i>b</i>,<i>f</i>]oxepin]-3-yl)-1,2,3,6-tetrahydro-4-pyridinecarboxylic Acid (<b>69</b>)</h3><div class="NLM_p last">To a solution of methyl 1-(11′<i>H</i>-spiro[cyclopentane-1,10′-dibenzo[<i>b</i>,<i>f</i>]oxepin]-3-yl)-1,2,3,6-tetrahydro-4-pyridinecarboxylate (<b>34′</b> isomer 2, 27 mg, 0.069 mmol) in methanol (2 mL) were added water (1 mL) and lithium hydroxide (1.660 mg, 0.069 mmol). The mixture was heated at 45 °C for 4 h. The MeOH was evaporated and the water phase acidified with HCl (2 N in water) until pH < 1. The suspension was purified by C18 cartridge (5 g) by using water and then MeOH as eluent to obtain, after solvent evaporation, a cream solid (17 mg). The product was further purified by Fraction Lynx HPLC to give the title compound as a white solid (<b>69</b>, 8.2 mg). <i>m</i>/<i>z</i> (ES): 376.1 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 7.32−7.39 (m, 1 H), 7.04−7.30 (m, 7 H), 6.74−6.84 (m, 1 H), 3.40−2.20 (m, 15 H).</div></div><div id="sec5_11_46" class="NLM_sec NLM_sec_level_2"><div id="ac_i78" class="anchor-spacer"></div><h3 class="article-section__title" id="_i78"> 1-(11′<i>H</i>-Spiro[cyclopentane-1,10′-dibenzo[<i>b</i>,<i>f</i>]oxepin]-3-yl)-3-azetidinecarboxylic Acid Formic Acid Salt (<b>73</b>)</h3><div class="NLM_p last">To a colorless solution of methyl 1-(11′<i>H</i>-spiro[cyclopentane-1,10′-dibenzo[<i>b</i>,<i>f</i>]oxepin]-3-yl)-3-azetidinecarboxylate (<b>38′</b>, 19 mg, 0.052 mmol) in methanol (2 mL) and water (1 mL) was added KOH (11.73 mg, 0.209 mmol), and the mixture was stirred at room temperature overnight. UPLC/MS monitor showed that the reaction was complete. The solvent was removed and the product was purified by Fraction Lynx acid method to give the title compound as white solid (<b>73</b>, 20 mg). UPLC/MS <i>R<sub>f</sub></i> = 0.57; <i>m</i>/<i>z</i> (ES) 350.04 [M + H]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, chloroform-<i>d</i>) δ: 8.40 (bs, 1H), 7.22−6.90 (m, 8 H), 4.34−2.95 (m, 8 H), 2.75−1.84 (m, 6 H).</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i79"><a href="/doi/suppl/10.1021/jm100856p">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_08326" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_08326" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Experimental procedures and supporting data for compounds <b>43</b>, <b>44</b>, <b>49</b>, <b>50</b>, <b>52</b>, <b>53</b>, <b>55</b>−<b>63</b>, <b>66</b>−<b>68</b>, and <b>70</b>−<b>72</b>. This material is available free of charge via the Internet at <a href="http://pubs.acs.org" class="extLink">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm100856p/suppl_file/jm100856p_si_001.pdf">jm100856p_si_001.pdf (297.32 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/jm100856p" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_17536" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_17536" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Massimo Gianotti</span> - <span class="hlFld-Affiliation affiliation">Neurosciences CEDD, GlaxoSmithKline, Medicines Research Centre, Via A. Fleming 4, 37135 Verona, Italy</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#dfb2beacb8b6beb19fb3b6bdbaadb0f1b6ab"><span class="__cf_email__" data-cfemail="35585446525c545b75595c5750475a1b5c41">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Maurizio Botta</span> - <span class="hlFld-Affiliation affiliation">Dipartimento Farmaco Chimico Tecnologico, Universitá degli Studi di Siena, Via Aldo Moro 2, I-53100 Siena, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stephen Brough</span> - <span class="hlFld-Affiliation affiliation">GlaxoSmithKline, New Frontiers Science Park, Third Avenue, Harlow, Essex, CM19 5AW, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Renzo Carletti</span> - <span class="hlFld-Affiliation affiliation">Neurosciences CEDD, GlaxoSmithKline, Medicines Research Centre, Via A. Fleming 4, 37135 Verona, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Emiliano Castiglioni</span> - <span class="hlFld-Affiliation affiliation">Neurosciences CEDD, GlaxoSmithKline, Medicines Research Centre, Via A. Fleming 4, 37135 Verona, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Corrado Corti</span> - <span class="hlFld-Affiliation affiliation">Neurosciences CEDD, GlaxoSmithKline, Medicines Research Centre, Via A. Fleming 4, 37135 Verona, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michele Dal-Cin</span> - <span class="hlFld-Affiliation affiliation">Neurosciences CEDD, GlaxoSmithKline, Medicines Research Centre, Via A. Fleming 4, 37135 Verona, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sonia Delle Fratte</span> - <span class="hlFld-Affiliation affiliation">Neurosciences CEDD, GlaxoSmithKline, Medicines Research Centre, Via A. Fleming 4, 37135 Verona, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Denana Korajac</span> - <span class="hlFld-Affiliation affiliation">Integrated Research Unit, IRU Chemistry, Prilaz Baruna Filipovica 29, 10000 Zagreb, Croatia</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Marija Lovric</span> - <span class="hlFld-Affiliation affiliation">Integrated Research Unit, IRU Chemistry, Prilaz Baruna Filipovica 29, 10000 Zagreb, Croatia</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Giancarlo Merlo</span> - <span class="hlFld-Affiliation affiliation">Neurosciences CEDD, GlaxoSmithKline, Medicines Research Centre, Via A. Fleming 4, 37135 Verona, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Milan Mesic</span> - <span class="hlFld-Affiliation affiliation">Integrated Research Unit, IRU Chemistry, Prilaz Baruna Filipovica 29, 10000 Zagreb, Croatia</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Francesca Pavone</span> - <span class="hlFld-Affiliation affiliation">Neurosciences CEDD, GlaxoSmithKline, Medicines Research Centre, Via A. Fleming 4, 37135 Verona, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Laura Piccoli</span> - <span class="hlFld-Affiliation affiliation">Neurosciences CEDD, GlaxoSmithKline, Medicines Research Centre, Via A. Fleming 4, 37135 Verona, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Slavko Rast</span> - <span class="hlFld-Affiliation affiliation">Integrated Research Unit, IRU Chemistry, Prilaz Baruna Filipovica 29, 10000 Zagreb, Croatia</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Maja Roscic</span> - <span class="hlFld-Affiliation affiliation">Integrated Research Unit, IRU Chemistry, Prilaz Baruna Filipovica 29, 10000 Zagreb, Croatia</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Anna Sava</span> - <span class="hlFld-Affiliation affiliation">Neurosciences CEDD, GlaxoSmithKline, Medicines Research Centre, Via A. Fleming 4, 37135 Verona, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mario Smehil</span> - <span class="hlFld-Affiliation affiliation">Integrated Research Unit, IRU Chemistry, Prilaz Baruna Filipovica 29, 10000 Zagreb, Croatia</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Luigi Stasi</span> - <span class="hlFld-Affiliation affiliation">Neurosciences CEDD, GlaxoSmithKline, Medicines Research Centre, Via A. Fleming 4, 37135 Verona, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andrea Togninelli</span> - <span class="hlFld-Affiliation affiliation">Dipartimento Farmaco Chimico Tecnologico, Universitá degli Studi di Siena, Via Aldo Moro 2, I-53100 Siena, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mark J. Wigglesworth</span> - <span class="hlFld-Affiliation affiliation">GlaxoSmithKline, New Frontiers Science Park, Third Avenue, Harlow, Essex, CM19 5AW, U.K.</span></div></li></ul></li><li></li><li></li><li></li></ul></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i80">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_14568" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_14568" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 29 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span>National Sleep Foundation. Sleep in America Poll Highlight & Key Findings. <a href="http://www.sleepfoundation.org/" class="extLink">http://www.sleepfoundation.org/</a>,<span class="NLM_x"> </span><span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=National+Sleep+Foundation.+Sleep+in+America+Poll+Highlight+%26+Key+Findings.+http%3A%2F%2Fwww.sleepfoundation.org%2F%2C+2010."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Wafford, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ebert, B.</span><span> </span><span class="NLM_article-title">Emerging anti-insomnia drugs: tackling sleeplessness and the quality of wake time</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">530</span><span class="NLM_x">–</span> <span class="NLM_lpage">540</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=530-540&issue=6&author=K.+Waffordauthor=B.+Ebert&title=Emerging+anti-insomnia+drugs%3A+tackling+sleeplessness+and+the+quality+of+wake+time"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWafford%26aufirst%3DK.%26aulast%3DEbert%26aufirst%3DB.%26atitle%3DEmerging%2520anti-insomnia%2520drugs%253A%2520tackling%2520sleeplessness%2520and%2520the%2520quality%2520of%2520wake%2520time%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2008%26volume%3D7%26issue%3D6%26spage%3D530%26epage%3D540" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit2b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Ohayon, M.</span><span> </span><span class="NLM_article-title">Epidemiology of insomnia: what we know and what we still need to learn</span> <span class="citation_source-journal">Sleep Med. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">97</span><span class="NLM_x">–</span> <span class="NLM_lpage">111</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=16&amp;doi=10.1021%2Fjm100856p&amp;key=10.1053%2Fsmrv.2002.0186" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=8&amp;doi=10.1021%2Fjm100856p&amp;key=12531146" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=32&amp;doi=10.1021%2Fjm100856p&amp;key=1%3ACAS%3A280%3ADC%252BD3s%252FisFGhtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2002&pages=97-111&issue=2&author=M.+Ohayon&title=Epidemiology+of+insomnia%3A+what+we+know+and+what+we+still+need+to+learn"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2bR"><div class="casContent"><span class="casTitleNuber">2b</span><div class="casTitle"><span class="NLM_cas:atitle">Epidemiology of insomnia: what we know and what we still need to learn</span></div><div class="casAuthors">Ohayon Maurice M</div><div class="citationInfo"><span class="NLM_cas:title">Sleep medicine reviews</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">97-111</span>
        ISSN:<span class="NLM_cas:issn">1087-0792</span>.
    </div><div class="casAbstract">Epidemiologists have published more than 50 studies of insomnia based on data collected in various representative community-dwelling samples or populations.  These surveys provide estimates of the prevalence of insomnia according to four definitions: insomnia symptoms, insomnia symptoms with daytime consequences, sleep dissatisfaction and insomnia diagnoses.  The first definition, based on insomnia criteria as defined by the DSM-IV, recognizes that about one-third of a general population presents at least one of them.  The second definition shows that, when daytime consequences of insomnia are taken into account, the prevalence is between 9% and 15%.  The third definition represents 8-18% of the general population.  The last definition, more precise and corresponding to a decision-making diagnosis, sets the prevalence at 6% of insomnia diagnoses according to the DSM-IV classification.  These four definitions of insomnia have higher prevalence rates in women than in men.  The prevalence of insomnia symptoms generally increases with age, while the rates of sleep dissatisfaction and diagnoses have little variation with age.  Numerous factors can initiate or maintain insomnia.  Mental disorders and organic diseases are the factors that have been the most frequently studied.  The association between insomnia and major depressive episodes has been constantly reported: individuals with insomnia are more likely to have a major depressive illness.  Longitudinal studies have shown that the persistence of insomnia is associated with the appearance of a new depressive episode.  Future epidemiological studies should focus on the natural evolution of insomnia.  Epidemiological genetic links of insomnia are yet to be studied.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSsKd7ea0dqcbesJRIHUP1ofW6udTcc2eaeWrk-JDqal7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3s%252FisFGhtg%253D%253D&md5=78a4d8f470b7af6ac7ec0ec08c1c3b9c</span></div><a href="/servlet/linkout?suffix=cit2b&amp;dbid=16384&amp;doi=10.1053%2Fsmrv.2002.0186&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fsmrv.2002.0186%26sid%3Dliteratum%253Aachs%26aulast%3DOhayon%26aufirst%3DM.%26atitle%3DEpidemiology%2520of%2520insomnia%253A%2520what%2520we%2520know%2520and%2520what%2520we%2520still%2520need%2520to%2520learn%26jtitle%3DSleep%2520Med.%2520Rev.%26date%3D2002%26volume%3D6%26issue%3D2%26spage%3D97%26epage%3D111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit2c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Schutte-Rodin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Broch, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buysse, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dorsey, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sateia, M.</span><span> </span><span class="NLM_article-title">Clinical guideline for the evaluation and management of chronic insomnia in adults</span> <span class="citation_source-journal">J. Clin. Sleep Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">487</span><span class="NLM_x">–</span> <span class="NLM_lpage">504</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=8&amp;doi=10.1021%2Fjm100856p&amp;key=18853708" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=32&amp;doi=10.1021%2Fjm100856p&amp;key=1%3ACAS%3A280%3ADC%252BD1cnlvFGhtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2008&pages=487-504&issue=5&author=S.+Schutte-Rodinauthor=L.+Brochauthor=D.+Buysseauthor=C.+Dorseyauthor=M.+Sateia&title=Clinical+guideline+for+the+evaluation+and+management+of+chronic+insomnia+in+adults"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2cR"><div class="casContent"><span class="casTitleNuber">2c</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical guideline for the evaluation and management of chronic insomnia in adults</span></div><div class="casAuthors">Schutte-Rodin Sharon; Broch Lauren; Buysse Daniel; Dorsey Cynthia; Sateia Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">487-504</span>
        ISSN:<span class="NLM_cas:issn">1550-9389</span>.
    </div><div class="casAbstract">Insomnia is the most prevalent sleep disorder in the general population, and is commonly encountered in medical practices.  Insomnia is defined as the subjective perception of difficulty with sleep initiation, duration, consolidation, or quality that occurs despite adequate opportunity for sleep, and that results in some form of daytime impairment.1 Insomnia may present with a variety of specific complaints and etiologies, making the evaluation and management of chronic insomnia demanding on a clinician's time.  The purpose of this clinical guideline is to provide clinicians with a practical framework for the assessment and disease management of chronic adult insomnia, using existing evidence-based insomnia practice parameters where available, and consensus-based recommendations to bridge areas where such parameters do not exist.  Unless otherwise stated, "insomnia" refers to chronic insomnia, which is present for at least a month, as opposed to acute or transient insomnia, which may last days to weeks.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTIa7hxRxemJO2mnZh2OgS0fW6udTcc2eZxeB5foVYQDbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1cnlvFGhtA%253D%253D&md5=ed6a59b517e2fff101ab9457979038bc</span></div><a href="/servlet/linkout?suffix=cit2c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSchutte-Rodin%26aufirst%3DS.%26aulast%3DBroch%26aufirst%3DL.%26aulast%3DBuysse%26aufirst%3DD.%26aulast%3DDorsey%26aufirst%3DC.%26aulast%3DSateia%26aufirst%3DM.%26atitle%3DClinical%2520guideline%2520for%2520the%2520evaluation%2520and%2520management%2520of%2520chronic%2520insomnia%2520in%2520adults%26jtitle%3DJ.%2520Clin.%2520Sleep%2520Med.%26date%3D2008%26volume%3D4%26issue%3D5%26spage%3D487%26epage%3D504" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span>Sleep Disorders in the Diagnostic and Statistical Manual of Mental Disorders DSM-IV-TR, <span class="NLM_edition">4</span>th ed.; <span class="NLM_publisher-name">American Psychiatric Association</span>: <span class="NLM_publisher-loc">Arlington, VA</span>,<span class="NLM_x"> </span><span class="NLM_year">2000</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">597</span>− <span class="NLM_lpage">661</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Sleep+Disorders+in+the+Diagnostic+and+Statistical+Manual+of+Mental+Disorders+DSM-IV-TR%2C+4th+ed.%3B+American+Psychiatric+Association%3A+Arlington%2C+VA%2C+2000%3B+pp+597%E2%88%92661."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26pub%3DAmerican%2520Psychiatric%2520Association%26date%3D2000%26spage%3D597%26epage%3D661" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Shigemoto, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shinomiya, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mio, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azuma, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamei, C.</span><span> </span><span class="NLM_article-title">Effects of second-generation histamine H<sub>1</sub> receptor antagonists on the sleep−wakefulness cycle in rats</span> <span class="citation_source-journal">Eur. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">494</span><span class="NLM_x"> (</span><span class="NLM_issue">2−3</span><span class="NLM_x">) </span> <span class="NLM_fpage">161</span><span class="NLM_x">–</span> <span class="NLM_lpage">165</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm100856p&amp;key=10.1016%2Fj.ejphar.2004.05.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm100856p&amp;key=15212970" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm100856p&amp;key=1%3ACAS%3A528%3ADC%252BD2cXltVGhs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=494&publication_year=2004&pages=161-165&issue=2%E2%88%923&author=Y.+Shigemotoauthor=K.+Shinomiyaauthor=M.+Mioauthor=N.+Azumaauthor=C.+Kamei&title=Effects+of+second-generation+histamine+H1+receptor+antagonists+on+the+sleep%E2%88%92wakefulness+cycle+in+rats"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of second-generation histamine H1 receptor antagonists on the sleep-wakefulness cycle in rats</span></div><div class="casAuthors">Shigemoto, Yuki; Shinomiya, Kazuaki; Mio, Mitsunobu; Azuma, Nobuhide; Kamei, Chiaki</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">494</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">161-165</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The present study was performed to examine the sedative effects of second-generation histamine H1 receptor antagonist using power spectrum anal. in the rat.  Similar to ketotifen, olopatadine caused a decrease in sleep latency at a dose of 50 mg/kg, while epinastine and cetirizine showed no significant effect even at a dose of 50 mg/kg.  No significant difference was obsd. in the total times of wakefulness, non-rapid eye movement sleep and rapid eye movement sleep by any drugs used in the expts.  The no. of sleep phases and interval between sleep phases were also unchanged by these drugs.  Ketotifen and olopatadine inhibited [3H]mepyramine binding to rat brain homogenates in parallel with a decrease in sleep latency.  No significant effect was obsd. with epinastine and cetirizine on [3H]mepyramine binding.  These findings suggest that the differences in the central nervous system (CNS) depressant effect obsd. in second generation H1 receptor antagonists may be due to their liability to penetrate into the CNS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDTqz597UkJbVg90H21EOLACvtfcHk0lg1xHUILoOLxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXltVGhs7o%253D&md5=2da1198330c82f014856ae0d8c1f8c51</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2004.05.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2004.05.010%26sid%3Dliteratum%253Aachs%26aulast%3DShigemoto%26aufirst%3DY.%26aulast%3DShinomiya%26aufirst%3DK.%26aulast%3DMio%26aufirst%3DM.%26aulast%3DAzuma%26aufirst%3DN.%26aulast%3DKamei%26aufirst%3DC.%26atitle%3DEffects%2520of%2520second-generation%2520histamine%2520H1%2520receptor%2520antagonists%2520on%2520the%2520sleep%25E2%2588%2592wakefulness%2520cycle%2520in%2520rats%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2004%26volume%3D494%26issue%3D2%25E2%2588%25923%26spage%3D161%26epage%3D165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Simons, F. E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fraser, T. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reggin, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simons, K. J.</span><span> </span><span class="NLM_article-title">Comparison of the central nervous system effects produced by six H<sub>1</sub>-receptor antagonists</span> <span class="citation_source-journal">Clin. Exp. Allergy</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x"> (</span><span class="NLM_issue">9</span><span class="NLM_x">) </span> <span class="NLM_fpage">1092</span><span class="NLM_x">–</span> <span class="NLM_lpage">1097</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm100856p&amp;key=10.1111%2Fj.1365-2222.1996.tb00649.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm100856p&amp;key=8889266" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm100856p&amp;key=1%3ACAS%3A528%3ADyaK2sXitlOlsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=1996&pages=1092-1097&issue=9&author=F.+E.+R.+Simonsauthor=T.+G.+Fraserauthor=J.+D.+Regginauthor=K.+J.+Simons&title=Comparison+of+the+central+nervous+system+effects+produced+by+six+H1-receptor+antagonists"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of the central nervous system effects produced by six H1-receptor antagonists</span></div><div class="casAuthors">Simons, F. E. R.; Fraser, T. G.; Reggin, J. D.; Simons, K. J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and Experimental Allergy</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1092-1097</span>CODEN:
                <span class="NLM_cas:coden">CLEAEN</span>;
        ISSN:<span class="NLM_cas:issn">0954-7894</span>.
    
            (<span class="NLM_cas:orgname">Blackwell</span>)
        </div><div class="casAbstract">A comprehensive comparative study of the central nervous system (CNS) properties of newer H1-receptor antagonists is needed.  The authors' objective was to investigate the central nervous system effects of a single manufacturer's recommended dose of six H1-receptor antagonists, using appropriate controls.  Fifteen healthy subjects received astemizole 10 mg, cetirizine 10 mg, ketotifen 2 mg, loratadine 10 mg, terfenadine 60 mg, diphenhydramine 50 mg or placebo.  Before and 2-2.5 h after dosing, cognitive function was assessed using the P300-event-related potential, somnolence was assessed using a subjective score, and histamine skin tests were performed.  In rank order from least to greatest effect on the P300 latency, the medications were: terfenadine, placebo, cetirizine, ketotifen, loratadine, astemizole and diphenhydramine.  Only diphenhydramine increased the P300 latency significantly compared with baseline and placebo.  Subjective somnolence was significantly greater than baseline and placebo after cetirizine, ketotifen and diphenhydramine.  All the H1-receptor antagonists suppressed the histamine-induced weal significantly compared with baseline.  The H1-receptor antagonists tested affected cognitive functioning and somnolence to different extents, although all produced satisfactory peripheral H1-blockade.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOOW7hatjUaLVg90H21EOLACvtfcHk0lg1xHUILoOLxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXitlOlsw%253D%253D&md5=4a2fd1c966fcaecba576ea5aae5fee94</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2222.1996.tb00649.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2222.1996.tb00649.x%26sid%3Dliteratum%253Aachs%26aulast%3DSimons%26aufirst%3DF.%2BE.%2BR.%26aulast%3DFraser%26aufirst%3DT.%2BG.%26aulast%3DReggin%26aufirst%3DJ.%2BD.%26aulast%3DSimons%26aufirst%3DK.%2BJ.%26atitle%3DComparison%2520of%2520the%2520central%2520nervous%2520system%2520effects%2520produced%2520by%2520six%2520H1-receptor%2520antagonists%26jtitle%3DClin.%2520Exp.%2520Allergy%26date%3D1996%26volume%3D26%26issue%3D9%26spage%3D1092%26epage%3D1097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Popa, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Léna, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabre, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prenat, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gingrich, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Escourrou, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamon, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adrien, J.</span><span> </span><span class="NLM_article-title">Contribution of 5-HT2 receptor subtypes to sleep−wakefulness and respiratory control, and functional adaptations in knock-out mice lacking 5-HT2A receptors</span> <span class="citation_source-journal">J. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x"> (</span><span class="NLM_issue">49</span><span class="NLM_x">) </span> <span class="NLM_fpage">11231</span><span class="NLM_x">–</span> <span class="NLM_lpage">11238</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm100856p&amp;key=10.1523%2FJNEUROSCI.1724-05.2005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm100856p&amp;key=16339018" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm100856p&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlaksr3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2005&pages=11231-11238&issue=49&author=D.+Popaauthor=C.+L%C3%A9naauthor=V.+Fabreauthor=C.+Prenatauthor=J.+Gingrichauthor=P.+Escourrouauthor=M.+Hamonauthor=J.+Adrien&title=Contribution+of+5-HT2+receptor+subtypes+to+sleep%E2%88%92wakefulness+and+respiratory+control%2C+and+functional+adaptations+in+knock-out+mice+lacking+5-HT2A+receptors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Contribution of 5-HT2 receptor subtypes to sleep-wakefulness and respiratory control, and functional adaptations in knock-out mice lacking 5-HT2A receptors</span></div><div class="casAuthors">Popa, Daniela; Lena, Clement; Fabre, Veronique; Prenat, Caroline; Gingrich, Jay; Escourrou, Pierre; Hamon, Michel; Adrien, Joelle</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">49</span>),
    <span class="NLM_cas:pages">11231-11238</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Serotonin (5-hydroxytryptamine; 5-HT) plays key roles in sleep-wakefulness regulation.  Evidence indicates that 5-HT2 receptors are involved mainly in non-rapid eye movement sleep (NREMS) regulation and respiratory control.  Here, we investigated the relative contribution of 5-HT2A, 5-HT2B, and 5-HT2C receptor subtypes to NREMS and breathing during sleep, using 5-HT2 subtype-selective ligands in wild-type (5-HT2A +/+) and knock-out (5-HT2A -/-) mice that do not express 5-HT2A receptors.  Acute blockade of 5-HT2A receptors induced an increase in NREMS in 5-HT2A +/+ mice, but not 5-HT2A -/- mutants, which spontaneously expressed less NREMS than wild-type animals.  In 5-HT2A +/+ mice, 5-HT2B receptor blockade produced a redn. of NREMS, whereas receptor activation induced an increase in this sleep stage.  These effects were less pronounced in 5-HT2A -/- mice, indicating a lower sensitivity of 5-HT2B receptors in mutants, with no change in 5-HT2B mRNA.  Blockade of 5-HT2C receptors had no effect on NREMS in both strains.  In addn., an increase in EEG power d. after sleep deprivation was obsd. in 5-HT2A +/+ mice but not in 5-HT2A -/- mice.  Whole-body plethysmog. recordings indicated that 5-HT2A receptor blockade in 5-HT2A +/+ mice reduced NREMS apneas and bradypneas that occurred after sighs.  In contrast, in 5-HT2A -/- mutants, NREMS apneas were not modified, and bradypnea after sighs were more pronounced.  Our results demonstrate that 5-HT exerts a 5-HT2B-mediated facilitation of NREMS, and an influence resp. inhibitory on NREMS and facilitatory on sleep apnea generation, via 5-HT2A receptors.  Moreover, 5-HT2A gene knock-out leads to functional compensations yielding adaptive changes opposite to those caused by pharmacol. blockade of 5-HT2A receptors in 5-HT2A +/+ mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbwV24-TPA6bVg90H21EOLACvtfcHk0lg1xHUILoOLxQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlaksr3M&md5=38633ca767730a707d73447291e42a3d</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.1724-05.2005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.1724-05.2005%26sid%3Dliteratum%253Aachs%26aulast%3DPopa%26aufirst%3DD.%26aulast%3DL%25C3%25A9na%26aufirst%3DC.%26aulast%3DFabre%26aufirst%3DV.%26aulast%3DPrenat%26aufirst%3DC.%26aulast%3DGingrich%26aufirst%3DJ.%26aulast%3DEscourrou%26aufirst%3DP.%26aulast%3DHamon%26aufirst%3DM.%26aulast%3DAdrien%26aufirst%3DJ.%26atitle%3DContribution%2520of%25205-HT2%2520receptor%2520subtypes%2520to%2520sleep%25E2%2588%2592wakefulness%2520and%2520respiratory%2520control%252C%2520and%2520functional%2520adaptations%2520in%2520knock-out%2520mice%2520lacking%25205-HT2A%2520receptors%26jtitle%3DJ.%2520Neurosci.%26date%3D2005%26volume%3D25%26issue%3D49%26spage%3D11231%26epage%3D11238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Viola, A. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandenberger, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toussaint, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouhours, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macher, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luthringer, R.</span><span> </span><span class="NLM_article-title">Ritanserin, a serotonin-2 receptor antagonist, improves ultradian sleep rhythmicity in young poor sleepers</span> <span class="citation_source-journal">Clin. Neurophysiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">113</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">429</span><span class="NLM_x">–</span> <span class="NLM_lpage">434</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm100856p&amp;key=10.1016%2FS1388-2457%2802%2900014-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm100856p&amp;key=11897543" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm100856p&amp;key=1%3ACAS%3A528%3ADC%252BD38XjvFGns7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2002&pages=429-434&issue=3&author=A.+U.+Violaauthor=G.+Brandenbergerauthor=M.+Toussaintauthor=P.+Bouhoursauthor=J.+P.+Macherauthor=R.+Luthringer&title=Ritanserin%2C+a+serotonin-2+receptor+antagonist%2C+improves+ultradian+sleep+rhythmicity+in+young+poor+sleepers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Ritanserin, a serotonin-2 receptor antagonist, improves ultradian sleep rhythmicity in young poor sleepers</span></div><div class="casAuthors">Viola, Antoine U.; Brandenberger, Gabrielle; Toussaint, Michel; Bouhours, Philippe; Macher, Jean Paul; Luthringer, Remy</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Neurophysiology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">429-434</span>CODEN:
                <span class="NLM_cas:coden">CNEUFU</span>;
        ISSN:<span class="NLM_cas:issn">1388-2457</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ireland Ltd.</span>)
        </div><div class="casAbstract">The aim was to det. the effect on sleep electroencephalog. (EEG) activity of ritanserin, a serotonin-2 (5-HT2) receptor antagonist in young poor sleepers.  Eight male subjects underwent two randomized night studies after receiving either a placebo or 5 mg ritanserin administered in the morning.  The overnight variations in the delta (0.5-4.0 Hz) and sigma (12.25-15.0 Hz) frequency bands were characterized using a peak anal. which provided a quant. evaluation of the time-courses in EEG activity.  In subjects under ritanserin, slow wave sleep duration and the no. of non-rapid eye movement (NREM)-REM sleep cycles were significantly enhanced (P < 0.01).  The no. of peaks in delta activity occurring in the normal 80-120 min range was significantly (P < 0.05) increased.  Using a delta peak anal., 4 periods contg. or not a significant peak were identified in each subject.  A significant increase in delta activity was obsd. in the areas under the averaged curves during the second and the third periods (P < 0.05), while sigma activity decreased under ritanserin during the first, second and third periods (P < 0.05).  These results demonstrate that ritanserin increases delta activity, possibly by opposing the inhibitory control of 5-HT2 receptor family.  It restores sleep ultradian rhythmicity and improves sleep quality in young poor sleepers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHAm1CxlOzTrVg90H21EOLACvtfcHk0liBP1AjwkIRNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjvFGns7o%253D&md5=160a8adfb6014e0fffb6107347f7ac4b</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2FS1388-2457%2802%2900014-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1388-2457%252802%252900014-7%26sid%3Dliteratum%253Aachs%26aulast%3DViola%26aufirst%3DA.%2BU.%26aulast%3DBrandenberger%26aufirst%3DG.%26aulast%3DToussaint%26aufirst%3DM.%26aulast%3DBouhours%26aufirst%3DP.%26aulast%3DMacher%26aufirst%3DJ.%2BP.%26aulast%3DLuthringer%26aufirst%3DR.%26atitle%3DRitanserin%252C%2520a%2520serotonin-2%2520receptor%2520antagonist%252C%2520improves%2520ultradian%2520sleep%2520rhythmicity%2520in%2520young%2520poor%2520sleepers%26jtitle%3DClin.%2520Neurophysiol.%26date%3D2002%26volume%3D113%26issue%3D3%26spage%3D429%26epage%3D434" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Renger, J. J.</span><span> </span><span class="NLM_article-title">Overview of experimental and conventional pharmacological approaches in the treatment of sleep and wake disorders</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">937</span><span class="NLM_x">–</span> <span class="NLM_lpage">953</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Fjm100856p&amp;key=10.2174%2F156802608784936755" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm100856p&amp;key=18673164" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm100856p&amp;key=1%3ACAS%3A528%3ADC%252BD1cXps1OhtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=937-953&author=J.+J.+Renger&title=Overview+of+experimental+and+conventional+pharmacological+approaches+in+the+treatment+of+sleep+and+wake+disorders"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Overview of experimental and conventional pharmacological approaches in the treatment of sleep and wake disorders</span></div><div class="casAuthors">Renger, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">937-953</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The fundamental purpose of sleep remains one of the most compelling questions yet to be answered in the area of neuroscience, if not all of biol.  A pervasive behavior among members of the animal kingdom, the functional necessity of engaging regularly in sleep is best demonstrated by showing that failing to do so leads to a broad repertoire of pathol. outcomes including cognitive, immunol., hormonal, and metabolic outcomes, among others.  Indeed, an abs. requirement for sleep has been shown in studies that have demonstrated that continuous total deprivation of sleep for as short a period as 15 days is generally lethal in some species.  The most common clin. sleep disorder, insomnia, is both a principal disease (primary insomnia) as well as a co-morbidity of a large no. of other ostensibly unrelated diseases including chronic pain, attention deficit hyperactivity disorder, and depression.  From a treatment perspective, restoring normal healthy sleep delivers subsequent benefits in waking cognitive function and mood with the potential for beneficial therapeutic impact on daily functioning across multiple diseases for which restorative healthy sleep is compromised.  Our remarkable escalation in understanding the anatomy and physiol. of sleep/wake control mechanisms provides new opportunities to modify the neurobiol. of sleep and wake-related behaviors in novel and exciting ways.  In parallel, expansion of sleep research into novel interfaces between sleep-wake biol. and disease states is revealing addnl. extensive implications of lost sleep.  Current investigational and conventional pharmacol. approaches for the treatment of sleep and wake disorders are discussed based on their mechanism of action within the CNS and their effect on sleep and wake.  This review of recent sleep biol. and sleep pharmacol. peers into the future of sleep therapeutics to highlight both mechanistic safety and functional outcomes as key for differentiating and establishing success for the next generation of arousal modifying therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6GNzViXvCXbVg90H21EOLACvtfcHk0liBP1AjwkIRNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXps1OhtLw%253D&md5=0f24539a5d8032bde88186f6df1a44a6</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.2174%2F156802608784936755&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802608784936755%26sid%3Dliteratum%253Aachs%26aulast%3DRenger%26aufirst%3DJ.%2BJ.%26atitle%3DOverview%2520of%2520experimental%2520and%2520conventional%2520pharmacological%2520approaches%2520in%2520the%2520treatment%2520of%2520sleep%2520and%2520wake%2520disorders%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2008%26volume%3D8%26spage%3D937%26epage%3D953" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Gianotti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corti, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delle Fratte, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Fabio, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leslie, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pavone, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piccoli, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stasi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wigglesworth, M. J.</span><span> </span><span class="NLM_article-title">Novel imidazobenzazepine derivatives as dual H<sub>1</sub>/5-HT<sub>2A</sub> antagonists for the treatment of sleep disorders</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">5069</span><span class="NLM_x">–</span> <span class="NLM_lpage">5073</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=5069-5073&author=M.+Gianottiauthor=C.+Cortiauthor=S.+Delle+Fratteauthor=R.+Di+Fabioauthor=C.+P.+Leslieauthor=F.+Pavoneauthor=L.+Piccoliauthor=L.+Stasiauthor=M.+J.+Wigglesworth&title=Novel+imidazobenzazepine+derivatives+as+dual+H1%2F5-HT2A+antagonists+for+the+treatment+of+sleep+disorders"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGianotti%26aufirst%3DM.%26aulast%3DCorti%26aufirst%3DC.%26aulast%3DDelle%2BFratte%26aufirst%3DS.%26aulast%3DDi%2BFabio%26aufirst%3DR.%26aulast%3DLeslie%26aufirst%3DC.%2BP.%26aulast%3DPavone%26aufirst%3DF.%26aulast%3DPiccoli%26aufirst%3DL.%26aulast%3DStasi%26aufirst%3DL.%26aulast%3DWigglesworth%26aufirst%3DM.%2BJ.%26atitle%3DNovel%2520imidazobenzazepine%2520derivatives%2520as%2520dual%2520H1%252F5-HT2A%2520antagonists%2520for%2520the%2520treatment%2520of%2520sleep%2520disorders%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D5069%26epage%3D5073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Castiglioni, E.; Di Fabio, R.; Togninelli, A.; Brough, S.; Brown, F.; Dal Cin, M.; Gianotti, M.; Marchioro, C.; Merlo, G.; Spinosa, R.; Wigglesworth, M. J.; Botta, M.</span><span> </span><span class="NLM_article-title">Towards the discovery on new hypnotic agents: synthesis and preliminary pharmacological evaluation of a novel class of dibenzo[<i>a</i>,<i>d</i>]cycloheptene derivatives</span>.  <span class="citation_source-journal">ChemMedChem.</span> [Online early access]. DOI: <span class="refDoi"> DOI: 10.1002/cmdc.201000280</span> . Published Online: Oct 4, 2010.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Fjm100856p&amp;key=10.1002%2Fcmdc.201000280" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Castiglioni%2C+E.%3B+Di+Fabio%2C+R.%3B+Togninelli%2C+A.%3B+Brough%2C+S.%3B+Brown%2C+F.%3B+Dal+Cin%2C+M.%3B+Gianotti%2C+M.%3B+Marchioro%2C+C.%3B+Merlo%2C+G.%3B+Spinosa%2C+R.%3B+Wigglesworth%2C+M.+J.%3B+Botta%2C+M.+Towards+the+discovery+on+new+hypnotic+agents%3A+synthesis+and+preliminary+pharmacological+evaluation+of+a+novel+class+of+dibenzo%5Ba%2Cd%5Dcycloheptene+derivatives.+ChemMedChem.+%5BOnline+early+access%5D.+DOI%3A+10.1002%2Fcmdc.201000280.+Published+Online%3A+Oct+4%2C+2010."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201000280&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201000280%26sid%3Dliteratum%253Aachs%26aulast%3DCastiglioni%26aufirst%3DE.%26atitle%3DTowards%2520the%2520discovery%2520on%2520new%2520hypnotic%2520agents%253A%2520synthesis%2520and%2520preliminary%2520pharmacological%2520evaluation%2520of%2520a%2520novel%2520class%2520of%2520dibenzo%255Ba%252Cd%255Dcycloheptene%2520derivatives%26jtitle%3DChemMedChem.%26doi%3D10.1002%2Fcmdc.201000280" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Kantor, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jakus, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balogh, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benko, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bagdy, G.</span><span> </span><span class="NLM_article-title">Increased wakefulness, motor activity and decreased theta activity after blockade of the 5-HT<sub>2B</sub> receptor by the subtype-selective antagonist SB-215505</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">142</span><span class="NLM_x">, </span> <span class="NLM_fpage">1332</span><span class="NLM_x">–</span> <span class="NLM_lpage">1342</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm100856p&amp;key=10.1038%2Fsj.bjp.0705887" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Fjm100856p&amp;key=15265808" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm100856p&amp;key=1%3ACAS%3A528%3ADC%252BD2cXntlCrt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=142&publication_year=2004&pages=1332-1342&author=S.+Kantorauthor=R.+Jakusauthor=B.+Baloghauthor=A.+Benkoauthor=G.+Bagdy&title=Increased+wakefulness%2C+motor+activity+and+decreased+theta+activity+after+blockade+of+the+5-HT2B+receptor+by+the+subtype-selective+antagonist+SB-215505"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Increased wakefulness, motor activity and decreased theta activity after blockade of the 5-HT2B receptor by the subtype-selective antagonist SB-215505</span></div><div class="casAuthors">Kantor, Sandor; Jakus, Rita; Balogh, Brigitta; Benko, Anita; Bagdy, Gyorgy</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">142</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1332-1342</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">1 Serotonin-2 receptor antagonists, like ritanserin, greatly enhance deep slow wave sleep (SWS-2) and low-frequency EEG power in humans and rodents.  5-HT2A and 5-HT2C receptors may be involved in these effects, but the role of the 5-HT2B receptor is still unclear.  2 To investigate the role of the 5-HT2B receptor in regulation of the sleep-wake cycle, the subtype-selective antagonist SB-215505 (0.1, 0.3 and 1.0 mg kg-1 i.p.) was administered to Sprague-Dawley rats at light onset (beginning of passive phase).  EEG, EMG and motor activity were recorded during the subsequent 8 h.  3 SB-215505 dose-dependently increased wakefulness (W) at the expense of the intermediate stage of sleep, paradoxical sleep (PS) and SWS-2 in the first hour.  Parallel to increased W, significantly increased motor activity was found.  Spectral anal. of the EEG in W showed a dose-dependent decrease in power d. in the 3-8 Hz frequency range (max. effect at 6 Hz).  In light slow wave sleep and SWS-2, the drug reduced low-frequency (<8 Hz) EEG power, suggesting decreased sleep intensity after SB-215505 treatment.  In PS, the drug dose-dependently decreased EEG power solely in the theta (6-9 Hz) band, primarily affecting the peak power value (7 Hz).  4 The well-known SWS-2 enhancing effect of 5-HT2 receptor antagonists is mediated by 5-HT2A and/or 5-HT2C receptors.  In contrast, blockade of 5-HT2B receptors increases motor activity and W along with decreased theta activity during W and PS.  Activation of 5-HT2B receptors may contribute to initiation of sleep and to theta generation during W and PS under physiol. conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotQO8zYUUA7LVg90H21EOLACvtfcHk0lgf3vtk02IluQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXntlCrt70%253D&md5=c59c0780f10c9a4f67538c3f3ebffe68</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0705887&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0705887%26sid%3Dliteratum%253Aachs%26aulast%3DKantor%26aufirst%3DS.%26aulast%3DJakus%26aufirst%3DR.%26aulast%3DBalogh%26aufirst%3DB.%26aulast%3DBenko%26aufirst%3DA.%26aulast%3DBagdy%26aufirst%3DG.%26atitle%3DIncreased%2520wakefulness%252C%2520motor%2520activity%2520and%2520decreased%2520theta%2520activity%2520after%2520blockade%2520of%2520the%25205-HT2B%2520receptor%2520by%2520the%2520subtype-selective%2520antagonist%2520SB-215505%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2004%26volume%3D142%26spage%3D1332%26epage%3D1342" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Smith, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piper, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duxon, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Upton, N.</span><span> </span><span class="NLM_article-title">Effect of SB-243213, a selective 5-HT<sub>2C</sub> receptor antagonist, on the rat sleep profile: a comparison to paroxetine</span> <span class="citation_source-journal">Pharmacol., Biochem. Behav.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">599</span><span class="NLM_x">–</span> <span class="NLM_lpage">605</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2002&pages=599-605&author=M.+I.+Smithauthor=D.+C.+Piperauthor=M.+S.+Duxonauthor=N.+Upton&title=Effect+of+SB-243213%2C+a+selective+5-HT2C+receptor+antagonist%2C+on+the+rat+sleep+profile%3A+a+comparison+to+paroxetine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DM.%2BI.%26aulast%3DPiper%26aufirst%3DD.%2BC.%26aulast%3DDuxon%26aufirst%3DM.%2BS.%26aulast%3DUpton%26aufirst%3DN.%26atitle%3DEffect%2520of%2520SB-243213%252C%2520a%2520selective%25205-HT2C%2520receptor%2520antagonist%252C%2520on%2520the%2520rat%2520sleep%2520profile%253A%2520a%2520comparison%2520to%2520paroxetine%26jtitle%3DPharmacol.%252C%2520Biochem.%2520Behav.%26date%3D2002%26volume%3D71%26spage%3D599%26epage%3D605" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Fonquerna, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miralpeix, M.</span><span> </span><span class="NLM_article-title">H<sub>1</sub> antihistamines: patent highlights 2000−2005</span> <span class="citation_source-journal">Expert Opin. Ther. Pat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">109</span><span class="NLM_x">–</span> <span class="NLM_lpage">117</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm100856p&amp;key=10.1517%2F13543776.16.2.109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm100856p&amp;key=1%3ACAS%3A528%3ADC%252BD28XotlGgtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=109-117&issue=2&author=S.+Fonquernaauthor=M.+Miralpeix&title=H1+antihistamines%3A+patent+highlights+2000%E2%88%922005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">H1 antihistamines: patent highlights 2000 - 2005</span></div><div class="casAuthors">Fonquerna, Silvia; Miralpeix, Montserrat</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">109-117</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Ashley Publications Ltd.</span>)
        </div><div class="casAbstract">A review.  Since the introduction of the first H1 antihistamine in 1945, much progress has been made in eliminating troublesome side effects.  Early efforts were directed at improving selectivity and avoiding sedative properties, and later at preventing the non-mechanism-related cardiotoxicity obsd. in some of the second-generation H1 antihistamines.  As the H1 antihistamines are still the first choice therapy against allergy symptoms, there remains an opportunity to obtain compds. with an improved and differentiated pharmacol. and therapeutic profile.  A patent literature review comprising the years 2000-2005 shows a redn. in the no. of new chem. entities as H1 antihistamines and a growing interest in dual H1-X compds.  With the introduction of dual H1-H3 and H1-CCR3 antagonists, a new direction of research has emerged that offers the potential of discovering a superior H1 antihistamine with anti-inflammatory properties able to deal with the inflammation and nasal congestion assocd. with allergic diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqz91toxGo37rVg90H21EOLACvtfcHk0lgf3vtk02IluQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XotlGgtw%253D%253D&md5=7f1fb5283af987ac69783caddf4af3bb</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1517%2F13543776.16.2.109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.16.2.109%26sid%3Dliteratum%253Aachs%26aulast%3DFonquerna%26aufirst%3DS.%26aulast%3DMiralpeix%26aufirst%3DM.%26atitle%3DH1%2520antihistamines%253A%2520patent%2520highlights%25202000%25E2%2588%25922005%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2006%26volume%3D16%26issue%3D2%26spage%3D109%26epage%3D117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Bousquet, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aria Workshop Group.</span><span> </span><span class="NLM_article-title">Allergic rhinitis and its impact on asthma</span> <span class="citation_source-journal">J. Allergy Clin. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">S147</span><span class="NLM_x">–</span> <span class="NLM_lpage">S333</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2001&pages=S147-S333&issue=5&author=J.+Bousquetauthor=Aria+Workshop+Group.&title=Allergic+rhinitis+and+its+impact+on+asthma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBousquet%26aufirst%3DJ.%26aulast%3D%26atitle%3DAllergic%2520rhinitis%2520and%2520its%2520impact%2520on%2520asthma%26jtitle%3DJ.%2520Allergy%2520Clin.%2520Immunol.%26date%3D2001%26volume%3D108%26issue%3D5%26spage%3DS147%26epage%3DS333" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Edgar, D. M.; Hangauer, D. G.; Leighton, H. J.; Mignot, E. J. M.; White, J. F.; Solomon, M.; Shiosaki, K.</span><span> </span><span class="NLM_article-title">Treatment of CNS Disorders Using CNS Target Modulators</span>. Patent WO2005/103041,<span class="NLM_x"> </span><span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=D.+M.+Edgar&author=D.+G.+Hangauer&author=H.+J.+Leighton&author=E.+J.+M.+Mignot&author=J.+F.+White&author=M.+Solomon&author=K.+Shiosaki&title=Treatment+of+CNS+Disorders+Using+CNS+Target+Modulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DEdgar%26aufirst%3DD.%2BM.%26atitle%3DTreatment%2520of%2520CNS%2520Disorders%2520Using%2520CNS%2520Target%2520Modulators%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit15b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Edgar, D. M.; Hangauer, D. G.; White, J. F.; Solomon, M.</span><span> </span><span class="NLM_article-title">Doxepin Analogs and Methods of Use Thereof</span>. Patent WO2005/058880,<span class="NLM_x"> </span><span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=D.+M.+Edgar&author=D.+G.+Hangauer&author=J.+F.+White&author=M.+Solomon&title=Doxepin+Analogs+and+Methods+of+Use+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DEdgar%26aufirst%3DD.%2BM.%26atitle%3DDoxepin%2520Analogs%2520and%2520Methods%2520of%2520Use%2520Thereof%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit15c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Edgar, D. M.; Hangauer, D. G.; White, J. F.; Solomon, M.; Shiosaki, K.</span><span> </span><span class="NLM_article-title">Loxepine Analogs and Methods of Use Thereof</span>. Patent WO2006/034414,<span class="NLM_x"> </span><span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=D.+M.+Edgar&author=D.+G.+Hangauer&author=J.+F.+White&author=M.+Solomon&author=K.+Shiosaki&title=Loxepine+Analogs+and+Methods+of+Use+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DEdgar%26aufirst%3DD.%2BM.%26atitle%3DLoxepine%2520Analogs%2520and%2520Methods%2520of%2520Use%2520Thereof%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Sullivan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guilleminault, C.</span><span> </span><span class="NLM_article-title">Emerging drugs for insomnia: new frontiers for old and novel targets</span> <span class="citation_source-journal">Expert Opin. Emerging Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">411</span><span class="NLM_x">–</span> <span class="NLM_lpage">422</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Fjm100856p&amp;key=10.1517%2F14728210903171948" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Fjm100856p&amp;key=19708818" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm100856p&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVCgurbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2009&pages=411-422&issue=3&author=S.+Sullivanauthor=C.+Guilleminault&title=Emerging+drugs+for+insomnia%3A+new+frontiers+for+old+and+novel+targets"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging drugs for insomnia: new frontiers for old and novel targets</span></div><div class="casAuthors">Sullivan, Shannon S.; Guilleminault, Christian</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Emerging Drugs</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">411-422</span>CODEN:
                <span class="NLM_cas:coden">EOEDA3</span>;
        ISSN:<span class="NLM_cas:issn">1472-8214</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Insomnia is the most prevalent sleep disorder, with up to 50% of the US adult population reporting symptoms of insomnia on a weekly basis and ∼ 12% with insomnia disorder.  Comorbid conditions such as depression and anxiety are frequent.  Insomnia is more common with older age, female gender and socioeconomic status.  Traditionally, therapy has focused on GABAA receptor agonists, and off-label antidepressant and antihistamine use.  With increased understanding of complex neural networks involved in sleep and wake, hypnotics are being developed to target a broader variety of receptors with increasing selectivity.  This review summarizes promising compds. in Phase II and III trials with evidence supporting efficacy for treatment of insomnia.  5-HT2A and 5-HT2C antagonists, melatonergic (MT1/MT2) agonists, orexin receptor (OX1/OX2) antagonists, as well as GABAA receptor agonists are reviewed and summarized.  Data are collected from PubMed and Pharmaprojects database searches, company websites, recent scientific meeting presentations and abstrs.  A variety of drugs targeting several pathways, including GABAA agonism, MT1/MT2 agonism, 5-HT2A antagonism, OX1/OX2 antagonism and others, are in Phase II and III trials.  More work should be done to understand the impact of these drugs in certain populations and in the context of comorbid conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKfbmX3Dwh4LVg90H21EOLACvtfcHk0ljKW-a4adlK7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVCgurbF&md5=33f28e611296310e8d3623290e20d7b3</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1517%2F14728210903171948&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14728210903171948%26sid%3Dliteratum%253Aachs%26aulast%3DSullivan%26aufirst%3DS.%26aulast%3DGuilleminault%26aufirst%3DC.%26atitle%3DEmerging%2520drugs%2520for%2520insomnia%253A%2520new%2520frontiers%2520for%2520old%2520and%2520novel%2520targets%26jtitle%3DExpert%2520Opin.%2520Emerging%2520Drugs%26date%3D2009%26volume%3D14%26issue%3D3%26spage%3D411%26epage%3D422" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">De Paulis, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Betts, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mobley, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manier, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sulser, F.</span><span> </span><span class="NLM_article-title">Synthesis of clozapine analogs and their affinity for clozapine and spiroperidol binding sites in rat brain</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1981</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x"> (</span><span class="NLM_issue">9</span><span class="NLM_x">) </span> <span class="NLM_fpage">1021</span><span class="NLM_x">–</span> <span class="NLM_lpage">1026</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm00141a001" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=1981&pages=1021-1026&issue=9&author=T.+De+Paulisauthor=C.+R.+Bettsauthor=H.+E.+Smithauthor=P.+L.+Mobleyauthor=D.+H.+Manierauthor=F.+Sulser&title=Synthesis+of+clozapine+analogs+and+their+affinity+for+clozapine+and+spiroperidol+binding+sites+in+rat+brain"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17a&amp;dbid=16384&amp;doi=10.1021%2Fjm00141a001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00141a001%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BPaulis%26aufirst%3DT.%26aulast%3DBetts%26aufirst%3DC.%2BR.%26aulast%3DSmith%26aufirst%3DH.%2BE.%26aulast%3DMobley%26aufirst%3DP.%2BL.%26aulast%3DManier%26aufirst%3DD.%2BH.%26aulast%3DSulser%26aufirst%3DF.%26atitle%3DSynthesis%2520of%2520clozapine%2520analogs%2520and%2520their%2520affinity%2520for%2520clozapine%2520and%2520spiroperidol%2520binding%2520sites%2520in%2520rat%2520brain%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1981%26volume%3D24%26issue%3D9%26spage%3D1021%26epage%3D1026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit17b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Jilek, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metysova, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pomykacek, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Protiva, M.</span><span> </span><span class="NLM_article-title">Neurotropic and psychotropic agents. XIX. 8-Halo derivatives of 10-(4-methyl-1-piperazinyl)-10,11-dihydrodibenzo[<i>b</i>,<i>f</i>]thiepin and related substances</span> <span class="citation_source-journal">Collect. Czech. Chem. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1968</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">1831</span><span class="NLM_x">–</span> <span class="NLM_lpage">1845</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=32&amp;doi=10.1021%2Fjm100856p&amp;key=1%3ACAS%3A528%3ADyaF1cXkvVKqtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=1968&pages=1831-1845&issue=6&author=J.+O.+Jilekauthor=J.+Metysovaauthor=J.+Pomykacekauthor=M.+Protiva&title=Neurotropic+and+psychotropic+agents.+XIX.+8-Halo+derivatives+of+10-%284-methyl-1-piperazinyl%29-10%2C11-dihydrodibenzo%5Bb%2Cf%5Dthiepin+and+related+substances"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17bR"><div class="casContent"><span class="casTitleNuber">17b</span><div class="casTitle"><span class="NLM_cas:atitle">Neurotropic and psychotropic agents.  XIX.  8-Halo derivatives of 10-(4-methyl-1-piperazinyl)-10,11-dihydrodibenzo[b,f]thiepin and related substances</span></div><div class="casAuthors">Jilek, J. O.; Metysova, J.; Pomykacek, J.; Protiva, M.</div><div class="citationInfo"><span class="NLM_cas:title">Collection of Czechoslovak Chemical Communications</span>
        (<span class="NLM_cas:date">1968</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1831-45</span>CODEN:
                <span class="NLM_cas:coden">CCCCAK</span>;
        ISSN:<span class="NLM_cas:issn">0010-0765</span>.
    </div><div class="casAbstract">The title compds. (I-III) are very active neuroleptics surpassing chlorpromazine considerably by their central nervous system depressant activityes.  4-FC6H4SH (50 g., b15 60°) treated with 97 g. 2-IC6H4CO2H, 5 g. Cu powder and 110 g. KOH in 1000 ml. H2O gave 87 g. 2-(4-fluorophenylthio)benzoic acid, m. 204-5° (EtOH).  4-BrC6H4SH (38.0 g., m. 74°) gave similarly 60 g. 2-(4-bromophenylthio)benzoic acid, m. 250° (AcOH).  2-(4-Chlorophenylthio)benzoic acid (200 g.) suspended in 1500 ml. Et2O added slowly to 32 g. LiAlH4 in 500 ml. Et2O, the mixt. stirred and refluxed 3 hrs., cooled, and decompd. dropwise with 200 ml. H2O and 1200 ml. dil. HCl (contg. 400 ml. concd. HCl) gave 165 g. 2-(4-chlorophenylthio)benzyl alc. (IV), b0.7 182°, m. 34-6°.  Similarly prepd. were 2-(4-fluorophenylthio)benzyl alc., m. 65-6° (C6H6-petroleum ether), and 2-(4-bromophenylthio)benzyl alc., b0.5 180°, m. 38°.  IV (163.3 g.) and 61.2 g. C5H5N cooled with ice and treated dropwise with 87.7 g. SOCl2, and the mixt. stirred 2 hrs. at room temp. gave 142.2 g. 2-(4-chlorophenylthio)benzyl chloride (V), m. 46-7° (EtOH), b0.5 162-4°.  Similarly prepd. were 2-(4-fluorophenylthio)benzyl chloride, b1 150°, and 2-(4-bromophenylthio)benzyl chloride, b0.25 162°, m. 52° (petroleum ether).  V (142.2 g.) in 160 ml. EtOH added to 33.9 g. NaCN in 53 ml. H2O and the mixt. stirred and refluxed 8 hrs. gave 134.1 g. 2-(4-chlorophenylthio)phenylacetonitrile (VI), m. 63-4° (Et2O-petroleum ether).  Similarly prepd. were 2-(4-fluorophenylthio)phenylacetonitrile, b0.2 147-8°, m. 49° (EtOH-petroleum ether), and 2-(4-bromophenylthio)phenylacetonitrile, m. 82° (EtOH-petroleum ether).  VI (134 g.) in 450 ml. EtOH treated with 130 g. KOH in 290 ml. H2O, the mixt. stirred and refluxed 5 hrs., evapd., the residue dissolved in 1750 ml. H2O, the soln. washed with Et2O, and acidified with 3N HCl gave 105 g. 2-(4-chlorophenylthio)phenylacetic acid (VII), m. 115-16° (C6H6 or 90% EtOH).  Similarly prepd. were 2-(4-fluorophenylthio)phenylacetic acid, m. 92-3° (50% EtOH or C6H6-petroleum ether), and 2-(4-bromophenylthio)phenylacetic acid, solvate with 0.5C6H6 m. 124-5° (C6H6-petroleum ether).  VII (11 g.) and 8 g. 1-methylpiperazine (VIII) heated 2 hrs. to 190°, the mixt. cooled, treated with 4 g. VIII and heated 2 hrs. to 190°, the procedure of heating with further 4 g. VIII repeated once more, the cooled product dissolved in 40 ml. EtOH, the soln. filtered with C, the filtrate evapd., the residue dissolved in 100 ml. C6H6, the soln. washed with 5% NaOH and H2O, shaken with 100 ml. 3N HCl, and the pptd. HCl salt decompd. with NH4OH gave 8.1 g. 1-methyl-4-[2-(4-chlorophenylthio)phenylacetyl]piperazine (IX), m. 92° (50% EtOH), HCl salt m. 212-15° (H2O).  VII (62.5 g.) and 250 g. polyphosphoric acid stirred and heated 2 hrs. to 125-30°, the mixt. cooled, decompd. with 1.2 kg. ice-cold H2O, and extd. with C6H6 gave 55 g. 8-chloro-10,11-dihydrodibenzo[b,f]thiepin-10-one (X), m. 125° (EtOH), uv and ir data given.  Similarly prepd. were XI, m. 104-6° (EtOH), and XII, m. 113° (uv and ir data given).  IX (1.9 g.) treated with a mixt. of 20 g. polyphosphoric acid and 2 ml. POCl3 and the mixt. heated 5 hrs. to 100-20°, 1 hr. to 130° and 1 hr. to 150-60° gave 1 g. X, m. 122-4°.  X (55 g.) in 1100 ml. EtOH refluxed and treated in 20 min. with 28 g. NaBH4 and 0.5 g. NaOH in 140 ml. H2O and the mixt. refluxed 4 hrs. gave 47.5 g. 8-chloro-10,11-dihydrodibenzo[b,f]thiepin-10-ol (XIII), m. 84-5° (Et2O-petroleum ether).  Similarly prepd. were 8-fluoro-10,11-dihydrodibenzo[b,f]thiepin-10-ol, m. 77-8° (cyclohexane), and 8-bromo-10,11-dihydrodibenzo[b,f]thiepin-10-ol, m. 107° (cyclohexane).  XIII (16 g.) and 40 ml. SOCl2 refluxed 3 hrs., gave 14.4 g. 8,10-dichloro-10,11-dihydrodibenzo[b,f]thiepin (XIV), m. 105-6° (cyclohexane).  XIII (120 g.) and 30 g. anhyd. CaCl2 in 700 ml. C6H6 satd. with dry HCl gave 120 g. XIV, m. 106-7°.  Similarly prepd. were 8-fluoro-10-chloro-10,11-dihydrodibenzo[b,f]thiepin, m. 98° (cyclohexane), and 8-bromo-10-chloro-10,11-dihydrodibenao[b,f]thiepin, m. 105-6° (cyclohexane).  XIII (13.1 g.), 70 ml. C6H6 and 4.0 g. 70% NaNH2 stirred 1 hr., the mixt. treated with 6.5 g. Me2N(CH2)2Cl, stirred 2 hrs. and refluxed 8 hrs., decompd. with H2O, the org. layer extd. with 100 ml. 1N HCl, the soln. made alk., and extd. with C6H6 gave 5.6 g. 8-chloro-10-(2-dimethylaminoethyoxy)-10,11-dihydrodibenzo[b,f]thiepin (XV), b0.4 194-8°, H maleate m. 108-10° (AcOEt).  Similarly prepd. was 8-chloro-10-(3-dimethylaminoproposy)-10,11-dihydrodibenzo[b,f]thiepin (XVI), b0.5 198-200°, H maleate m. 102-3° (AcOEt).  XIV (120 g.) and 180 ml. VIII heated 3.5 hrs. to 130°, the mixt. dild. with H2O and extd. with C6H6, the org. soln. extd. with dild. H2SO4, and the ext. made alk. gave 36.5 g. 8-chloro-10-(4-methylpiperazino)-10,11-dihydrodibenzo[b,f]thiepin (I), m. 99-101° (aq. EtOH), maleate m. 206-7° (aq. EtOH), HCl salt monohydrate m. 130-5° (H2O), 2HCl salt m. 190° (1N HCl).  XIV (10.0 g.), 12 g. VIII and 20 ml. CHCl3 refluxed 7 hrs. gave 9.2 g. I, m. 100-1° (EtOH).  Similarly were prepd. II, m. 144° (EtOH), maleate m. 175-7° (EtOH-Et2O), and III, m. 118-19° (aq. EtOH), maleate m. 203-4° (EtOH).  The described synthesis of XV gave as a neutral by-product 7.5 g. 2-chlorodibenzo[b,f]thiepin (XVII), m. 78-9° (Et2O-petroleum ether or MeOH).  The synthesis of I gave similarly 70 g. XVII, m. 77-8°.  Similarly were obtained XVIII, m. 82-3° (petroleum ether), and XIX, m. 93-5° (petroleum ether).  XIV (12 g.) and 24 ml. 1-phenylpiperazine heated 3.5 hrs. to 125-30° gave 10.5 g. 8-chloro-10-(4-phenylpiperazino)-10,11-dihydrodibenzo[b,f]thiepin, m. 135-6° (C6H6-EtOH), maleate m. 182-4° (EtOH-C6H6).  XIV (12 g.) and 24 ml. 1-benzylpiperazine gave similarly 13 g. 8-chloro-10-(4-benzylpiperazino)-10,11-dihydrodibenzo[b,f]thiepin, m. 150-1° (C6H6-EtOH); maleate m. 204-5° (EtOH).  XIV (5 g.), 8 g. 4-hydroxypiperidine (b15 115-18°) and 20 ml. CHCl3 refluxed 6 hrs. gave 6 g. 8-chloro-10-(4-hydroxypiperidino)-10,11-dihydrodibenzo[b,f]thiepin, m. 97-9° (EtOH), H maleate m. 188-9° (EtOH).  I (1.8 g.) in 20 ml. MeOH treated with 0.7 ml. 30% alc. HCl and 5 ml. H2O, the soln. treated dropwise with a soln. of 1.25 g. HIO4 and 0.22 g. NaOH in 12.5 ml. H2O, the mixt. kept at room temp. overnight, evapd., the residue made alk. with NH4OH, extd. with C6H6, the product transferred into 60 ml. 2N HCl, the soln. made alk., and extd. with C6H6 gave 1.85 g. 8-chloro-10-(4-methylpiperazino)-10,11-dihydrodibenzo[b,f]thiepin 5-oxide (XX), maleate m. 186-8° (EtOH).  XVII (3.0 g.) in 60 ml. HCO2H (90%) and 30 ml. AcOH treated dropwise in 20 min. with 7.5 ml. 30% H2O2 and the mixt. kept 12 hrs. at room temp., heated 3 hrs. to 40° and 1.5 hrs. to 90° gave 2.55 g. 2-chlorodibenzo[b,f]thiepin 5,5-dioxide, m. 131-2°.  Pharmacol. properties of I-III, XV, XVI, and XX (acute toxicity in mice, rotating rod, narcosis potentiation, antiserotonin activity) are tabulated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDv1YwNa4OYbVg90H21EOLACvtfcHk0ljKW-a4adlK7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF1cXkvVKqtrc%253D&md5=3c1399f9e670a86bf0d6376358ea045e</span></div><a href="/servlet/linkout?suffix=cit17b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJilek%26aufirst%3DJ.%2BO.%26aulast%3DMetysova%26aufirst%3DJ.%26aulast%3DPomykacek%26aufirst%3DJ.%26aulast%3DProtiva%26aufirst%3DM.%26atitle%3DNeurotropic%2520and%2520psychotropic%2520agents.%2520XIX.%25208-Halo%2520derivatives%2520of%252010-%25284-methyl-1-piperazinyl%2529-10%252C11-dihydrodibenzo%255Bb%252Cf%255Dthiepin%2520and%2520related%2520substances%26jtitle%3DCollect.%2520Czech.%2520Chem.%2520Commun.%26date%3D1968%26volume%3D33%26issue%3D6%26spage%3D1831%26epage%3D1845" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit17c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Ong, H. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Profitt, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, V. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spaulding, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilker, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geyer, H. M.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kruse, H.</span><span> </span><span class="NLM_article-title">Tricyclics with analgesic and antidepressant activity. 1. [[(Alkylamino)ethyl]thio]dibenz[<i>b</i>,<i>f</i>]oxepins and 10,11-dihydro derivatives</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1980</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">494</span><span class="NLM_x">–</span> <span class="NLM_lpage">501</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm00179a005" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1980&pages=494-501&issue=5&author=H.+H.+Ongauthor=J.+A.+Profittauthor=V.+B.+Andersonauthor=T.+C.+Spauldingauthor=J.+C.+Wilkerauthor=H.+M.+Geyerauthor=H.+Kruse&title=Tricyclics+with+analgesic+and+antidepressant+activity.+1.+%5B%5B%28Alkylamino%29ethyl%5Dthio%5Ddibenz%5Bb%2Cf%5Doxepins+and+10%2C11-dihydro+derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17c&amp;dbid=16384&amp;doi=10.1021%2Fjm00179a005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00179a005%26sid%3Dliteratum%253Aachs%26aulast%3DOng%26aufirst%3DH.%2BH.%26aulast%3DProfitt%26aufirst%3DJ.%2BA.%26aulast%3DAnderson%26aufirst%3DV.%2BB.%26aulast%3DSpaulding%26aufirst%3DT.%2BC.%26aulast%3DWilker%26aufirst%3DJ.%2BC.%26aulast%3DGeyer%26aufirst%3DH.%2BM.%26aulast%3DKruse%26aufirst%3DH.%26atitle%3DTricyclics%2520with%2520analgesic%2520and%2520antidepressant%2520activity.%25201.%2520%255B%255B%2528Alkylamino%2529ethyl%255Dthio%255Ddibenz%255Bb%252Cf%255Doxepins%2520and%252010%252C11-dihydro%2520derivatives%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1980%26volume%3D23%26issue%3D5%26spage%3D494%26epage%3D501" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit17d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Lang, Y. L.; Medaer, B. P. A. M. J.; Hoornaert, G. J. C.; Brossette, T.; Compernolle, F. J. C.; Guillaume, M. J. M. A.; Mao, H.; Kozlecki, T.</span><span> </span><span class="NLM_article-title">Preparation of Trans-Fused 11-Fluoro-3,3a,8,12b-tetrahydro-2<i>H</i>-dibenzo[3,4:6,7]cyclohepta[1,2-<i>b</i>]furans via Acid-Catalyzed Cyclization of Cis-Fused 8-Fluoro-11-(2,3-dihydroxypropyl)-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>]cyclohepten-10-yl Alkylcarboxylate Esters</span>. Patent WO2003048146A1,<span class="NLM_x"> </span><span class="NLM_year">2003</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2003&author=Y.+L.+Lang&author=B.+P.+A.+M.+J.+Medaer&author=G.+J.+C.+Hoornaert&author=T.+Brossette&author=F.+J.+C.+Compernolle&author=M.+J.+M.+A.+Guillaume&author=H.+Mao&author=T.+Kozlecki&title=Preparation+of+Trans-Fused+11-Fluoro-3%2C3a%2C8%2C12b-tetrahydro-2H-dibenzo%5B3%2C4%3A6%2C7%5Dcyclohepta%5B1%2C2-b%5Dfurans+via+Acid-Catalyzed+Cyclization+of+Cis-Fused+8-Fluoro-11-%282%2C3-dihydroxypropyl%29-10%2C11-dihydro-5H-dibenzo%5Ba%2Cd%5Dcyclohepten-10-yl+Alkylcarboxylate+Esters"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLang%26aufirst%3DY.%2BL.%26atitle%3DPreparation%2520of%2520Trans-Fused%252011-Fluoro-3%252C3a%252C8%252C12b-tetrahydro-2H-dibenzo%255B3%252C4%253A6%252C7%255Dcyclohepta%255B1%252C2-b%255Dfurans%2520via%2520Acid-Catalyzed%2520Cyclization%2520of%2520Cis-Fused%25208-Fluoro-11-%25282%252C3-dihydroxypropyl%2529-10%252C11-dihydro-5H-dibenzo%255Ba%252Cd%255Dcyclohepten-10-yl%2520Alkylcarboxylate%2520Esters%26date%3D2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Surter, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weston, A. W.</span><span> </span><span class="NLM_article-title">α-β Dialkylphenethylamines. Alkylation of phenylacetone</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1942</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">533</span><span class="NLM_x">–</span> <span class="NLM_lpage">536</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=1942&pages=533-536&author=C.+M.+Surterauthor=A.+W.+Weston&title=%CE%B1-%CE%B2+Dialkylphenethylamines.+Alkylation+of+phenylacetone"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSurter%26aufirst%3DC.%2BM.%26aulast%3DWeston%26aufirst%3DA.%2BW.%26atitle%3D%25CE%25B1-%25CE%25B2%2520Dialkylphenethylamines.%2520Alkylation%2520of%2520phenylacetone%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1942%26volume%3D64%26spage%3D533%26epage%3D536" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Kulkarni, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davawala, S. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doke, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pendharkar, D. S.</span><span> </span><span class="NLM_article-title">An expedient protocol for cyclopentenone annulation</span> <span class="citation_source-journal">Synthesis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">2919</span><span class="NLM_x">–</span> <span class="NLM_lpage">2926</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Fjm100856p&amp;key=10.1055%2Fs-2004-831208" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2004&pages=2919-2926&author=M.+G.+Kulkarniauthor=S.+I.+Davawalaauthor=A.+K.+Dokeauthor=D.+S.+Pendharkar&title=An+expedient+protocol+for+cyclopentenone+annulation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1055%2Fs-2004-831208&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-2004-831208%26sid%3Dliteratum%253Aachs%26aulast%3DKulkarni%26aufirst%3DM.%2BG.%26aulast%3DDavawala%26aufirst%3DS.%2BI.%26aulast%3DDoke%26aufirst%3DA.%2BK.%26aulast%3DPendharkar%26aufirst%3DD.%2BS.%26atitle%3DAn%2520expedient%2520protocol%2520for%2520cyclopentenone%2520annulation%26jtitle%3DSynthesis%26date%3D2004%26volume%3D17%26spage%3D2919%26epage%3D2926" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Bruysters, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jongejan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gillard, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van de Manakker, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bakker, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chatelain, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leurs, R.</span><span> </span><span class="NLM_article-title">Pharmacological differences between human and guinea pig histamine H<sub>1</sub> receptors: Asn84 (2.61) as key residue within an additional binding pocket in the H<sub>1</sub> receptor</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">1045</span><span class="NLM_x">–</span> <span class="NLM_lpage">1052</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2005&pages=1045-1052&author=M.+Bruystersauthor=A.+Jongejanauthor=M.+Gillardauthor=F.+van+de+Manakkerauthor=R.+A.+Bakkerauthor=P.+Chatelainauthor=R.+Leurs&title=Pharmacological+differences+between+human+and+guinea+pig+histamine+H1+receptors%3A+Asn84+%282.61%29+as+key+residue+within+an+additional+binding+pocket+in+the+H1+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBruysters%26aufirst%3DM.%26aulast%3DJongejan%26aufirst%3DA.%26aulast%3DGillard%26aufirst%3DM.%26aulast%3Dvan%2Bde%2BManakker%26aufirst%3DF.%26aulast%3DBakker%26aufirst%3DR.%2BA.%26aulast%3DChatelain%26aufirst%3DP.%26aulast%3DLeurs%26aufirst%3DR.%26atitle%3DPharmacological%2520differences%2520between%2520human%2520and%2520guinea%2520pig%2520histamine%2520H1%2520receptors%253A%2520Asn84%2520%25282.61%2529%2520as%2520key%2520residue%2520within%2520an%2520additional%2520binding%2520pocket%2520in%2520the%2520H1%2520receptor%26jtitle%3DMol.%2520Pharmacol.%26date%3D2005%26volume%3D67%26spage%3D1045%26epage%3D1052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit20b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Nonaka, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohshima, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kono, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kase, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohta, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukui, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ichimura, M.</span><span> </span><span class="NLM_article-title">Unique binding pocket for KW-4679 in the histamine H<sub>1</sub> receptor</span> <span class="citation_source-journal">Eur. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">345</span><span class="NLM_x">, </span> <span class="NLM_fpage">111</span><span class="NLM_x">–</span> <span class="NLM_lpage">117</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20b&amp;dbid=16&amp;doi=10.1021%2Fjm100856p&amp;key=10.1016%2FS0014-2999%2897%2901620-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20b&amp;dbid=8&amp;doi=10.1021%2Fjm100856p&amp;key=9593602" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20b&amp;dbid=32&amp;doi=10.1021%2Fjm100856p&amp;key=1%3ACAS%3A528%3ADyaK1cXitVKis7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=345&publication_year=1998&pages=111-117&author=H.+Nonakaauthor=S.+Otakiauthor=E.+Ohshimaauthor=M.+Konoauthor=H.+Kaseauthor=K.+Ohtaauthor=H.+Fukuiauthor=M.+Ichimura&title=Unique+binding+pocket+for+KW-4679+in+the+histamine+H1+receptor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20bR"><div class="casContent"><span class="casTitleNuber">20b</span><div class="casTitle"><span class="NLM_cas:atitle">Unique binding pocket for KW-4679 in the histamine H1 receptor</span></div><div class="casAuthors">Nonaka, Hiromi; Otaki, Shizuo; Ohshima, Etsuo; Kono, Motomichi; Kase, Hiroshi; Ohta, Kazumi; Fukui, Hiroyuki; Ichimura, Michio</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">345</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">111-117</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">The histamine H1 receptor has an aspartate (Asp) residue in transmembrane helix 3 (TM3), which is well-conserved among biogenic amine receptors.  The Asp residue is one of the most crucial amino acids for ligand binding.  The tested histamine H1 receptor antagonists with tri- and tetracyclic structures were not selective for histamine H1 receptors and showed affinity for several other biogenic amine receptors.  In contrast, KW-4679 ((Z)-11-[3-(dimethylamino)propylidene]-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid-HCl), a tricyclic compd., was a selective histamine H1 receptor antagonist.  [3H]KW-4679 had high affinity (Kd value of 2.5 nM) for wild-type human histamine H receptors.  In the [3H]KW-4679 binding assay, replacement of Asp107 by alanine by site-directed mutagenesis greatly reduced the affinities (280-2100-fold) of tri- and tetracyclic compds., whereas this mutation led to a comparatively small redn. (14-fold) in KW-4679 affinity.  These results demonstrate that the tested tri- and tetracyclic histamine H1 receptor antagonists which have a tight interaction with the Asp residue are not selective for the histamine H1 receptor.  Furthermore, the high selectivity of KW-4679 might be explained by a unique binding pocket, which consists of the Asp residue and other acceptor sites, in the histamine H1 receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBNMM_S2KXtrVg90H21EOLACvtfcHk0ljgNOqfqpLaKQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXitVKis7k%253D&md5=383232ccc6640311241b59ed226331c8</span></div><a href="/servlet/linkout?suffix=cit20b&amp;dbid=16384&amp;doi=10.1016%2FS0014-2999%2897%2901620-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-2999%252897%252901620-8%26sid%3Dliteratum%253Aachs%26aulast%3DNonaka%26aufirst%3DH.%26aulast%3DOtaki%26aufirst%3DS.%26aulast%3DOhshima%26aufirst%3DE.%26aulast%3DKono%26aufirst%3DM.%26aulast%3DKase%26aufirst%3DH.%26aulast%3DOhta%26aufirst%3DK.%26aulast%3DFukui%26aufirst%3DH.%26aulast%3DIchimura%26aufirst%3DM.%26atitle%3DUnique%2520binding%2520pocket%2520for%2520KW-4679%2520in%2520the%2520histamine%2520H1%2520receptor%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D1998%26volume%3D345%26spage%3D111%26epage%3D117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Kehne, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baron, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carr, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaney, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elands, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feldman, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frank, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Giersbergen, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCloskey, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCarty, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poirot, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senyah, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siegel, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Widmaier, C.</span><span> </span><span class="NLM_article-title">Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT<sub>2A</sub> antagonist with a favorable CNS safety profile</span> <span class="citation_source-journal">J. Pharmacol Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">277</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">968</span><span class="NLM_x">–</span> <span class="NLM_lpage">981</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Fjm100856p&amp;key=8627580" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm100856p&amp;key=1%3ACAS%3A528%3ADyaK28XivFeht7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=1996&pages=968-981&issue=2&author=J.+H.+Kehneauthor=B.+M.+Baronauthor=A.+A.+Carrauthor=S.+F.+Chaneyauthor=J.+Elandsauthor=D.+J.+Feldmanauthor=R.+A.+Frankauthor=P.+L.+van+Giersbergenauthor=T.+C.+McCloskeyauthor=M.+P.+Johnsonauthor=D.+R.+McCartyauthor=M.+Poirotauthor=Y.+Senyahauthor=B.+W.+Siegelauthor=C.+Widmaier&title=Preclinical+characterization+of+the+potential+of+the+putative+atypical+antipsychotic+MDL+100%2C907+as+a+potent+5-HT2A+antagonist+with+a+favorable+CNS+safety+profile"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile</span></div><div class="casAuthors">Kehne, John H.; Baron, Bruce M.; Carr, Albert A.; Chaney, Stephen F.; Elands, Jack; Feldman, Daniel J.; Frank, Robert A.; Van Giersbergen, Paul L. M.; McCloskey, Timothy C.; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">277</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">968-981</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">In preclin. studies, [R-(+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol] (MDL 100,907), a putative atypical antipsychotic, was characterized in vitro as a potent and selective ligand for the serotonin2A (5-HT2A) receptor and was evaluated in vitro and in vivo as a potent 5-HT2A receptor antagonist.  Furthermore, MDL 100,907's potential CNS safety profile and selectivity as a potential antipsychotic agent were evaluated and compared with benchmark compds.  MDL 100,907 demonstrated low nanomolar or subnanomolar binding in vitro at the 5-HT2A receptor and showed a > 100-fold sepn. from all other receptors measured.  MDL 100,907 has subnanomolar potency as a 5-HT2A antagonist in vitro in reversing 5-HT-stimulated inositol phosphate accumulation in NIH 3T3 cells transfected with the rat 5-HT2A receptor.  In vivo, MDL 100,907 potently inhibited 5-methoxy-N,N-dimethyltryptamine-induced head twitches in mice or 5-hydroxytrypophan-induced head twitched in rats.  In vivo functional tests in mice revealed a > 500-fold sepn. between doses that produced 5-HT2A antagonism and doses that produced α1-adrenergic or striatal D2 antagonism.  Using inhibition of D-amphetamine-stimulated locomotion in mice as a measure of potential antipsychotic efficacy, MDL 100,907 showed a superior CNS safety index relative to the ref. compds., haloperidol, clozapine, risperidone,ritanserin, and amperozide, in each of five tests for side effect potential, including measures of ataxia, general depressant effects, α1-adrenergic antagonism, striatal D2 receptor antagonism, and muscle relaxation.  MDL 100,907 did not antagonize apomorphine-induced stereotypies in rats, suggesting that it potentially lacks extrapyramidal side effect liability.  MDL 100,907 showed selectivity as a potential antipsychotic in that it lacked consistent activity in selected rodent models of anticonvulsant, anti-depressant, analgesic, or anxiolytic activity.  In summary, these preclin. data indicate that MDL 100,907 is a potent and selective ligand at the 5-HT2A receptor.  MDL 100,907's potent 5-HT2A antagonist activity might account for its activity in preclin. models of antipsychotic potential.  Ongoing clin. evaluation with MDL 100,907 will test the hypothesis that 5-HT2A receptor antagonism is sufficient for antipsychotic activity in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqravKtRD4ZLbVg90H21EOLACvtfcHk0ljjyr89nYMjDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XivFeht7s%253D&md5=01a7031bf3ef86ac47fe60ac14493a64</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKehne%26aufirst%3DJ.%2BH.%26aulast%3DBaron%26aufirst%3DB.%2BM.%26aulast%3DCarr%26aufirst%3DA.%2BA.%26aulast%3DChaney%26aufirst%3DS.%2BF.%26aulast%3DElands%26aufirst%3DJ.%26aulast%3DFeldman%26aufirst%3DD.%2BJ.%26aulast%3DFrank%26aufirst%3DR.%2BA.%26aulast%3Dvan%2BGiersbergen%26aufirst%3DP.%2BL.%26aulast%3DMcCloskey%26aufirst%3DT.%2BC.%26aulast%3DJohnson%26aufirst%3DM.%2BP.%26aulast%3DMcCarty%26aufirst%3DD.%2BR.%26aulast%3DPoirot%26aufirst%3DM.%26aulast%3DSenyah%26aufirst%3DY.%26aulast%3DSiegel%26aufirst%3DB.%2BW.%26aulast%3DWidmaier%26aufirst%3DC.%26atitle%3DPreclinical%2520characterization%2520of%2520the%2520potential%2520of%2520the%2520putative%2520atypical%2520antipsychotic%2520MDL%2520100%252C907%2520as%2520a%2520potent%25205-HT2A%2520antagonist%2520with%2520a%2520favorable%2520CNS%2520safety%2520profile%26jtitle%3DJ.%2520Pharmacol%2520Exp.%2520Ther.%26date%3D1996%26volume%3D277%26issue%3D2%26spage%3D968%26epage%3D981" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="note"><p class="first last">Parent spiroketone of compound <b>43</b> is <b>8a</b>(<i>R</i>). This is the only example where the <i>R</i> isomer is more active then the <i>S</i> isomer, for the spiroketone <b>8a</b>. The activity of corresponding compound obtained from <b>8a</b>(<i>S</i>) is <i>f</i>-p<i>K</i><sub>i</sub> hH<sub>1</sub> = 7.2 (FLIPR)/<i>f</i>-p<i>K</i><sub>i</sub> h5-HT<sub>2A</sub> = 5.7 (aequorin).</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Fernandez, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alonso, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andre′s, J. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cid, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dıaz, A</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iturrino, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gil, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Megens, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sipido, V. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trabanco, A. A.</span><span> </span><span class="NLM_article-title">Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">1709</span><span class="NLM_x">–</span> <span class="NLM_lpage">1712</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm049632c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=1709-1712&author=J.+Fernandezauthor=J.+M.+Alonsoauthor=J.+I.+Andre%E2%80%B2sauthor=J.+M.+Cidauthor=A+D%C4%B1azauthor=L.+Iturrinoauthor=P.+Gilauthor=A.+Megensauthor=V.+K.+Sipidoauthor=A.+A.+Trabanco&title=Discovery+of+new+tetracyclic+tetrahydrofuran+derivatives+as+potential+broad-spectrum+psychotropic+agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fjm049632c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm049632c%26sid%3Dliteratum%253Aachs%26aulast%3DFernandez%26aufirst%3DJ.%26aulast%3DAlonso%26aufirst%3DJ.%2BM.%26aulast%3DAndre%25E2%2580%25B2s%26aufirst%3DJ.%2BI.%26aulast%3DCid%26aufirst%3DJ.%2BM.%26aulast%3DD%25C4%25B1az%26aufirst%3DA%26aulast%3DIturrino%26aufirst%3DL.%26aulast%3DGil%26aufirst%3DP.%26aulast%3DMegens%26aufirst%3DA.%26aulast%3DSipido%26aufirst%3DV.%2BK.%26aulast%3DTrabanco%26aufirst%3DA.%2BA.%26atitle%3DDiscovery%2520of%2520new%2520tetracyclic%2520tetrahydrofuran%2520derivatives%2520as%2520potential%2520broad-spectrum%2520psychotropic%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D1709%26epage%3D1712" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Kalgutgar, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardner, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott Obach, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaffer, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Callegari, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henne, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mutlib, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalvie, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Donnel, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harriman, S. P.</span><span> </span><span class="NLM_article-title">A comprehensive listing of bioactivation pathways of organic fuctional groups</span> <span class="citation_source-journal">Curr. Drug Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">161</span><span class="NLM_x">–</span> <span class="NLM_lpage">225</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Fjm100856p&amp;key=10.2174%2F1389200054021799" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Fjm100856p&amp;key=15975040" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2005&pages=161-225&author=A.+S.+Kalgutgarauthor=I.+Gardnerauthor=R.+Scott+Obachauthor=C.+L.+Shafferauthor=E.+Callegariauthor=K.+R.+Henneauthor=A.+E.+Mutlibauthor=D.+K.+Dalvieauthor=J.+S.+Leeauthor=Y.+Nakaiauthor=J.+P.+O%E2%80%99Donnelauthor=J.+Boerauthor=S.+P.+Harriman&title=A+comprehensive+listing+of+bioactivation+pathways+of+organic+fuctional+groups"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.2174%2F1389200054021799&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389200054021799%26sid%3Dliteratum%253Aachs%26aulast%3DKalgutgar%26aufirst%3DA.%2BS.%26aulast%3DGardner%26aufirst%3DI.%26aulast%3DScott%2BObach%26aufirst%3DR.%26aulast%3DShaffer%26aufirst%3DC.%2BL.%26aulast%3DCallegari%26aufirst%3DE.%26aulast%3DHenne%26aufirst%3DK.%2BR.%26aulast%3DMutlib%26aufirst%3DA.%2BE.%26aulast%3DDalvie%26aufirst%3DD.%2BK.%26aulast%3DLee%26aufirst%3DJ.%2BS.%26aulast%3DNakai%26aufirst%3DY.%26aulast%3DO%25E2%2580%2599Donnel%26aufirst%3DJ.%2BP.%26aulast%3DBoer%26aufirst%3DJ.%26aulast%3DHarriman%26aufirst%3DS.%2BP.%26atitle%3DA%2520comprehensive%2520listing%2520of%2520bioactivation%2520pathways%2520of%2520organic%2520fuctional%2520groups%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2005%26volume%3D6%26spage%3D161%26epage%3D225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Tokunaga, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeda, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shinomiya, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirase, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamei, C.</span><span> </span><span class="NLM_article-title">Effects of some H<sub>1</sub>-antagonists on the sleep−wake cycle in sleep-disturbed rats</span> <span class="citation_source-journal">J. Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">201</span><span class="NLM_x">–</span> <span class="NLM_lpage">206</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Fjm100856p&amp;key=10.1254%2Fjphs.FP0061173" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Fjm100856p&amp;key=17287588" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm100856p&amp;key=1%3ACAS%3A528%3ADC%252BD2sXisFGnsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2007&pages=201-206&author=S.+Tokunagaauthor=Y.+Takedaauthor=K.+Shinomiyaauthor=M.+Hiraseauthor=C.+Kamei&title=Effects+of+some+H1-antagonists+on+the+sleep%E2%88%92wake+cycle+in+sleep-disturbed+rats"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of some H1-antagonists on the sleep-wake cycle in sleep-disturbed rats</span></div><div class="casAuthors">Tokunaga, Shin; Takeda, Yasuhiro; Shinomiya, Kazuaki; Hirase, Masahiro; Kamei, Chiaki</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacological Sciences (Tokyo, Japan)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">201-206</span>CODEN:
                <span class="NLM_cas:coden">JPSTGJ</span>;
        ISSN:<span class="NLM_cas:issn">1347-8613</span>.
    
            (<span class="NLM_cas:orgname">Japanese Pharmacological Society</span>)
        </div><div class="casAbstract">The present study was undertaken to investigate the effects of some H1-antagonists on the sleep-wake cycle in sleep-disturbed rats in comparison with those of nitrazepam.  Electrodes were chronically implanted into the frontal cortex and the dorsal neck muscle of rats for the EEG and electromyogram (EMG), resp.  EEG and EMG were recorded with an electroencephalograph.  SleepSign ver.2.0 was used for EEG and EMG anal.  The total times of waking, non-rapid eye movement (non-REM), and rapid eye movement (REM) sleep were measured from 10:00 to 16:00.  Nitrazepam showed a significant decrease in sleep latency, total waking time, and delta activity and an increase in the total non-REM sleep time.  A significant decrease in the sleep latency was obsd. with diphenhydramine, chlorpheniramine, and cyproheptadine.  Cyproheptadine also caused a significant decrease in the total waking time and increases in total non-REM sleep time, REM sleep time, slow wave sleep, and delta activity, although no remarkable effects were obsd. with diphenhydramine and chlorpheniramine.  In conclusion, cyproheptadine can be useful as a hypnotic, having not only sleep inducing-effects, but also sleep quantity- and quality-increasing effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQmVwKtvLJd7Vg90H21EOLACvtfcHk0ljjyr89nYMjDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXisFGnsr0%253D&md5=2a0a95848f78eb2e57aaa95d2eb58e0f</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1254%2Fjphs.FP0061173&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1254%252Fjphs.FP0061173%26sid%3Dliteratum%253Aachs%26aulast%3DTokunaga%26aufirst%3DS.%26aulast%3DTakeda%26aufirst%3DY.%26aulast%3DShinomiya%26aufirst%3DK.%26aulast%3DHirase%26aufirst%3DM.%26aulast%3DKamei%26aufirst%3DC.%26atitle%3DEffects%2520of%2520some%2520H1-antagonists%2520on%2520the%2520sleep%25E2%2588%2592wake%2520cycle%2520in%2520sleep-disturbed%2520rats%26jtitle%3DJ.%2520Pharmacol.%2520Sci.%26date%3D2007%26volume%3D103%26spage%3D201%26epage%3D206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Wigglesworth, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawless, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Standing, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mackenzie, E. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitchen, V. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mckay, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brough, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stylianou, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jewitt, F. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mclaren-Douglas, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jowet, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamayama, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finnigan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wise, A.</span><span> </span><span class="NLM_article-title">Use of cryopreserved cells for enabling greater flexibility in compound profiling</span> <span class="citation_source-journal">J. Biomol. Screening</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">354</span><span class="NLM_x">–</span> <span class="NLM_lpage">362</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Fjm100856p&amp;key=10.1177%2F1087057108317768" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Fjm100856p&amp;key=18467669" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Fjm100856p&amp;key=1%3ACAS%3A528%3ADC%252BD1cXotlCms7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2008&pages=354-362&author=M.+J.+Wigglesworthauthor=K.+J.+Lawlessauthor=D.+J.+Standingauthor=E.+K.+Mackenzieauthor=V.+R.+Kitchenauthor=F.+Mckayauthor=E.+Wardauthor=S.+J.+Broughauthor=M.+Stylianouauthor=F.+R.+Jewittauthor=A.+M.+Mclaren-Douglasauthor=M.+I.+Jowetauthor=N.+Tamayamaauthor=D.+Finniganauthor=J.+Dingauthor=A.+Wise&title=Use+of+cryopreserved+cells+for+enabling+greater+flexibility+in+compound+profiling"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Use of cryopreserved cells for enabling greater flexibility in compound profiling</span></div><div class="casAuthors">Wigglesworth, M. J.; Lawless, K. J.; Standing, D. J.; Mackenzie, E. K.; Kitchen, V. R.; McKay, F.; Ward, E.; Brough, S. J.; Stylianou, M.; Jewitt, F. R.; McLaren-Douglas, A. M.; Jowet, M. I.; Tamayama, N.; Finnigan, D.; Ding, J.; Wise, A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biomolecular Screening</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">354-362</span>CODEN:
                <span class="NLM_cas:coden">JBISF3</span>;
        ISSN:<span class="NLM_cas:issn">1087-0571</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Measurement of intracellular calcium release following agonist challenge within cells expressing the relevant membrane protein is a commonly used format to derive structure-activity relationship (SAR) data within a compd. profiling assay.  The Fluorometric Imaging Plate Reader (FLIPR) has become the gold std. for this purpose.  FLIPR traditionally uses cells that are maintained in continuous culture for compd. profiling of iterative chem. campaigns.  This supply dictates that assays can only be run on 4 of 5 weekdays, or alternative cell culture machinery is required such that plating can occur remotely at the weekend.  The data reported here demonstrate that high-quality compd. profiling data can be generated from the use of cryopreserved cells and that these cells can also be plated at various densities to generate equiv. data between 24 and 72 h post-plating.  Hence, the authors report a method that allows data generation throughout the week and without the requirement of highly automated cell culture or continuous culture.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGou2A9-oUY2m7Vg90H21EOLACvtfcHk0li4akXk-F6b-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXotlCms7g%253D&md5=e8767082b55d7d687534eebe5871eb04</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1177%2F1087057108317768&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1087057108317768%26sid%3Dliteratum%253Aachs%26aulast%3DWigglesworth%26aufirst%3DM.%2BJ.%26aulast%3DLawless%26aufirst%3DK.%2BJ.%26aulast%3DStanding%26aufirst%3DD.%2BJ.%26aulast%3DMackenzie%26aufirst%3DE.%2BK.%26aulast%3DKitchen%26aufirst%3DV.%2BR.%26aulast%3DMckay%26aufirst%3DF.%26aulast%3DWard%26aufirst%3DE.%26aulast%3DBrough%26aufirst%3DS.%2BJ.%26aulast%3DStylianou%26aufirst%3DM.%26aulast%3DJewitt%26aufirst%3DF.%2BR.%26aulast%3DMclaren-Douglas%26aufirst%3DA.%2BM.%26aulast%3DJowet%26aufirst%3DM.%2BI.%26aulast%3DTamayama%26aufirst%3DN.%26aulast%3DFinnigan%26aufirst%3DD.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DWise%26aufirst%3DA.%26atitle%3DUse%2520of%2520cryopreserved%2520cells%2520for%2520enabling%2520greater%2520flexibility%2520in%2520compound%2520profiling%26jtitle%3DJ.%2520Biomol.%2520Screening%26date%3D2008%26volume%3D13%26spage%3D354%26epage%3D362" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Brough, S. J.; Shah, P.</span><span> </span><span class="NLM_article-title">Use of Aequorin for G-Protein Coupled Receptor Hit Identification and Compound Profiling</span>. In  <span class="citation_source-book">G Protein-Coupled Receptors in Drug Discovery</span>, <span class="NLM_edition">5</span>th ed.; <span class="NLM_contrib-group">Leifert, W.</span>, Ed.; Methods in Molecular Biology, Vol. 552; <span class="NLM_publisher-name">Humana Press</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">2009</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">181</span>− <span class="NLM_lpage">198</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Fjm100856p&amp;key=10.1007%2F978-1-60327-317-6_13" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&pages=181-198&author=S.+J.+Brough&author=P.+Shahauthor=W.+Leifert&title=G+Protein-Coupled+Receptors+in+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1007%2F978-1-60327-317-6_13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-1-60327-317-6_13%26sid%3Dliteratum%253Aachs%26aulast%3DBrough%26aufirst%3DS.%2BJ.%26atitle%3DUse%2520of%2520Aequorin%2520for%2520G-Protein%2520Coupled%2520Receptor%2520Hit%2520Identification%2520and%2520Compound%2520Profiling%26btitle%3DG%2520Protein-Coupled%2520Receptors%2520in%2520Drug%2520Discovery%26aulast%3DLeifert%26aufirst%3DW.%26pub%3DHumana%2520Press%26date%3D2009%26spage%3D181%26epage%3D198" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Aslanian, R. G.; Shih, N.-Y.; Ting, P. C.; Berlin, M. Y.; Rosenblum, S. B.; McCormick, K. D.; Tom, W. C.; Boyce, C. W.; Mangiaracina, P.; Mutahi, M. W.; Piwinski, J. J.</span><span> </span><span class="NLM_article-title">Piperidine Compounds as Anti-Allergic</span>. WO/2002/032893,<span class="NLM_x"> </span><span class="NLM_year">2002</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2002&author=R.+G.+Aslanian&author=N.-Y.+Shih&author=P.+C.+Ting&author=M.+Y.+Berlin&author=S.+B.+Rosenblum&author=K.+D.+McCormick&author=W.+C.+Tom&author=C.+W.+Boyce&author=P.+Mangiaracina&author=M.+W.+Mutahi&author=J.+J.+Piwinski&title=Piperidine+Compounds+as+Anti-Allergic"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAslanian%26aufirst%3DR.%2BG.%26atitle%3DPiperidine%2520Compounds%2520as%2520Anti-Allergic%26date%3D2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Sugita, K.; Otsuka, M.; Oki, H.; Haginoya, N.; Ichikawa, M.; Itoh, M.</span><span> </span><span class="NLM_article-title">Tricyclic Compound</span>. WO/2007/055093,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=K.+Sugita&author=M.+Otsuka&author=H.+Oki&author=N.+Haginoya&author=M.+Ichikawa&author=M.+Itoh&title=Tricyclic+Compound"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSugita%26aufirst%3DK.%26atitle%3DTricyclic%2520Compound%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2a','cit2b','cit2c'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15a','cit15b','cit15c'],'ref16':['cit16'],'ref17':['cit17a','cit17b','cit17c','cit17d'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20a','cit20b'],'ref21':['cit21'],'ref22':[],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 18 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="NLM_string-name hlFld-ContribAuthor">Zoran Rankovic</span>. </span><span class="cited-content_cbyCitation_article-title">CNS Physicochemical Property Space Shaped by a Diverse Set of Molecules with Experimentally Determined Exposure in the Mouse Brain. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (14)
                                     , 5943-5954. <a href="https://doi.org/10.1021/acs.jmedchem.6b01469" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b01469</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b01469&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b01469%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DCNS%252BPhysicochemical%252BProperty%252BSpace%252BShaped%252Bby%252Ba%252BDiverse%252BSet%252Bof%252BMolecules%252Bwith%252BExperimentally%252BDetermined%252BExposure%252Bin%252Bthe%252BMouse%252BBrain%26aulast%3DRankovic%26aufirst%3DZoran%26date%3D2017%26date%3D2017%26date%3D2016%26date%3D2019%26date%3D05022019%26date%3D06102016%26date%3D07042017%26volume%3D60%26issue%3D14%26spage%3D5943%26epage%3D5954" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zoran  Rankovic</span>  . </span><span class="cited-content_cbyCitation_article-title">CNS Drug Design: Balancing Physicochemical Properties for Optimal Brain Exposure. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>58 </em>
                                    (6)
                                     , 2584-2608. <a href="https://doi.org/10.1021/jm501535r" title="DOI URL">https://doi.org/10.1021/jm501535r</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm501535r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm501535r%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DCNS%252BDrug%252BDesign%25253A%252BBalancing%252BPhysicochemical%252BProperties%252Bfor%252BOptimal%252BBrain%252BExposure%26aulast%3DRankovic%26aufirst%3DZoran%26date%3D2015%26date%3D2015%26date%3D2014%26date%3D05102014%26date%3D06012015%26date%3D26032015%26date%3D11122014%26volume%3D58%26issue%3D6%26spage%3D2584%26epage%3D2608" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">C.M.  Tice</span>, <span class="hlFld-ContribAuthor ">Y.  Zheng</span>, <span class="hlFld-ContribAuthor ">S.B.  Singh</span>. </span><span class="cited-content_cbyCitation_article-title">Spirocyclic Scaffolds in Drug Discovery. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 211-263. <a href="https://doi.org/10.1016/B978-0-12-409547-2.12291-7" title="DOI URL">https://doi.org/10.1016/B978-0-12-409547-2.12291-7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-409547-2.12291-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-409547-2.12291-7%26sid%3Dliteratum%253Aachs%26atitle%3DSpirocyclic%252BScaffolds%252Bin%252BDrug%252BDiscovery%26aulast%3DTice%26aufirst%3DC.M.%26date%3D2017%26spage%3D211%26epage%3D263%26pub%3DElsevier%26atitle%3DComprehensive%252BMedicinal%252BChemistry%252BIII%26date%3D2017%26volume%3D33" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zi-Jun  Wang</span>, <span class="hlFld-ContribAuthor ">Jian-Feng  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">The Molecular Basis of Insomnia: Implication for Therapeutic Approaches. </span><span class="cited-content_cbyCitation_journal-name">Drug Development Research</span><span> <strong>2016,</strong> <em>77 </em>
                                    (8)
                                     , 427-436. <a href="https://doi.org/10.1002/ddr.21338" title="DOI URL">https://doi.org/10.1002/ddr.21338</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ddr.21338&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fddr.21338%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Development%2520Research%26atitle%3DThe%252BMolecular%252BBasis%252Bof%252BInsomnia%25253A%252BImplication%252Bfor%252BTherapeutic%252BApproaches%26aulast%3DWang%26aufirst%3DZi-Jun%26date%3D2016%26date%3D2016%26volume%3D77%26issue%3D8%26spage%3D427%26epage%3D436" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Franziska  Naporra</span>, <span class="hlFld-ContribAuthor ">Susanne  Gobleder</span>, <span class="hlFld-ContribAuthor ">Hans-Joachim  Wittmann</span>, <span class="hlFld-ContribAuthor ">Julia  Spindler</span>, <span class="hlFld-ContribAuthor ">Michael  Bodensteiner</span>, <span class="hlFld-ContribAuthor ">Günther  Bernhardt</span>, <span class="hlFld-ContribAuthor ">Harald  Hübner</span>, <span class="hlFld-ContribAuthor ">Peter  Gmeiner</span>, <span class="hlFld-ContribAuthor ">Sigurd  Elz</span>, <span class="hlFld-ContribAuthor ">Andrea  Strasser</span>. </span><span class="cited-content_cbyCitation_article-title">Dibenzo[ b , f ][1,4]oxazepines and dibenzo[ b , e ]oxepines: Influence of the chlorine substitution pattern on the pharmacology at the H 1 R, H 4 R, 5-HT 2A R and other selected GPCRs. </span><span class="cited-content_cbyCitation_journal-name">Pharmacological Research</span><span> <strong>2016,</strong> <em>113 </em>, 610-625. <a href="https://doi.org/10.1016/j.phrs.2016.09.042" title="DOI URL">https://doi.org/10.1016/j.phrs.2016.09.042</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.phrs.2016.09.042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.phrs.2016.09.042%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacological%2520Research%26atitle%3DDibenzo%25255B%252Bb%252B%25252C%252Bf%252B%25255D%25255B1%25252C4%25255Doxazepines%252Band%252Bdibenzo%25255B%252Bb%252B%25252C%252Be%252B%25255Doxepines%25253A%252BInfluence%252Bof%252Bthe%252Bchlorine%252Bsubstitution%252Bpattern%252Bon%252Bthe%252Bpharmacology%252Bat%252Bthe%252BH%252B1%252BR%25252C%252BH%252B4%252BR%25252C%252B5-HT%252B2A%252BR%252Band%252Bother%252Bselected%252BGPCRs%26aulast%3DNaporra%26aufirst%3DFranziska%26date%3D2016%26volume%3D113%26spage%3D610%26epage%3D625" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yuan  Hu</span>, <span class="hlFld-ContribAuthor ">Yu-Nin  Wang</span>, <span class="hlFld-ContribAuthor ">Gang-Qiang  Zhang</span>, <span class="hlFld-ContribAuthor ">Xian-Zhe  Dong</span>, <span class="hlFld-ContribAuthor ">Wan-Wan  Liu</span>, <span class="hlFld-ContribAuthor ">Ping  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Gan-Dan-Liang-Yi-Tang alleviates p-chlorophenylalanine-induced insomnia through modification of the serotonergic and immune system. </span><span class="cited-content_cbyCitation_journal-name">Experimental and Therapeutic Medicine</span><span> <strong>2016,</strong> <em>12 </em>
                                    (5)
                                     , 3087-3092. <a href="https://doi.org/10.3892/etm.2016.3737" title="DOI URL">https://doi.org/10.3892/etm.2016.3737</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3892/etm.2016.3737&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3892%2Fetm.2016.3737%26sid%3Dliteratum%253Aachs%26jtitle%3DExperimental%2520and%2520Therapeutic%2520Medicine%26atitle%3DGan-Dan-Liang-Yi-Tang%252Balleviates%252Bp-chlorophenylalanine-induced%252Binsomnia%252Bthrough%252Bmodification%252Bof%252Bthe%252Bserotonergic%252Band%252Bimmune%252Bsystem%26aulast%3DHu%26aufirst%3DYuan%26date%3D2016%26date%3D2016%26volume%3D12%26issue%3D5%26spage%3D3087%26epage%3D3092" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">T. A. M.  Mocking</span>, <span class="hlFld-ContribAuthor ">R.  Bosma</span>, <span class="hlFld-ContribAuthor ">S. N.  Rahman</span>, <span class="hlFld-ContribAuthor ">E. W. E.  Verweij</span>, <span class="hlFld-ContribAuthor ">Daniel A.  McNaught-Flores</span>, <span class="hlFld-ContribAuthor ">Henry F.  Vischer</span>, <span class="hlFld-ContribAuthor ">Rob  Leurs</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular Aspects of Histamine Receptors. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2016,</strong>,, 1-49. <a href="https://doi.org/10.1007/978-3-319-40308-3_1" title="DOI URL">https://doi.org/10.1007/978-3-319-40308-3_1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-3-319-40308-3_1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-3-319-40308-3_1%26sid%3Dliteratum%253Aachs%26atitle%3DMolecular%252BAspects%252Bof%252BHistamine%252BReceptors%26aulast%3DMocking%26aufirst%3DT.%2BA.%2BM.%26date%3D2016%26date%3D2016%26spage%3D1%26epage%3D49%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DHistamine%252BReceptors%26aulast%3DBlandina%26aufirst%3DPatrizio%26date%3D2016%26volume%3D28" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zoran  Rankovic</span>. </span><span class="cited-content_cbyCitation_article-title">Designing CNS Drugs for Optimal Brain Exposure. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2015,</strong>,, 385-424. <a href="https://doi.org/10.1002/9781118788523.ch18" title="DOI URL">https://doi.org/10.1002/9781118788523.ch18</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9781118788523.ch18&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9781118788523.ch18%26sid%3Dliteratum%253Aachs%26atitle%3DDesigning%252BCNS%252BDrugs%252Bfor%252BOptimal%252BBrain%252BExposure%26aulast%3DRankovic%26aufirst%3DZoran%26date%3D2015%26date%3D2015%26spage%3D385%26epage%3D424%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%252C%2520Inc%26atitle%3DBlood-Brain%252BBarrier%252Bin%252BDrug%252BDiscovery%26aulast%3DDi%26aufirst%3DLi%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Derek J  Leishman</span>, <span class="hlFld-ContribAuthor ">Zoran  Rankovic</span>. </span><span class="cited-content_cbyCitation_article-title">Drug Discovery vs hERG. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2014,</strong>,, 225-259. <a href="https://doi.org/10.1007/7355_2014_38" title="DOI URL">https://doi.org/10.1007/7355_2014_38</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/7355_2014_38&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F7355_2014_38%26sid%3Dliteratum%253Aachs%26atitle%3DDrug%252BDiscovery%252Bvs%252BhERG%26aulast%3DLeishman%26aufirst%3DDerek%2BJ%26date%3D2014%26date%3D2014%26spage%3D225%26epage%3D259%26pub%3DSpringer%2520Berlin%2520Heidelberg%26atitle%3DTactics%252Bin%252BContemporary%252BDrug%252BDesign%26aulast%3DMeanwell%26aufirst%3DNicholas%2BA.%26date%3D2015%26volume%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">J.W.  Burton</span>. </span><span class="cited-content_cbyCitation_article-title">8.12 Reduction of CX to CH2. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2014,</strong>,, 446-478. <a href="https://doi.org/10.1016/B978-0-08-097742-3.00814-4" title="DOI URL">https://doi.org/10.1016/B978-0-08-097742-3.00814-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-08-097742-3.00814-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-08-097742-3.00814-4%26sid%3Dliteratum%253Aachs%26atitle%3D8.12%252BReduction%252Bof%252BCX%252Bto%252BCH2%26aulast%3DBurton%26aufirst%3DJ.W.%26date%3D2014%26spage%3D446%26epage%3D478%26pub%3DElsevier%26atitle%3DComprehensive%252BOrganic%252BSynthesis%252BII%26date%3D2014%26volume%3D104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yang  Gao</span>, <span class="hlFld-ContribAuthor ">Wanqing  Wu</span>, <span class="hlFld-ContribAuthor ">Huawen  Huang</span>, <span class="hlFld-ContribAuthor ">Yubing  Huang</span>, <span class="hlFld-ContribAuthor ">Huanfeng  Jiang</span>. </span><span class="cited-content_cbyCitation_article-title">Palladium-catalyzed intermolecular [3 + 2] carbocyclization of alkynols and propiolates: an efficient entry to halo-cyclopentadienes. </span><span class="cited-content_cbyCitation_journal-name">Chem. Commun.</span><span> <strong>2014,</strong> <em>50 </em>
                                    (7)
                                     , 846-848. <a href="https://doi.org/10.1039/C3CC47310D" title="DOI URL">https://doi.org/10.1039/C3CC47310D</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C3CC47310D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC3CC47310D%26sid%3Dliteratum%253Aachs%26jtitle%3DChem.%2520Commun.%26atitle%3DPalladium-catalyzed%252Bintermolecular%252B%25255B3%252B%25252B%252B2%25255D%252Bcarbocyclization%252Bof%252Balkynols%252Band%252Bpropiolates%25253A%252Ban%252Befficient%252Bentry%252Bto%252Bhalo-cyclopentadienes%26aulast%3DGao%26aufirst%3DYang%26date%3D2014%26date%3D2014%26volume%3D50%26issue%3D7%26spage%3D846%26epage%3D848" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Taryn L.  March</span>, <span class="hlFld-ContribAuthor ">Jamie A.  Freemont</span>, <span class="hlFld-ContribAuthor ">Geoff  Dumsday</span>, <span class="hlFld-ContribAuthor ">Martin R.  Johnston</span>, <span class="hlFld-ContribAuthor ">Peter J.  Duggan</span>. </span><span class="cited-content_cbyCitation_article-title">The Synthesis of Enantiopure α-Fluoro and α,α-Difluoro-β3-Arginine Derivatives. </span><span class="cited-content_cbyCitation_journal-name">Australian Journal of Chemistry</span><span> <strong>2014,</strong> <em>67 </em>
                                    (7)
                                     , 997. <a href="https://doi.org/10.1071/CH13590" title="DOI URL">https://doi.org/10.1071/CH13590</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1071/CH13590&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1071%2FCH13590%26sid%3Dliteratum%253Aachs%26jtitle%3DAustralian%2520Journal%2520of%2520Chemistry%26atitle%3DThe%252BSynthesis%252Bof%252BEnantiopure%252B%2525CE%2525B1-Fluoro%252Band%252B%2525CE%2525B1%25252C%2525CE%2525B1-Difluoro-%2525CE%2525B23-Arginine%252BDerivatives%26aulast%3DMarch%26aufirst%3DTaryn%2BL.%26date%3D2014%26volume%3D67%26issue%3D7%26spage%3D997" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shovan  Mondal</span>, <span class="hlFld-ContribAuthor ">Jean-Valère  Naubron</span>, <span class="hlFld-ContribAuthor ">Damien  Campolo</span>, <span class="hlFld-ContribAuthor ">Michel  Giorgi</span>, <span class="hlFld-ContribAuthor ">Michéle P.  Bertrand</span>, <span class="hlFld-ContribAuthor ">Malek  Nechab</span>. </span><span class="cited-content_cbyCitation_article-title">Cooperative Use of VCD and XRD for the Determination of Tetrahydrobenzoisoquinolines Absolute Configuration: A Reliable Proof of Memory of Chirality and Retention of Configuration in Enediyne Rearrangements. </span><span class="cited-content_cbyCitation_journal-name">Chirality</span><span> <strong>2013,</strong> <em>25 </em>
                                    (12)
                                     , 832-839. <a href="https://doi.org/10.1002/chir.22221" title="DOI URL">https://doi.org/10.1002/chir.22221</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/chir.22221&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fchir.22221%26sid%3Dliteratum%253Aachs%26jtitle%3DChirality%26atitle%3DCooperative%252BUse%252Bof%252BVCD%252Band%252BXRD%252Bfor%252Bthe%252BDetermination%252Bof%252BTetrahydrobenzoisoquinolines%252BAbsolute%252BConfiguration%25253A%252BA%252BReliable%252BProof%252Bof%252BMemory%252Bof%252BChirality%252Band%252BRetention%252Bof%252BConfiguration%252Bin%252BEnediyne%252BRearrangements%26aulast%3DMondal%26aufirst%3DShovan%26date%3D2013%26date%3D2013%26volume%3D25%26issue%3D12%26spage%3D832%26epage%3D839" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andrew G.  Leach</span>. </span><span class="cited-content_cbyCitation_article-title">Tactics to Avoid Inhibition of Cytochrome P450s. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2013,</strong>,, 107-158. <a href="https://doi.org/10.1007/7355_2013_25" title="DOI URL">https://doi.org/10.1007/7355_2013_25</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/7355_2013_25&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F7355_2013_25%26sid%3Dliteratum%253Aachs%26atitle%3DTactics%252Bto%252BAvoid%252BInhibition%252Bof%252BCytochrome%252BP450s%26aulast%3DLeach%26aufirst%3DAndrew%2BG.%26date%3D2013%26date%3D2013%26spage%3D107%26epage%3D158%26pub%3DSpringer%2520Berlin%2520Heidelberg%26atitle%3DTactics%252Bin%252BContemporary%252BDrug%252BDesign%26aulast%3DMeanwell%26aufirst%3DNicholas%2BA.%26date%3D2015%26volume%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Taryn L.  March</span>, <span class="hlFld-ContribAuthor ">Martin R.  Johnston</span>, <span class="hlFld-ContribAuthor ">Peter J.  Duggan</span>, <span class="hlFld-ContribAuthor ">James  Gardiner</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis, Structure, and Biological Applications of
              α
              -Fluorinated
              β
              -Amino Acids and Derivatives. </span><span class="cited-content_cbyCitation_journal-name">Chemistry & Biodiversity</span><span> <strong>2012,</strong> <em>9 </em>
                                    (11)
                                     , 2410-2441. <a href="https://doi.org/10.1002/cbdv.201200307" title="DOI URL">https://doi.org/10.1002/cbdv.201200307</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cbdv.201200307&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcbdv.201200307%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistry%2520%2526%2520Biodiversity%26atitle%3DSynthesis%25252C%252BStructure%25252C%252Band%252BBiological%252BApplications%252Bof%252B%2525CE%2525B1%252B-Fluorinated%252B%2525CE%2525B2%252B-Amino%252BAcids%252Band%252BDerivatives%26aulast%3DMarch%26aufirst%3DTaryn%2BL.%26date%3D2012%26date%3D2012%26volume%3D9%26issue%3D11%26spage%3D2410%26epage%3D2441" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shovan  Mondal</span>, <span class="hlFld-ContribAuthor ">Malek  Nechab</span>, <span class="hlFld-ContribAuthor ">Nicolas  Vanthuyne</span>, <span class="hlFld-ContribAuthor ">Michèle P.  Bertrand</span>. </span><span class="cited-content_cbyCitation_article-title">One-pot Crabbé homologation-radical cascade cyclisation with memory of chirality. </span><span class="cited-content_cbyCitation_journal-name">Chemical Communications</span><span> <strong>2012,</strong> <em>48 </em>
                                    (19)
                                     , 2549. <a href="https://doi.org/10.1039/c2cc17830c" title="DOI URL">https://doi.org/10.1039/c2cc17830c</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/c2cc17830c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2Fc2cc17830c%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Communications%26atitle%3DOne-pot%252BCrabb%2525C3%2525A9%252Bhomologation-radical%252Bcascade%252Bcyclisation%252Bwith%252Bmemory%252Bof%252Bchirality%26aulast%3DMondal%26aufirst%3DShovan%26date%3D2012%26volume%3D48%26issue%3D19%26spage%3D2549" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Benito  Alcaide</span>, <span class="hlFld-ContribAuthor ">Pedro  Almendros</span>. </span><span class="cited-content_cbyCitation_article-title">Four-Membered Ring Systems. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2011,</strong>,, 101-125. <a href="https://doi.org/10.1016/B978-0-08-096805-6.00004-8" title="DOI URL">https://doi.org/10.1016/B978-0-08-096805-6.00004-8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-08-096805-6.00004-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-08-096805-6.00004-8%26sid%3Dliteratum%253Aachs%26atitle%3DFour-Membered%252BRing%252BSystems%26aulast%3DAlcaide%26aufirst%3DBenito%26date%3D2011%26spage%3D101%26epage%3D125%26pub%3DElsevier%26date%3D2011%26volume%3D23" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Massimo  Gianotti</span>, <span class="hlFld-ContribAuthor ">Daniele  Andreotti</span>, <span class="hlFld-ContribAuthor ">Davide  Casotto</span>, <span class="hlFld-ContribAuthor ">Mario  Mattioli</span>, <span class="hlFld-ContribAuthor ">Anna  Mingardi</span>, <span class="hlFld-ContribAuthor ">Francesca  Pavone</span>, <span class="hlFld-ContribAuthor ">Roberto  Profeta</span>, <span class="hlFld-ContribAuthor ">Filippo  Valente</span>. </span><span class="cited-content_cbyCitation_article-title">Asymmetric route to spirotetracyclic (1S)-5′,11′-dihydro-3H-spiro[cyclopentane-1,10′-dibenzo[a,d]cyclohepten]-3-one derivatives. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron Letters</span><span> <strong>2011,</strong> <em>52 </em>
                                    (2)
                                     , 329-331. <a href="https://doi.org/10.1016/j.tetlet.2010.11.039" title="DOI URL">https://doi.org/10.1016/j.tetlet.2010.11.039</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tetlet.2010.11.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tetlet.2010.11.039%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%2520Letters%26atitle%3DAsymmetric%252Broute%252Bto%252Bspirotetracyclic%252B%2525281S%252529-5%2525E2%252580%2525B2%25252C11%2525E2%252580%2525B2-dihydro-3H-spiro%25255Bcyclopentane-1%25252C10%2525E2%252580%2525B2-dibenzo%25255Ba%25252Cd%25255Dcyclohepten%25255D-3-one%252Bderivatives%26aulast%3DGianotti%26aufirst%3DMassimo%26date%3D2011%26volume%3D52%26issue%3D2%26spage%3D329%26epage%3D331" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-21/jm100856p/production/images/medium/jm-2010-00856p_0004.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-21/jm100856p/production/images/large/jm-2010-00856p_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100856p&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-21/jm100856p/production/images/medium/jm-2010-00856p_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-21/jm100856p/production/images/large/jm-2010-00856p_0005.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. In vitro and physicochemical data of compound <b>9′a</b>. Superscript letters indicate the following: (a) functional p<i>K</i><sub>i</sub> measured in FLIPR (fluorescent imaging plate reader) assay;<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> (b) pharmacokinetics; (c) intrinsic clearance in human (h) and rat (r) liver microsomes (mL/min/g liver); (d) CYPEX (see experimental for details); (e) fraction unbound in rat brain; (f) ACD logD 7.4, version 11; (g) Å<sup>2</sup>; (h) dofetilide binding. See <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a> for details.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-21/jm100856p/production/images/large/jm-2010-00856p_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100856p&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-21/jm100856p/production/images/medium/jm-2010-00856p_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-21/jm100856p/production/images/large/jm-2010-00856p_0006.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. General Synthetic Procedure for the Preparation of Compounds <b>9</b> and <b>43</b>−<b>77</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2010/jmcmar.2010.53.issue-21/jm100856p/production/images/large/jm-2010-00856p_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm100856p&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(i) <i>tert</i>-Butanol, potassium <i>tert</i>-butoxide, allyl bromide, 35 °C (starting from <b>1c</b> and <b>1d</b>, the reaction led directly to <b>3</b>); (ii) Claisen rearrangement; (iii) degassed CH<sub>2</sub>Cl<sub>2</sub>, Grubbs second generation catalyst, room temp; (iv) BH<sub>3</sub> in THF, room temp, H<sub>2</sub>O, then NaOH 3 M, H<sub>2</sub>O<sub>2</sub>, room temp; (v) DMP, dry CH<sub>2</sub>Cl<sub>2</sub>, room temp; (vi) THF/acetic acid, Pd/C, H<sub>2</sub>, room temp; (vii) dimethylamine or appropriate amino esters (R<sup>1</sup>; see Tables <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>−<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>), DCE, NaBH(OAc)<sub>3</sub>, room temp; (viii) KOH, MeOH/H<sub>2</sub>O. (ix) To obtain <b>8b</b>: (a) H-Cube hydrogenation (30 atm at 60 °C); (b) DMP, dry CH<sub>2</sub>Cl<sub>2</sub>, room temp.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i80">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_55316" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_55316" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 29 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span>National Sleep Foundation. Sleep in America Poll Highlight & Key Findings. <a href="http://www.sleepfoundation.org/" class="extLink">http://www.sleepfoundation.org/</a>,<span class="NLM_x"> </span><span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=National+Sleep+Foundation.+Sleep+in+America+Poll+Highlight+%26+Key+Findings.+http%3A%2F%2Fwww.sleepfoundation.org%2F%2C+2010."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Wafford, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ebert, B.</span><span> </span><span class="NLM_article-title">Emerging anti-insomnia drugs: tackling sleeplessness and the quality of wake time</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">530</span><span class="NLM_x">–</span> <span class="NLM_lpage">540</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=530-540&issue=6&author=K.+Waffordauthor=B.+Ebert&title=Emerging+anti-insomnia+drugs%3A+tackling+sleeplessness+and+the+quality+of+wake+time"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWafford%26aufirst%3DK.%26aulast%3DEbert%26aufirst%3DB.%26atitle%3DEmerging%2520anti-insomnia%2520drugs%253A%2520tackling%2520sleeplessness%2520and%2520the%2520quality%2520of%2520wake%2520time%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2008%26volume%3D7%26issue%3D6%26spage%3D530%26epage%3D540" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit2b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Ohayon, M.</span><span> </span><span class="NLM_article-title">Epidemiology of insomnia: what we know and what we still need to learn</span> <span class="citation_source-journal">Sleep Med. Rev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">97</span><span class="NLM_x">–</span> <span class="NLM_lpage">111</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=16&amp;doi=10.1021%2Fjm100856p&amp;key=10.1053%2Fsmrv.2002.0186" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=8&amp;doi=10.1021%2Fjm100856p&amp;key=12531146" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2b&amp;dbid=32&amp;doi=10.1021%2Fjm100856p&amp;key=1%3ACAS%3A280%3ADC%252BD3s%252FisFGhtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2002&pages=97-111&issue=2&author=M.+Ohayon&title=Epidemiology+of+insomnia%3A+what+we+know+and+what+we+still+need+to+learn"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2bR"><div class="casContent"><span class="casTitleNuber">2b</span><div class="casTitle"><span class="NLM_cas:atitle">Epidemiology of insomnia: what we know and what we still need to learn</span></div><div class="casAuthors">Ohayon Maurice M</div><div class="citationInfo"><span class="NLM_cas:title">Sleep medicine reviews</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">97-111</span>
        ISSN:<span class="NLM_cas:issn">1087-0792</span>.
    </div><div class="casAbstract">Epidemiologists have published more than 50 studies of insomnia based on data collected in various representative community-dwelling samples or populations.  These surveys provide estimates of the prevalence of insomnia according to four definitions: insomnia symptoms, insomnia symptoms with daytime consequences, sleep dissatisfaction and insomnia diagnoses.  The first definition, based on insomnia criteria as defined by the DSM-IV, recognizes that about one-third of a general population presents at least one of them.  The second definition shows that, when daytime consequences of insomnia are taken into account, the prevalence is between 9% and 15%.  The third definition represents 8-18% of the general population.  The last definition, more precise and corresponding to a decision-making diagnosis, sets the prevalence at 6% of insomnia diagnoses according to the DSM-IV classification.  These four definitions of insomnia have higher prevalence rates in women than in men.  The prevalence of insomnia symptoms generally increases with age, while the rates of sleep dissatisfaction and diagnoses have little variation with age.  Numerous factors can initiate or maintain insomnia.  Mental disorders and organic diseases are the factors that have been the most frequently studied.  The association between insomnia and major depressive episodes has been constantly reported: individuals with insomnia are more likely to have a major depressive illness.  Longitudinal studies have shown that the persistence of insomnia is associated with the appearance of a new depressive episode.  Future epidemiological studies should focus on the natural evolution of insomnia.  Epidemiological genetic links of insomnia are yet to be studied.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSsKd7ea0dqcbesJRIHUP1ofW6udTcc2eaP1rJNUEh4B7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3s%252FisFGhtg%253D%253D&md5=78a4d8f470b7af6ac7ec0ec08c1c3b9c</span></div><a href="/servlet/linkout?suffix=cit2b&amp;dbid=16384&amp;doi=10.1053%2Fsmrv.2002.0186&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fsmrv.2002.0186%26sid%3Dliteratum%253Aachs%26aulast%3DOhayon%26aufirst%3DM.%26atitle%3DEpidemiology%2520of%2520insomnia%253A%2520what%2520we%2520know%2520and%2520what%2520we%2520still%2520need%2520to%2520learn%26jtitle%3DSleep%2520Med.%2520Rev.%26date%3D2002%26volume%3D6%26issue%3D2%26spage%3D97%26epage%3D111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit2c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Schutte-Rodin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Broch, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buysse, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dorsey, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sateia, M.</span><span> </span><span class="NLM_article-title">Clinical guideline for the evaluation and management of chronic insomnia in adults</span> <span class="citation_source-journal">J. Clin. Sleep Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">487</span><span class="NLM_x">–</span> <span class="NLM_lpage">504</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=8&amp;doi=10.1021%2Fjm100856p&amp;key=18853708" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2c&amp;dbid=32&amp;doi=10.1021%2Fjm100856p&amp;key=1%3ACAS%3A280%3ADC%252BD1cnlvFGhtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2008&pages=487-504&issue=5&author=S.+Schutte-Rodinauthor=L.+Brochauthor=D.+Buysseauthor=C.+Dorseyauthor=M.+Sateia&title=Clinical+guideline+for+the+evaluation+and+management+of+chronic+insomnia+in+adults"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2cR"><div class="casContent"><span class="casTitleNuber">2c</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical guideline for the evaluation and management of chronic insomnia in adults</span></div><div class="casAuthors">Schutte-Rodin Sharon; Broch Lauren; Buysse Daniel; Dorsey Cynthia; Sateia Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">487-504</span>
        ISSN:<span class="NLM_cas:issn">1550-9389</span>.
    </div><div class="casAbstract">Insomnia is the most prevalent sleep disorder in the general population, and is commonly encountered in medical practices.  Insomnia is defined as the subjective perception of difficulty with sleep initiation, duration, consolidation, or quality that occurs despite adequate opportunity for sleep, and that results in some form of daytime impairment.1 Insomnia may present with a variety of specific complaints and etiologies, making the evaluation and management of chronic insomnia demanding on a clinician's time.  The purpose of this clinical guideline is to provide clinicians with a practical framework for the assessment and disease management of chronic adult insomnia, using existing evidence-based insomnia practice parameters where available, and consensus-based recommendations to bridge areas where such parameters do not exist.  Unless otherwise stated, "insomnia" refers to chronic insomnia, which is present for at least a month, as opposed to acute or transient insomnia, which may last days to weeks.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTIa7hxRxemJO2mnZh2OgS0fW6udTcc2eaP1rJNUEh4B7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1cnlvFGhtA%253D%253D&md5=ed6a59b517e2fff101ab9457979038bc</span></div><a href="/servlet/linkout?suffix=cit2c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSchutte-Rodin%26aufirst%3DS.%26aulast%3DBroch%26aufirst%3DL.%26aulast%3DBuysse%26aufirst%3DD.%26aulast%3DDorsey%26aufirst%3DC.%26aulast%3DSateia%26aufirst%3DM.%26atitle%3DClinical%2520guideline%2520for%2520the%2520evaluation%2520and%2520management%2520of%2520chronic%2520insomnia%2520in%2520adults%26jtitle%3DJ.%2520Clin.%2520Sleep%2520Med.%26date%3D2008%26volume%3D4%26issue%3D5%26spage%3D487%26epage%3D504" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span>Sleep Disorders in the Diagnostic and Statistical Manual of Mental Disorders DSM-IV-TR, <span class="NLM_edition">4</span>th ed.; <span class="NLM_publisher-name">American Psychiatric Association</span>: <span class="NLM_publisher-loc">Arlington, VA</span>,<span class="NLM_x"> </span><span class="NLM_year">2000</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">597</span>− <span class="NLM_lpage">661</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Sleep+Disorders+in+the+Diagnostic+and+Statistical+Manual+of+Mental+Disorders+DSM-IV-TR%2C+4th+ed.%3B+American+Psychiatric+Association%3A+Arlington%2C+VA%2C+2000%3B+pp+597%E2%88%92661."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26pub%3DAmerican%2520Psychiatric%2520Association%26date%3D2000%26spage%3D597%26epage%3D661" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Shigemoto, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shinomiya, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mio, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azuma, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamei, C.</span><span> </span><span class="NLM_article-title">Effects of second-generation histamine H<sub>1</sub> receptor antagonists on the sleep−wakefulness cycle in rats</span> <span class="citation_source-journal">Eur. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">494</span><span class="NLM_x"> (</span><span class="NLM_issue">2−3</span><span class="NLM_x">) </span> <span class="NLM_fpage">161</span><span class="NLM_x">–</span> <span class="NLM_lpage">165</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm100856p&amp;key=10.1016%2Fj.ejphar.2004.05.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm100856p&amp;key=15212970" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm100856p&amp;key=1%3ACAS%3A528%3ADC%252BD2cXltVGhs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=494&publication_year=2004&pages=161-165&issue=2%E2%88%923&author=Y.+Shigemotoauthor=K.+Shinomiyaauthor=M.+Mioauthor=N.+Azumaauthor=C.+Kamei&title=Effects+of+second-generation+histamine+H1+receptor+antagonists+on+the+sleep%E2%88%92wakefulness+cycle+in+rats"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of second-generation histamine H1 receptor antagonists on the sleep-wakefulness cycle in rats</span></div><div class="casAuthors">Shigemoto, Yuki; Shinomiya, Kazuaki; Mio, Mitsunobu; Azuma, Nobuhide; Kamei, Chiaki</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">494</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">161-165</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The present study was performed to examine the sedative effects of second-generation histamine H1 receptor antagonist using power spectrum anal. in the rat.  Similar to ketotifen, olopatadine caused a decrease in sleep latency at a dose of 50 mg/kg, while epinastine and cetirizine showed no significant effect even at a dose of 50 mg/kg.  No significant difference was obsd. in the total times of wakefulness, non-rapid eye movement sleep and rapid eye movement sleep by any drugs used in the expts.  The no. of sleep phases and interval between sleep phases were also unchanged by these drugs.  Ketotifen and olopatadine inhibited [3H]mepyramine binding to rat brain homogenates in parallel with a decrease in sleep latency.  No significant effect was obsd. with epinastine and cetirizine on [3H]mepyramine binding.  These findings suggest that the differences in the central nervous system (CNS) depressant effect obsd. in second generation H1 receptor antagonists may be due to their liability to penetrate into the CNS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDTqz597UkJbVg90H21EOLACvtfcHk0lg3q32nR9d4Fg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXltVGhs7o%253D&md5=2da1198330c82f014856ae0d8c1f8c51</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2004.05.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2004.05.010%26sid%3Dliteratum%253Aachs%26aulast%3DShigemoto%26aufirst%3DY.%26aulast%3DShinomiya%26aufirst%3DK.%26aulast%3DMio%26aufirst%3DM.%26aulast%3DAzuma%26aufirst%3DN.%26aulast%3DKamei%26aufirst%3DC.%26atitle%3DEffects%2520of%2520second-generation%2520histamine%2520H1%2520receptor%2520antagonists%2520on%2520the%2520sleep%25E2%2588%2592wakefulness%2520cycle%2520in%2520rats%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2004%26volume%3D494%26issue%3D2%25E2%2588%25923%26spage%3D161%26epage%3D165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Simons, F. E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fraser, T. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reggin, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simons, K. J.</span><span> </span><span class="NLM_article-title">Comparison of the central nervous system effects produced by six H<sub>1</sub>-receptor antagonists</span> <span class="citation_source-journal">Clin. Exp. Allergy</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x"> (</span><span class="NLM_issue">9</span><span class="NLM_x">) </span> <span class="NLM_fpage">1092</span><span class="NLM_x">–</span> <span class="NLM_lpage">1097</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm100856p&amp;key=10.1111%2Fj.1365-2222.1996.tb00649.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm100856p&amp;key=8889266" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm100856p&amp;key=1%3ACAS%3A528%3ADyaK2sXitlOlsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=1996&pages=1092-1097&issue=9&author=F.+E.+R.+Simonsauthor=T.+G.+Fraserauthor=J.+D.+Regginauthor=K.+J.+Simons&title=Comparison+of+the+central+nervous+system+effects+produced+by+six+H1-receptor+antagonists"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison of the central nervous system effects produced by six H1-receptor antagonists</span></div><div class="casAuthors">Simons, F. E. R.; Fraser, T. G.; Reggin, J. D.; Simons, K. J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical and Experimental Allergy</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1092-1097</span>CODEN:
                <span class="NLM_cas:coden">CLEAEN</span>;
        ISSN:<span class="NLM_cas:issn">0954-7894</span>.
    
            (<span class="NLM_cas:orgname">Blackwell</span>)
        </div><div class="casAbstract">A comprehensive comparative study of the central nervous system (CNS) properties of newer H1-receptor antagonists is needed.  The authors' objective was to investigate the central nervous system effects of a single manufacturer's recommended dose of six H1-receptor antagonists, using appropriate controls.  Fifteen healthy subjects received astemizole 10 mg, cetirizine 10 mg, ketotifen 2 mg, loratadine 10 mg, terfenadine 60 mg, diphenhydramine 50 mg or placebo.  Before and 2-2.5 h after dosing, cognitive function was assessed using the P300-event-related potential, somnolence was assessed using a subjective score, and histamine skin tests were performed.  In rank order from least to greatest effect on the P300 latency, the medications were: terfenadine, placebo, cetirizine, ketotifen, loratadine, astemizole and diphenhydramine.  Only diphenhydramine increased the P300 latency significantly compared with baseline and placebo.  Subjective somnolence was significantly greater than baseline and placebo after cetirizine, ketotifen and diphenhydramine.  All the H1-receptor antagonists suppressed the histamine-induced weal significantly compared with baseline.  The H1-receptor antagonists tested affected cognitive functioning and somnolence to different extents, although all produced satisfactory peripheral H1-blockade.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOOW7hatjUaLVg90H21EOLACvtfcHk0lg3q32nR9d4Fg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXitlOlsw%253D%253D&md5=4a2fd1c966fcaecba576ea5aae5fee94</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1111%2Fj.1365-2222.1996.tb00649.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1365-2222.1996.tb00649.x%26sid%3Dliteratum%253Aachs%26aulast%3DSimons%26aufirst%3DF.%2BE.%2BR.%26aulast%3DFraser%26aufirst%3DT.%2BG.%26aulast%3DReggin%26aufirst%3DJ.%2BD.%26aulast%3DSimons%26aufirst%3DK.%2BJ.%26atitle%3DComparison%2520of%2520the%2520central%2520nervous%2520system%2520effects%2520produced%2520by%2520six%2520H1-receptor%2520antagonists%26jtitle%3DClin.%2520Exp.%2520Allergy%26date%3D1996%26volume%3D26%26issue%3D9%26spage%3D1092%26epage%3D1097" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Popa, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Léna, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fabre, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prenat, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gingrich, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Escourrou, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamon, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adrien, J.</span><span> </span><span class="NLM_article-title">Contribution of 5-HT2 receptor subtypes to sleep−wakefulness and respiratory control, and functional adaptations in knock-out mice lacking 5-HT2A receptors</span> <span class="citation_source-journal">J. Neurosci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x"> (</span><span class="NLM_issue">49</span><span class="NLM_x">) </span> <span class="NLM_fpage">11231</span><span class="NLM_x">–</span> <span class="NLM_lpage">11238</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm100856p&amp;key=10.1523%2FJNEUROSCI.1724-05.2005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm100856p&amp;key=16339018" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm100856p&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlaksr3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2005&pages=11231-11238&issue=49&author=D.+Popaauthor=C.+L%C3%A9naauthor=V.+Fabreauthor=C.+Prenatauthor=J.+Gingrichauthor=P.+Escourrouauthor=M.+Hamonauthor=J.+Adrien&title=Contribution+of+5-HT2+receptor+subtypes+to+sleep%E2%88%92wakefulness+and+respiratory+control%2C+and+functional+adaptations+in+knock-out+mice+lacking+5-HT2A+receptors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Contribution of 5-HT2 receptor subtypes to sleep-wakefulness and respiratory control, and functional adaptations in knock-out mice lacking 5-HT2A receptors</span></div><div class="casAuthors">Popa, Daniela; Lena, Clement; Fabre, Veronique; Prenat, Caroline; Gingrich, Jay; Escourrou, Pierre; Hamon, Michel; Adrien, Joelle</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">49</span>),
    <span class="NLM_cas:pages">11231-11238</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">Serotonin (5-hydroxytryptamine; 5-HT) plays key roles in sleep-wakefulness regulation.  Evidence indicates that 5-HT2 receptors are involved mainly in non-rapid eye movement sleep (NREMS) regulation and respiratory control.  Here, we investigated the relative contribution of 5-HT2A, 5-HT2B, and 5-HT2C receptor subtypes to NREMS and breathing during sleep, using 5-HT2 subtype-selective ligands in wild-type (5-HT2A +/+) and knock-out (5-HT2A -/-) mice that do not express 5-HT2A receptors.  Acute blockade of 5-HT2A receptors induced an increase in NREMS in 5-HT2A +/+ mice, but not 5-HT2A -/- mutants, which spontaneously expressed less NREMS than wild-type animals.  In 5-HT2A +/+ mice, 5-HT2B receptor blockade produced a redn. of NREMS, whereas receptor activation induced an increase in this sleep stage.  These effects were less pronounced in 5-HT2A -/- mice, indicating a lower sensitivity of 5-HT2B receptors in mutants, with no change in 5-HT2B mRNA.  Blockade of 5-HT2C receptors had no effect on NREMS in both strains.  In addn., an increase in EEG power d. after sleep deprivation was obsd. in 5-HT2A +/+ mice but not in 5-HT2A -/- mice.  Whole-body plethysmog. recordings indicated that 5-HT2A receptor blockade in 5-HT2A +/+ mice reduced NREMS apneas and bradypneas that occurred after sighs.  In contrast, in 5-HT2A -/- mutants, NREMS apneas were not modified, and bradypnea after sighs were more pronounced.  Our results demonstrate that 5-HT exerts a 5-HT2B-mediated facilitation of NREMS, and an influence resp. inhibitory on NREMS and facilitatory on sleep apnea generation, via 5-HT2A receptors.  Moreover, 5-HT2A gene knock-out leads to functional compensations yielding adaptive changes opposite to those caused by pharmacol. blockade of 5-HT2A receptors in 5-HT2A +/+ mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbwV24-TPA6bVg90H21EOLACvtfcHk0lg3q32nR9d4Fg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlaksr3M&md5=38633ca767730a707d73447291e42a3d</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.1724-05.2005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.1724-05.2005%26sid%3Dliteratum%253Aachs%26aulast%3DPopa%26aufirst%3DD.%26aulast%3DL%25C3%25A9na%26aufirst%3DC.%26aulast%3DFabre%26aufirst%3DV.%26aulast%3DPrenat%26aufirst%3DC.%26aulast%3DGingrich%26aufirst%3DJ.%26aulast%3DEscourrou%26aufirst%3DP.%26aulast%3DHamon%26aufirst%3DM.%26aulast%3DAdrien%26aufirst%3DJ.%26atitle%3DContribution%2520of%25205-HT2%2520receptor%2520subtypes%2520to%2520sleep%25E2%2588%2592wakefulness%2520and%2520respiratory%2520control%252C%2520and%2520functional%2520adaptations%2520in%2520knock-out%2520mice%2520lacking%25205-HT2A%2520receptors%26jtitle%3DJ.%2520Neurosci.%26date%3D2005%26volume%3D25%26issue%3D49%26spage%3D11231%26epage%3D11238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Viola, A. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandenberger, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toussaint, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouhours, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macher, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luthringer, R.</span><span> </span><span class="NLM_article-title">Ritanserin, a serotonin-2 receptor antagonist, improves ultradian sleep rhythmicity in young poor sleepers</span> <span class="citation_source-journal">Clin. Neurophysiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">113</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">429</span><span class="NLM_x">–</span> <span class="NLM_lpage">434</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm100856p&amp;key=10.1016%2FS1388-2457%2802%2900014-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm100856p&amp;key=11897543" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm100856p&amp;key=1%3ACAS%3A528%3ADC%252BD38XjvFGns7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=113&publication_year=2002&pages=429-434&issue=3&author=A.+U.+Violaauthor=G.+Brandenbergerauthor=M.+Toussaintauthor=P.+Bouhoursauthor=J.+P.+Macherauthor=R.+Luthringer&title=Ritanserin%2C+a+serotonin-2+receptor+antagonist%2C+improves+ultradian+sleep+rhythmicity+in+young+poor+sleepers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Ritanserin, a serotonin-2 receptor antagonist, improves ultradian sleep rhythmicity in young poor sleepers</span></div><div class="casAuthors">Viola, Antoine U.; Brandenberger, Gabrielle; Toussaint, Michel; Bouhours, Philippe; Macher, Jean Paul; Luthringer, Remy</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Neurophysiology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">113</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">429-434</span>CODEN:
                <span class="NLM_cas:coden">CNEUFU</span>;
        ISSN:<span class="NLM_cas:issn">1388-2457</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ireland Ltd.</span>)
        </div><div class="casAbstract">The aim was to det. the effect on sleep electroencephalog. (EEG) activity of ritanserin, a serotonin-2 (5-HT2) receptor antagonist in young poor sleepers.  Eight male subjects underwent two randomized night studies after receiving either a placebo or 5 mg ritanserin administered in the morning.  The overnight variations in the delta (0.5-4.0 Hz) and sigma (12.25-15.0 Hz) frequency bands were characterized using a peak anal. which provided a quant. evaluation of the time-courses in EEG activity.  In subjects under ritanserin, slow wave sleep duration and the no. of non-rapid eye movement (NREM)-REM sleep cycles were significantly enhanced (P < 0.01).  The no. of peaks in delta activity occurring in the normal 80-120 min range was significantly (P < 0.05) increased.  Using a delta peak anal., 4 periods contg. or not a significant peak were identified in each subject.  A significant increase in delta activity was obsd. in the areas under the averaged curves during the second and the third periods (P < 0.05), while sigma activity decreased under ritanserin during the first, second and third periods (P < 0.05).  These results demonstrate that ritanserin increases delta activity, possibly by opposing the inhibitory control of 5-HT2 receptor family.  It restores sleep ultradian rhythmicity and improves sleep quality in young poor sleepers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHAm1CxlOzTrVg90H21EOLACvtfcHk0liQs5huw843jw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjvFGns7o%253D&md5=160a8adfb6014e0fffb6107347f7ac4b</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2FS1388-2457%2802%2900014-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1388-2457%252802%252900014-7%26sid%3Dliteratum%253Aachs%26aulast%3DViola%26aufirst%3DA.%2BU.%26aulast%3DBrandenberger%26aufirst%3DG.%26aulast%3DToussaint%26aufirst%3DM.%26aulast%3DBouhours%26aufirst%3DP.%26aulast%3DMacher%26aufirst%3DJ.%2BP.%26aulast%3DLuthringer%26aufirst%3DR.%26atitle%3DRitanserin%252C%2520a%2520serotonin-2%2520receptor%2520antagonist%252C%2520improves%2520ultradian%2520sleep%2520rhythmicity%2520in%2520young%2520poor%2520sleepers%26jtitle%3DClin.%2520Neurophysiol.%26date%3D2002%26volume%3D113%26issue%3D3%26spage%3D429%26epage%3D434" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Renger, J. J.</span><span> </span><span class="NLM_article-title">Overview of experimental and conventional pharmacological approaches in the treatment of sleep and wake disorders</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">937</span><span class="NLM_x">–</span> <span class="NLM_lpage">953</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Fjm100856p&amp;key=10.2174%2F156802608784936755" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm100856p&amp;key=18673164" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm100856p&amp;key=1%3ACAS%3A528%3ADC%252BD1cXps1OhtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=937-953&author=J.+J.+Renger&title=Overview+of+experimental+and+conventional+pharmacological+approaches+in+the+treatment+of+sleep+and+wake+disorders"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Overview of experimental and conventional pharmacological approaches in the treatment of sleep and wake disorders</span></div><div class="casAuthors">Renger, John J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">937-953</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  The fundamental purpose of sleep remains one of the most compelling questions yet to be answered in the area of neuroscience, if not all of biol.  A pervasive behavior among members of the animal kingdom, the functional necessity of engaging regularly in sleep is best demonstrated by showing that failing to do so leads to a broad repertoire of pathol. outcomes including cognitive, immunol., hormonal, and metabolic outcomes, among others.  Indeed, an abs. requirement for sleep has been shown in studies that have demonstrated that continuous total deprivation of sleep for as short a period as 15 days is generally lethal in some species.  The most common clin. sleep disorder, insomnia, is both a principal disease (primary insomnia) as well as a co-morbidity of a large no. of other ostensibly unrelated diseases including chronic pain, attention deficit hyperactivity disorder, and depression.  From a treatment perspective, restoring normal healthy sleep delivers subsequent benefits in waking cognitive function and mood with the potential for beneficial therapeutic impact on daily functioning across multiple diseases for which restorative healthy sleep is compromised.  Our remarkable escalation in understanding the anatomy and physiol. of sleep/wake control mechanisms provides new opportunities to modify the neurobiol. of sleep and wake-related behaviors in novel and exciting ways.  In parallel, expansion of sleep research into novel interfaces between sleep-wake biol. and disease states is revealing addnl. extensive implications of lost sleep.  Current investigational and conventional pharmacol. approaches for the treatment of sleep and wake disorders are discussed based on their mechanism of action within the CNS and their effect on sleep and wake.  This review of recent sleep biol. and sleep pharmacol. peers into the future of sleep therapeutics to highlight both mechanistic safety and functional outcomes as key for differentiating and establishing success for the next generation of arousal modifying therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6GNzViXvCXbVg90H21EOLACvtfcHk0liQs5huw843jw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXps1OhtLw%253D&md5=0f24539a5d8032bde88186f6df1a44a6</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.2174%2F156802608784936755&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F156802608784936755%26sid%3Dliteratum%253Aachs%26aulast%3DRenger%26aufirst%3DJ.%2BJ.%26atitle%3DOverview%2520of%2520experimental%2520and%2520conventional%2520pharmacological%2520approaches%2520in%2520the%2520treatment%2520of%2520sleep%2520and%2520wake%2520disorders%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2008%26volume%3D8%26spage%3D937%26epage%3D953" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Gianotti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corti, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delle Fratte, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Fabio, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leslie, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pavone, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piccoli, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stasi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wigglesworth, M. J.</span><span> </span><span class="NLM_article-title">Novel imidazobenzazepine derivatives as dual H<sub>1</sub>/5-HT<sub>2A</sub> antagonists for the treatment of sleep disorders</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">5069</span><span class="NLM_x">–</span> <span class="NLM_lpage">5073</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=5069-5073&author=M.+Gianottiauthor=C.+Cortiauthor=S.+Delle+Fratteauthor=R.+Di+Fabioauthor=C.+P.+Leslieauthor=F.+Pavoneauthor=L.+Piccoliauthor=L.+Stasiauthor=M.+J.+Wigglesworth&title=Novel+imidazobenzazepine+derivatives+as+dual+H1%2F5-HT2A+antagonists+for+the+treatment+of+sleep+disorders"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGianotti%26aufirst%3DM.%26aulast%3DCorti%26aufirst%3DC.%26aulast%3DDelle%2BFratte%26aufirst%3DS.%26aulast%3DDi%2BFabio%26aufirst%3DR.%26aulast%3DLeslie%26aufirst%3DC.%2BP.%26aulast%3DPavone%26aufirst%3DF.%26aulast%3DPiccoli%26aufirst%3DL.%26aulast%3DStasi%26aufirst%3DL.%26aulast%3DWigglesworth%26aufirst%3DM.%2BJ.%26atitle%3DNovel%2520imidazobenzazepine%2520derivatives%2520as%2520dual%2520H1%252F5-HT2A%2520antagonists%2520for%2520the%2520treatment%2520of%2520sleep%2520disorders%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D5069%26epage%3D5073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Castiglioni, E.; Di Fabio, R.; Togninelli, A.; Brough, S.; Brown, F.; Dal Cin, M.; Gianotti, M.; Marchioro, C.; Merlo, G.; Spinosa, R.; Wigglesworth, M. J.; Botta, M.</span><span> </span><span class="NLM_article-title">Towards the discovery on new hypnotic agents: synthesis and preliminary pharmacological evaluation of a novel class of dibenzo[<i>a</i>,<i>d</i>]cycloheptene derivatives</span>.  <span class="citation_source-journal">ChemMedChem.</span> [Online early access]. DOI: <span class="refDoi"> DOI: 10.1002/cmdc.201000280</span> . Published Online: Oct 4, 2010.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Fjm100856p&amp;key=10.1002%2Fcmdc.201000280" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Castiglioni%2C+E.%3B+Di+Fabio%2C+R.%3B+Togninelli%2C+A.%3B+Brough%2C+S.%3B+Brown%2C+F.%3B+Dal+Cin%2C+M.%3B+Gianotti%2C+M.%3B+Marchioro%2C+C.%3B+Merlo%2C+G.%3B+Spinosa%2C+R.%3B+Wigglesworth%2C+M.+J.%3B+Botta%2C+M.+Towards+the+discovery+on+new+hypnotic+agents%3A+synthesis+and+preliminary+pharmacological+evaluation+of+a+novel+class+of+dibenzo%5Ba%2Cd%5Dcycloheptene+derivatives.+ChemMedChem.+%5BOnline+early+access%5D.+DOI%3A+10.1002%2Fcmdc.201000280.+Published+Online%3A+Oct+4%2C+2010."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201000280&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201000280%26sid%3Dliteratum%253Aachs%26aulast%3DCastiglioni%26aufirst%3DE.%26atitle%3DTowards%2520the%2520discovery%2520on%2520new%2520hypnotic%2520agents%253A%2520synthesis%2520and%2520preliminary%2520pharmacological%2520evaluation%2520of%2520a%2520novel%2520class%2520of%2520dibenzo%255Ba%252Cd%255Dcycloheptene%2520derivatives%26jtitle%3DChemMedChem.%26doi%3D10.1002%2Fcmdc.201000280" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Kantor, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jakus, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Balogh, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benko, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bagdy, G.</span><span> </span><span class="NLM_article-title">Increased wakefulness, motor activity and decreased theta activity after blockade of the 5-HT<sub>2B</sub> receptor by the subtype-selective antagonist SB-215505</span> <span class="citation_source-journal">Br. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">142</span><span class="NLM_x">, </span> <span class="NLM_fpage">1332</span><span class="NLM_x">–</span> <span class="NLM_lpage">1342</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm100856p&amp;key=10.1038%2Fsj.bjp.0705887" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Fjm100856p&amp;key=15265808" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm100856p&amp;key=1%3ACAS%3A528%3ADC%252BD2cXntlCrt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=142&publication_year=2004&pages=1332-1342&author=S.+Kantorauthor=R.+Jakusauthor=B.+Baloghauthor=A.+Benkoauthor=G.+Bagdy&title=Increased+wakefulness%2C+motor+activity+and+decreased+theta+activity+after+blockade+of+the+5-HT2B+receptor+by+the+subtype-selective+antagonist+SB-215505"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Increased wakefulness, motor activity and decreased theta activity after blockade of the 5-HT2B receptor by the subtype-selective antagonist SB-215505</span></div><div class="casAuthors">Kantor, Sandor; Jakus, Rita; Balogh, Brigitta; Benko, Anita; Bagdy, Gyorgy</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">142</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1332-1342</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">1 Serotonin-2 receptor antagonists, like ritanserin, greatly enhance deep slow wave sleep (SWS-2) and low-frequency EEG power in humans and rodents.  5-HT2A and 5-HT2C receptors may be involved in these effects, but the role of the 5-HT2B receptor is still unclear.  2 To investigate the role of the 5-HT2B receptor in regulation of the sleep-wake cycle, the subtype-selective antagonist SB-215505 (0.1, 0.3 and 1.0 mg kg-1 i.p.) was administered to Sprague-Dawley rats at light onset (beginning of passive phase).  EEG, EMG and motor activity were recorded during the subsequent 8 h.  3 SB-215505 dose-dependently increased wakefulness (W) at the expense of the intermediate stage of sleep, paradoxical sleep (PS) and SWS-2 in the first hour.  Parallel to increased W, significantly increased motor activity was found.  Spectral anal. of the EEG in W showed a dose-dependent decrease in power d. in the 3-8 Hz frequency range (max. effect at 6 Hz).  In light slow wave sleep and SWS-2, the drug reduced low-frequency (<8 Hz) EEG power, suggesting decreased sleep intensity after SB-215505 treatment.  In PS, the drug dose-dependently decreased EEG power solely in the theta (6-9 Hz) band, primarily affecting the peak power value (7 Hz).  4 The well-known SWS-2 enhancing effect of 5-HT2 receptor antagonists is mediated by 5-HT2A and/or 5-HT2C receptors.  In contrast, blockade of 5-HT2B receptors increases motor activity and W along with decreased theta activity during W and PS.  Activation of 5-HT2B receptors may contribute to initiation of sleep and to theta generation during W and PS under physiol. conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotQO8zYUUA7LVg90H21EOLACvtfcHk0liQs5huw843jw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXntlCrt70%253D&md5=c59c0780f10c9a4f67538c3f3ebffe68</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0705887&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0705887%26sid%3Dliteratum%253Aachs%26aulast%3DKantor%26aufirst%3DS.%26aulast%3DJakus%26aufirst%3DR.%26aulast%3DBalogh%26aufirst%3DB.%26aulast%3DBenko%26aufirst%3DA.%26aulast%3DBagdy%26aufirst%3DG.%26atitle%3DIncreased%2520wakefulness%252C%2520motor%2520activity%2520and%2520decreased%2520theta%2520activity%2520after%2520blockade%2520of%2520the%25205-HT2B%2520receptor%2520by%2520the%2520subtype-selective%2520antagonist%2520SB-215505%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2004%26volume%3D142%26spage%3D1332%26epage%3D1342" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Smith, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piper, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duxon, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Upton, N.</span><span> </span><span class="NLM_article-title">Effect of SB-243213, a selective 5-HT<sub>2C</sub> receptor antagonist, on the rat sleep profile: a comparison to paroxetine</span> <span class="citation_source-journal">Pharmacol., Biochem. Behav.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">599</span><span class="NLM_x">–</span> <span class="NLM_lpage">605</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2002&pages=599-605&author=M.+I.+Smithauthor=D.+C.+Piperauthor=M.+S.+Duxonauthor=N.+Upton&title=Effect+of+SB-243213%2C+a+selective+5-HT2C+receptor+antagonist%2C+on+the+rat+sleep+profile%3A+a+comparison+to+paroxetine"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DM.%2BI.%26aulast%3DPiper%26aufirst%3DD.%2BC.%26aulast%3DDuxon%26aufirst%3DM.%2BS.%26aulast%3DUpton%26aufirst%3DN.%26atitle%3DEffect%2520of%2520SB-243213%252C%2520a%2520selective%25205-HT2C%2520receptor%2520antagonist%252C%2520on%2520the%2520rat%2520sleep%2520profile%253A%2520a%2520comparison%2520to%2520paroxetine%26jtitle%3DPharmacol.%252C%2520Biochem.%2520Behav.%26date%3D2002%26volume%3D71%26spage%3D599%26epage%3D605" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Fonquerna, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miralpeix, M.</span><span> </span><span class="NLM_article-title">H<sub>1</sub> antihistamines: patent highlights 2000−2005</span> <span class="citation_source-journal">Expert Opin. Ther. Pat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">109</span><span class="NLM_x">–</span> <span class="NLM_lpage">117</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm100856p&amp;key=10.1517%2F13543776.16.2.109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm100856p&amp;key=1%3ACAS%3A528%3ADC%252BD28XotlGgtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=109-117&issue=2&author=S.+Fonquernaauthor=M.+Miralpeix&title=H1+antihistamines%3A+patent+highlights+2000%E2%88%922005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">H1 antihistamines: patent highlights 2000 - 2005</span></div><div class="casAuthors">Fonquerna, Silvia; Miralpeix, Montserrat</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">109-117</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Ashley Publications Ltd.</span>)
        </div><div class="casAbstract">A review.  Since the introduction of the first H1 antihistamine in 1945, much progress has been made in eliminating troublesome side effects.  Early efforts were directed at improving selectivity and avoiding sedative properties, and later at preventing the non-mechanism-related cardiotoxicity obsd. in some of the second-generation H1 antihistamines.  As the H1 antihistamines are still the first choice therapy against allergy symptoms, there remains an opportunity to obtain compds. with an improved and differentiated pharmacol. and therapeutic profile.  A patent literature review comprising the years 2000-2005 shows a redn. in the no. of new chem. entities as H1 antihistamines and a growing interest in dual H1-X compds.  With the introduction of dual H1-H3 and H1-CCR3 antagonists, a new direction of research has emerged that offers the potential of discovering a superior H1 antihistamine with anti-inflammatory properties able to deal with the inflammation and nasal congestion assocd. with allergic diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqz91toxGo37rVg90H21EOLACvtfcHk0li4BChyLW4c1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XotlGgtw%253D%253D&md5=7f1fb5283af987ac69783caddf4af3bb</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1517%2F13543776.16.2.109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.16.2.109%26sid%3Dliteratum%253Aachs%26aulast%3DFonquerna%26aufirst%3DS.%26aulast%3DMiralpeix%26aufirst%3DM.%26atitle%3DH1%2520antihistamines%253A%2520patent%2520highlights%25202000%25E2%2588%25922005%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2006%26volume%3D16%26issue%3D2%26spage%3D109%26epage%3D117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Bousquet, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aria Workshop Group.</span><span> </span><span class="NLM_article-title">Allergic rhinitis and its impact on asthma</span> <span class="citation_source-journal">J. Allergy Clin. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">S147</span><span class="NLM_x">–</span> <span class="NLM_lpage">S333</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2001&pages=S147-S333&issue=5&author=J.+Bousquetauthor=Aria+Workshop+Group.&title=Allergic+rhinitis+and+its+impact+on+asthma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBousquet%26aufirst%3DJ.%26aulast%3D%26atitle%3DAllergic%2520rhinitis%2520and%2520its%2520impact%2520on%2520asthma%26jtitle%3DJ.%2520Allergy%2520Clin.%2520Immunol.%26date%3D2001%26volume%3D108%26issue%3D5%26spage%3DS147%26epage%3DS333" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Edgar, D. M.; Hangauer, D. G.; Leighton, H. J.; Mignot, E. J. M.; White, J. F.; Solomon, M.; Shiosaki, K.</span><span> </span><span class="NLM_article-title">Treatment of CNS Disorders Using CNS Target Modulators</span>. Patent WO2005/103041,<span class="NLM_x"> </span><span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=D.+M.+Edgar&author=D.+G.+Hangauer&author=H.+J.+Leighton&author=E.+J.+M.+Mignot&author=J.+F.+White&author=M.+Solomon&author=K.+Shiosaki&title=Treatment+of+CNS+Disorders+Using+CNS+Target+Modulators"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DEdgar%26aufirst%3DD.%2BM.%26atitle%3DTreatment%2520of%2520CNS%2520Disorders%2520Using%2520CNS%2520Target%2520Modulators%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit15b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Edgar, D. M.; Hangauer, D. G.; White, J. F.; Solomon, M.</span><span> </span><span class="NLM_article-title">Doxepin Analogs and Methods of Use Thereof</span>. Patent WO2005/058880,<span class="NLM_x"> </span><span class="NLM_year">2005</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&author=D.+M.+Edgar&author=D.+G.+Hangauer&author=J.+F.+White&author=M.+Solomon&title=Doxepin+Analogs+and+Methods+of+Use+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DEdgar%26aufirst%3DD.%2BM.%26atitle%3DDoxepin%2520Analogs%2520and%2520Methods%2520of%2520Use%2520Thereof%26date%3D2005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit15c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Edgar, D. M.; Hangauer, D. G.; White, J. F.; Solomon, M.; Shiosaki, K.</span><span> </span><span class="NLM_article-title">Loxepine Analogs and Methods of Use Thereof</span>. Patent WO2006/034414,<span class="NLM_x"> </span><span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=D.+M.+Edgar&author=D.+G.+Hangauer&author=J.+F.+White&author=M.+Solomon&author=K.+Shiosaki&title=Loxepine+Analogs+and+Methods+of+Use+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DEdgar%26aufirst%3DD.%2BM.%26atitle%3DLoxepine%2520Analogs%2520and%2520Methods%2520of%2520Use%2520Thereof%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Sullivan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guilleminault, C.</span><span> </span><span class="NLM_article-title">Emerging drugs for insomnia: new frontiers for old and novel targets</span> <span class="citation_source-journal">Expert Opin. Emerging Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">411</span><span class="NLM_x">–</span> <span class="NLM_lpage">422</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Fjm100856p&amp;key=10.1517%2F14728210903171948" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Fjm100856p&amp;key=19708818" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm100856p&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVCgurbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2009&pages=411-422&issue=3&author=S.+Sullivanauthor=C.+Guilleminault&title=Emerging+drugs+for+insomnia%3A+new+frontiers+for+old+and+novel+targets"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Emerging drugs for insomnia: new frontiers for old and novel targets</span></div><div class="casAuthors">Sullivan, Shannon S.; Guilleminault, Christian</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Emerging Drugs</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">411-422</span>CODEN:
                <span class="NLM_cas:coden">EOEDA3</span>;
        ISSN:<span class="NLM_cas:issn">1472-8214</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Insomnia is the most prevalent sleep disorder, with up to 50% of the US adult population reporting symptoms of insomnia on a weekly basis and ∼ 12% with insomnia disorder.  Comorbid conditions such as depression and anxiety are frequent.  Insomnia is more common with older age, female gender and socioeconomic status.  Traditionally, therapy has focused on GABAA receptor agonists, and off-label antidepressant and antihistamine use.  With increased understanding of complex neural networks involved in sleep and wake, hypnotics are being developed to target a broader variety of receptors with increasing selectivity.  This review summarizes promising compds. in Phase II and III trials with evidence supporting efficacy for treatment of insomnia.  5-HT2A and 5-HT2C antagonists, melatonergic (MT1/MT2) agonists, orexin receptor (OX1/OX2) antagonists, as well as GABAA receptor agonists are reviewed and summarized.  Data are collected from PubMed and Pharmaprojects database searches, company websites, recent scientific meeting presentations and abstrs.  A variety of drugs targeting several pathways, including GABAA agonism, MT1/MT2 agonism, 5-HT2A antagonism, OX1/OX2 antagonism and others, are in Phase II and III trials.  More work should be done to understand the impact of these drugs in certain populations and in the context of comorbid conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKfbmX3Dwh4LVg90H21EOLACvtfcHk0li4BChyLW4c1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVCgurbF&md5=33f28e611296310e8d3623290e20d7b3</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1517%2F14728210903171948&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14728210903171948%26sid%3Dliteratum%253Aachs%26aulast%3DSullivan%26aufirst%3DS.%26aulast%3DGuilleminault%26aufirst%3DC.%26atitle%3DEmerging%2520drugs%2520for%2520insomnia%253A%2520new%2520frontiers%2520for%2520old%2520and%2520novel%2520targets%26jtitle%3DExpert%2520Opin.%2520Emerging%2520Drugs%26date%3D2009%26volume%3D14%26issue%3D3%26spage%3D411%26epage%3D422" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">De Paulis, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Betts, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, H. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mobley, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manier, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sulser, F.</span><span> </span><span class="NLM_article-title">Synthesis of clozapine analogs and their affinity for clozapine and spiroperidol binding sites in rat brain</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1981</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x"> (</span><span class="NLM_issue">9</span><span class="NLM_x">) </span> <span class="NLM_fpage">1021</span><span class="NLM_x">–</span> <span class="NLM_lpage">1026</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm00141a001" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=1981&pages=1021-1026&issue=9&author=T.+De+Paulisauthor=C.+R.+Bettsauthor=H.+E.+Smithauthor=P.+L.+Mobleyauthor=D.+H.+Manierauthor=F.+Sulser&title=Synthesis+of+clozapine+analogs+and+their+affinity+for+clozapine+and+spiroperidol+binding+sites+in+rat+brain"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17a&amp;dbid=16384&amp;doi=10.1021%2Fjm00141a001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00141a001%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BPaulis%26aufirst%3DT.%26aulast%3DBetts%26aufirst%3DC.%2BR.%26aulast%3DSmith%26aufirst%3DH.%2BE.%26aulast%3DMobley%26aufirst%3DP.%2BL.%26aulast%3DManier%26aufirst%3DD.%2BH.%26aulast%3DSulser%26aufirst%3DF.%26atitle%3DSynthesis%2520of%2520clozapine%2520analogs%2520and%2520their%2520affinity%2520for%2520clozapine%2520and%2520spiroperidol%2520binding%2520sites%2520in%2520rat%2520brain%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1981%26volume%3D24%26issue%3D9%26spage%3D1021%26epage%3D1026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit17b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Jilek, J. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Metysova, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pomykacek, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Protiva, M.</span><span> </span><span class="NLM_article-title">Neurotropic and psychotropic agents. XIX. 8-Halo derivatives of 10-(4-methyl-1-piperazinyl)-10,11-dihydrodibenzo[<i>b</i>,<i>f</i>]thiepin and related substances</span> <span class="citation_source-journal">Collect. Czech. Chem. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1968</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">1831</span><span class="NLM_x">–</span> <span class="NLM_lpage">1845</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=32&amp;doi=10.1021%2Fjm100856p&amp;key=1%3ACAS%3A528%3ADyaF1cXkvVKqtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=1968&pages=1831-1845&issue=6&author=J.+O.+Jilekauthor=J.+Metysovaauthor=J.+Pomykacekauthor=M.+Protiva&title=Neurotropic+and+psychotropic+agents.+XIX.+8-Halo+derivatives+of+10-%284-methyl-1-piperazinyl%29-10%2C11-dihydrodibenzo%5Bb%2Cf%5Dthiepin+and+related+substances"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17bR"><div class="casContent"><span class="casTitleNuber">17b</span><div class="casTitle"><span class="NLM_cas:atitle">Neurotropic and psychotropic agents.  XIX.  8-Halo derivatives of 10-(4-methyl-1-piperazinyl)-10,11-dihydrodibenzo[b,f]thiepin and related substances</span></div><div class="casAuthors">Jilek, J. O.; Metysova, J.; Pomykacek, J.; Protiva, M.</div><div class="citationInfo"><span class="NLM_cas:title">Collection of Czechoslovak Chemical Communications</span>
        (<span class="NLM_cas:date">1968</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1831-45</span>CODEN:
                <span class="NLM_cas:coden">CCCCAK</span>;
        ISSN:<span class="NLM_cas:issn">0010-0765</span>.
    </div><div class="casAbstract">The title compds. (I-III) are very active neuroleptics surpassing chlorpromazine considerably by their central nervous system depressant activityes.  4-FC6H4SH (50 g., b15 60°) treated with 97 g. 2-IC6H4CO2H, 5 g. Cu powder and 110 g. KOH in 1000 ml. H2O gave 87 g. 2-(4-fluorophenylthio)benzoic acid, m. 204-5° (EtOH).  4-BrC6H4SH (38.0 g., m. 74°) gave similarly 60 g. 2-(4-bromophenylthio)benzoic acid, m. 250° (AcOH).  2-(4-Chlorophenylthio)benzoic acid (200 g.) suspended in 1500 ml. Et2O added slowly to 32 g. LiAlH4 in 500 ml. Et2O, the mixt. stirred and refluxed 3 hrs., cooled, and decompd. dropwise with 200 ml. H2O and 1200 ml. dil. HCl (contg. 400 ml. concd. HCl) gave 165 g. 2-(4-chlorophenylthio)benzyl alc. (IV), b0.7 182°, m. 34-6°.  Similarly prepd. were 2-(4-fluorophenylthio)benzyl alc., m. 65-6° (C6H6-petroleum ether), and 2-(4-bromophenylthio)benzyl alc., b0.5 180°, m. 38°.  IV (163.3 g.) and 61.2 g. C5H5N cooled with ice and treated dropwise with 87.7 g. SOCl2, and the mixt. stirred 2 hrs. at room temp. gave 142.2 g. 2-(4-chlorophenylthio)benzyl chloride (V), m. 46-7° (EtOH), b0.5 162-4°.  Similarly prepd. were 2-(4-fluorophenylthio)benzyl chloride, b1 150°, and 2-(4-bromophenylthio)benzyl chloride, b0.25 162°, m. 52° (petroleum ether).  V (142.2 g.) in 160 ml. EtOH added to 33.9 g. NaCN in 53 ml. H2O and the mixt. stirred and refluxed 8 hrs. gave 134.1 g. 2-(4-chlorophenylthio)phenylacetonitrile (VI), m. 63-4° (Et2O-petroleum ether).  Similarly prepd. were 2-(4-fluorophenylthio)phenylacetonitrile, b0.2 147-8°, m. 49° (EtOH-petroleum ether), and 2-(4-bromophenylthio)phenylacetonitrile, m. 82° (EtOH-petroleum ether).  VI (134 g.) in 450 ml. EtOH treated with 130 g. KOH in 290 ml. H2O, the mixt. stirred and refluxed 5 hrs., evapd., the residue dissolved in 1750 ml. H2O, the soln. washed with Et2O, and acidified with 3N HCl gave 105 g. 2-(4-chlorophenylthio)phenylacetic acid (VII), m. 115-16° (C6H6 or 90% EtOH).  Similarly prepd. were 2-(4-fluorophenylthio)phenylacetic acid, m. 92-3° (50% EtOH or C6H6-petroleum ether), and 2-(4-bromophenylthio)phenylacetic acid, solvate with 0.5C6H6 m. 124-5° (C6H6-petroleum ether).  VII (11 g.) and 8 g. 1-methylpiperazine (VIII) heated 2 hrs. to 190°, the mixt. cooled, treated with 4 g. VIII and heated 2 hrs. to 190°, the procedure of heating with further 4 g. VIII repeated once more, the cooled product dissolved in 40 ml. EtOH, the soln. filtered with C, the filtrate evapd., the residue dissolved in 100 ml. C6H6, the soln. washed with 5% NaOH and H2O, shaken with 100 ml. 3N HCl, and the pptd. HCl salt decompd. with NH4OH gave 8.1 g. 1-methyl-4-[2-(4-chlorophenylthio)phenylacetyl]piperazine (IX), m. 92° (50% EtOH), HCl salt m. 212-15° (H2O).  VII (62.5 g.) and 250 g. polyphosphoric acid stirred and heated 2 hrs. to 125-30°, the mixt. cooled, decompd. with 1.2 kg. ice-cold H2O, and extd. with C6H6 gave 55 g. 8-chloro-10,11-dihydrodibenzo[b,f]thiepin-10-one (X), m. 125° (EtOH), uv and ir data given.  Similarly prepd. were XI, m. 104-6° (EtOH), and XII, m. 113° (uv and ir data given).  IX (1.9 g.) treated with a mixt. of 20 g. polyphosphoric acid and 2 ml. POCl3 and the mixt. heated 5 hrs. to 100-20°, 1 hr. to 130° and 1 hr. to 150-60° gave 1 g. X, m. 122-4°.  X (55 g.) in 1100 ml. EtOH refluxed and treated in 20 min. with 28 g. NaBH4 and 0.5 g. NaOH in 140 ml. H2O and the mixt. refluxed 4 hrs. gave 47.5 g. 8-chloro-10,11-dihydrodibenzo[b,f]thiepin-10-ol (XIII), m. 84-5° (Et2O-petroleum ether).  Similarly prepd. were 8-fluoro-10,11-dihydrodibenzo[b,f]thiepin-10-ol, m. 77-8° (cyclohexane), and 8-bromo-10,11-dihydrodibenzo[b,f]thiepin-10-ol, m. 107° (cyclohexane).  XIII (16 g.) and 40 ml. SOCl2 refluxed 3 hrs., gave 14.4 g. 8,10-dichloro-10,11-dihydrodibenzo[b,f]thiepin (XIV), m. 105-6° (cyclohexane).  XIII (120 g.) and 30 g. anhyd. CaCl2 in 700 ml. C6H6 satd. with dry HCl gave 120 g. XIV, m. 106-7°.  Similarly prepd. were 8-fluoro-10-chloro-10,11-dihydrodibenzo[b,f]thiepin, m. 98° (cyclohexane), and 8-bromo-10-chloro-10,11-dihydrodibenao[b,f]thiepin, m. 105-6° (cyclohexane).  XIII (13.1 g.), 70 ml. C6H6 and 4.0 g. 70% NaNH2 stirred 1 hr., the mixt. treated with 6.5 g. Me2N(CH2)2Cl, stirred 2 hrs. and refluxed 8 hrs., decompd. with H2O, the org. layer extd. with 100 ml. 1N HCl, the soln. made alk., and extd. with C6H6 gave 5.6 g. 8-chloro-10-(2-dimethylaminoethyoxy)-10,11-dihydrodibenzo[b,f]thiepin (XV), b0.4 194-8°, H maleate m. 108-10° (AcOEt).  Similarly prepd. was 8-chloro-10-(3-dimethylaminoproposy)-10,11-dihydrodibenzo[b,f]thiepin (XVI), b0.5 198-200°, H maleate m. 102-3° (AcOEt).  XIV (120 g.) and 180 ml. VIII heated 3.5 hrs. to 130°, the mixt. dild. with H2O and extd. with C6H6, the org. soln. extd. with dild. H2SO4, and the ext. made alk. gave 36.5 g. 8-chloro-10-(4-methylpiperazino)-10,11-dihydrodibenzo[b,f]thiepin (I), m. 99-101° (aq. EtOH), maleate m. 206-7° (aq. EtOH), HCl salt monohydrate m. 130-5° (H2O), 2HCl salt m. 190° (1N HCl).  XIV (10.0 g.), 12 g. VIII and 20 ml. CHCl3 refluxed 7 hrs. gave 9.2 g. I, m. 100-1° (EtOH).  Similarly were prepd. II, m. 144° (EtOH), maleate m. 175-7° (EtOH-Et2O), and III, m. 118-19° (aq. EtOH), maleate m. 203-4° (EtOH).  The described synthesis of XV gave as a neutral by-product 7.5 g. 2-chlorodibenzo[b,f]thiepin (XVII), m. 78-9° (Et2O-petroleum ether or MeOH).  The synthesis of I gave similarly 70 g. XVII, m. 77-8°.  Similarly were obtained XVIII, m. 82-3° (petroleum ether), and XIX, m. 93-5° (petroleum ether).  XIV (12 g.) and 24 ml. 1-phenylpiperazine heated 3.5 hrs. to 125-30° gave 10.5 g. 8-chloro-10-(4-phenylpiperazino)-10,11-dihydrodibenzo[b,f]thiepin, m. 135-6° (C6H6-EtOH), maleate m. 182-4° (EtOH-C6H6).  XIV (12 g.) and 24 ml. 1-benzylpiperazine gave similarly 13 g. 8-chloro-10-(4-benzylpiperazino)-10,11-dihydrodibenzo[b,f]thiepin, m. 150-1° (C6H6-EtOH); maleate m. 204-5° (EtOH).  XIV (5 g.), 8 g. 4-hydroxypiperidine (b15 115-18°) and 20 ml. CHCl3 refluxed 6 hrs. gave 6 g. 8-chloro-10-(4-hydroxypiperidino)-10,11-dihydrodibenzo[b,f]thiepin, m. 97-9° (EtOH), H maleate m. 188-9° (EtOH).  I (1.8 g.) in 20 ml. MeOH treated with 0.7 ml. 30% alc. HCl and 5 ml. H2O, the soln. treated dropwise with a soln. of 1.25 g. HIO4 and 0.22 g. NaOH in 12.5 ml. H2O, the mixt. kept at room temp. overnight, evapd., the residue made alk. with NH4OH, extd. with C6H6, the product transferred into 60 ml. 2N HCl, the soln. made alk., and extd. with C6H6 gave 1.85 g. 8-chloro-10-(4-methylpiperazino)-10,11-dihydrodibenzo[b,f]thiepin 5-oxide (XX), maleate m. 186-8° (EtOH).  XVII (3.0 g.) in 60 ml. HCO2H (90%) and 30 ml. AcOH treated dropwise in 20 min. with 7.5 ml. 30% H2O2 and the mixt. kept 12 hrs. at room temp., heated 3 hrs. to 40° and 1.5 hrs. to 90° gave 2.55 g. 2-chlorodibenzo[b,f]thiepin 5,5-dioxide, m. 131-2°.  Pharmacol. properties of I-III, XV, XVI, and XX (acute toxicity in mice, rotating rod, narcosis potentiation, antiserotonin activity) are tabulated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqDv1YwNa4OYbVg90H21EOLACvtfcHk0li_loXQ7ItVYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF1cXkvVKqtrc%253D&md5=3c1399f9e670a86bf0d6376358ea045e</span></div><a href="/servlet/linkout?suffix=cit17b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJilek%26aufirst%3DJ.%2BO.%26aulast%3DMetysova%26aufirst%3DJ.%26aulast%3DPomykacek%26aufirst%3DJ.%26aulast%3DProtiva%26aufirst%3DM.%26atitle%3DNeurotropic%2520and%2520psychotropic%2520agents.%2520XIX.%25208-Halo%2520derivatives%2520of%252010-%25284-methyl-1-piperazinyl%2529-10%252C11-dihydrodibenzo%255Bb%252Cf%255Dthiepin%2520and%2520related%2520substances%26jtitle%3DCollect.%2520Czech.%2520Chem.%2520Commun.%26date%3D1968%26volume%3D33%26issue%3D6%26spage%3D1831%26epage%3D1845" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit17c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Ong, H. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Profitt, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, V. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spaulding, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilker, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geyer, H. M.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kruse, H.</span><span> </span><span class="NLM_article-title">Tricyclics with analgesic and antidepressant activity. 1. [[(Alkylamino)ethyl]thio]dibenz[<i>b</i>,<i>f</i>]oxepins and 10,11-dihydro derivatives</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1980</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">494</span><span class="NLM_x">–</span> <span class="NLM_lpage">501</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm00179a005" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1980&pages=494-501&issue=5&author=H.+H.+Ongauthor=J.+A.+Profittauthor=V.+B.+Andersonauthor=T.+C.+Spauldingauthor=J.+C.+Wilkerauthor=H.+M.+Geyerauthor=H.+Kruse&title=Tricyclics+with+analgesic+and+antidepressant+activity.+1.+%5B%5B%28Alkylamino%29ethyl%5Dthio%5Ddibenz%5Bb%2Cf%5Doxepins+and+10%2C11-dihydro+derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17c&amp;dbid=16384&amp;doi=10.1021%2Fjm00179a005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00179a005%26sid%3Dliteratum%253Aachs%26aulast%3DOng%26aufirst%3DH.%2BH.%26aulast%3DProfitt%26aufirst%3DJ.%2BA.%26aulast%3DAnderson%26aufirst%3DV.%2BB.%26aulast%3DSpaulding%26aufirst%3DT.%2BC.%26aulast%3DWilker%26aufirst%3DJ.%2BC.%26aulast%3DGeyer%26aufirst%3DH.%2BM.%26aulast%3DKruse%26aufirst%3DH.%26atitle%3DTricyclics%2520with%2520analgesic%2520and%2520antidepressant%2520activity.%25201.%2520%255B%255B%2528Alkylamino%2529ethyl%255Dthio%255Ddibenz%255Bb%252Cf%255Doxepins%2520and%252010%252C11-dihydro%2520derivatives%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1980%26volume%3D23%26issue%3D5%26spage%3D494%26epage%3D501" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit17d"><span><span class="NLM_label">(d) </span><span class="NLM_contrib-group">Lang, Y. L.; Medaer, B. P. A. M. J.; Hoornaert, G. J. C.; Brossette, T.; Compernolle, F. J. C.; Guillaume, M. J. M. A.; Mao, H.; Kozlecki, T.</span><span> </span><span class="NLM_article-title">Preparation of Trans-Fused 11-Fluoro-3,3a,8,12b-tetrahydro-2<i>H</i>-dibenzo[3,4:6,7]cyclohepta[1,2-<i>b</i>]furans via Acid-Catalyzed Cyclization of Cis-Fused 8-Fluoro-11-(2,3-dihydroxypropyl)-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>]cyclohepten-10-yl Alkylcarboxylate Esters</span>. Patent WO2003048146A1,<span class="NLM_x"> </span><span class="NLM_year">2003</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2003&author=Y.+L.+Lang&author=B.+P.+A.+M.+J.+Medaer&author=G.+J.+C.+Hoornaert&author=T.+Brossette&author=F.+J.+C.+Compernolle&author=M.+J.+M.+A.+Guillaume&author=H.+Mao&author=T.+Kozlecki&title=Preparation+of+Trans-Fused+11-Fluoro-3%2C3a%2C8%2C12b-tetrahydro-2H-dibenzo%5B3%2C4%3A6%2C7%5Dcyclohepta%5B1%2C2-b%5Dfurans+via+Acid-Catalyzed+Cyclization+of+Cis-Fused+8-Fluoro-11-%282%2C3-dihydroxypropyl%29-10%2C11-dihydro-5H-dibenzo%5Ba%2Cd%5Dcyclohepten-10-yl+Alkylcarboxylate+Esters"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17d&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DLang%26aufirst%3DY.%2BL.%26atitle%3DPreparation%2520of%2520Trans-Fused%252011-Fluoro-3%252C3a%252C8%252C12b-tetrahydro-2H-dibenzo%255B3%252C4%253A6%252C7%255Dcyclohepta%255B1%252C2-b%255Dfurans%2520via%2520Acid-Catalyzed%2520Cyclization%2520of%2520Cis-Fused%25208-Fluoro-11-%25282%252C3-dihydroxypropyl%2529-10%252C11-dihydro-5H-dibenzo%255Ba%252Cd%255Dcyclohepten-10-yl%2520Alkylcarboxylate%2520Esters%26date%3D2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Surter, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weston, A. W.</span><span> </span><span class="NLM_article-title">α-β Dialkylphenethylamines. Alkylation of phenylacetone</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1942</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">533</span><span class="NLM_x">–</span> <span class="NLM_lpage">536</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=1942&pages=533-536&author=C.+M.+Surterauthor=A.+W.+Weston&title=%CE%B1-%CE%B2+Dialkylphenethylamines.+Alkylation+of+phenylacetone"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSurter%26aufirst%3DC.%2BM.%26aulast%3DWeston%26aufirst%3DA.%2BW.%26atitle%3D%25CE%25B1-%25CE%25B2%2520Dialkylphenethylamines.%2520Alkylation%2520of%2520phenylacetone%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1942%26volume%3D64%26spage%3D533%26epage%3D536" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Kulkarni, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davawala, S. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doke, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pendharkar, D. S.</span><span> </span><span class="NLM_article-title">An expedient protocol for cyclopentenone annulation</span> <span class="citation_source-journal">Synthesis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">2919</span><span class="NLM_x">–</span> <span class="NLM_lpage">2926</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Fjm100856p&amp;key=10.1055%2Fs-2004-831208" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2004&pages=2919-2926&author=M.+G.+Kulkarniauthor=S.+I.+Davawalaauthor=A.+K.+Dokeauthor=D.+S.+Pendharkar&title=An+expedient+protocol+for+cyclopentenone+annulation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1055%2Fs-2004-831208&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-2004-831208%26sid%3Dliteratum%253Aachs%26aulast%3DKulkarni%26aufirst%3DM.%2BG.%26aulast%3DDavawala%26aufirst%3DS.%2BI.%26aulast%3DDoke%26aufirst%3DA.%2BK.%26aulast%3DPendharkar%26aufirst%3DD.%2BS.%26atitle%3DAn%2520expedient%2520protocol%2520for%2520cyclopentenone%2520annulation%26jtitle%3DSynthesis%26date%3D2004%26volume%3D17%26spage%3D2919%26epage%3D2926" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Bruysters, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jongejan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gillard, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van de Manakker, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bakker, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chatelain, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leurs, R.</span><span> </span><span class="NLM_article-title">Pharmacological differences between human and guinea pig histamine H<sub>1</sub> receptors: Asn84 (2.61) as key residue within an additional binding pocket in the H<sub>1</sub> receptor</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">1045</span><span class="NLM_x">–</span> <span class="NLM_lpage">1052</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2005&pages=1045-1052&author=M.+Bruystersauthor=A.+Jongejanauthor=M.+Gillardauthor=F.+van+de+Manakkerauthor=R.+A.+Bakkerauthor=P.+Chatelainauthor=R.+Leurs&title=Pharmacological+differences+between+human+and+guinea+pig+histamine+H1+receptors%3A+Asn84+%282.61%29+as+key+residue+within+an+additional+binding+pocket+in+the+H1+receptor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBruysters%26aufirst%3DM.%26aulast%3DJongejan%26aufirst%3DA.%26aulast%3DGillard%26aufirst%3DM.%26aulast%3Dvan%2Bde%2BManakker%26aufirst%3DF.%26aulast%3DBakker%26aufirst%3DR.%2BA.%26aulast%3DChatelain%26aufirst%3DP.%26aulast%3DLeurs%26aufirst%3DR.%26atitle%3DPharmacological%2520differences%2520between%2520human%2520and%2520guinea%2520pig%2520histamine%2520H1%2520receptors%253A%2520Asn84%2520%25282.61%2529%2520as%2520key%2520residue%2520within%2520an%2520additional%2520binding%2520pocket%2520in%2520the%2520H1%2520receptor%26jtitle%3DMol.%2520Pharmacol.%26date%3D2005%26volume%3D67%26spage%3D1045%26epage%3D1052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit20b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Nonaka, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Otaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohshima, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kono, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kase, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohta, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukui, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ichimura, M.</span><span> </span><span class="NLM_article-title">Unique binding pocket for KW-4679 in the histamine H<sub>1</sub> receptor</span> <span class="citation_source-journal">Eur. J. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">345</span><span class="NLM_x">, </span> <span class="NLM_fpage">111</span><span class="NLM_x">–</span> <span class="NLM_lpage">117</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20b&amp;dbid=16&amp;doi=10.1021%2Fjm100856p&amp;key=10.1016%2FS0014-2999%2897%2901620-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20b&amp;dbid=8&amp;doi=10.1021%2Fjm100856p&amp;key=9593602" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20b&amp;dbid=32&amp;doi=10.1021%2Fjm100856p&amp;key=1%3ACAS%3A528%3ADyaK1cXitVKis7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=345&publication_year=1998&pages=111-117&author=H.+Nonakaauthor=S.+Otakiauthor=E.+Ohshimaauthor=M.+Konoauthor=H.+Kaseauthor=K.+Ohtaauthor=H.+Fukuiauthor=M.+Ichimura&title=Unique+binding+pocket+for+KW-4679+in+the+histamine+H1+receptor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20bR"><div class="casContent"><span class="casTitleNuber">20b</span><div class="casTitle"><span class="NLM_cas:atitle">Unique binding pocket for KW-4679 in the histamine H1 receptor</span></div><div class="casAuthors">Nonaka, Hiromi; Otaki, Shizuo; Ohshima, Etsuo; Kono, Motomichi; Kase, Hiroshi; Ohta, Kazumi; Fukui, Hiroyuki; Ichimura, Michio</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">345</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">111-117</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">The histamine H1 receptor has an aspartate (Asp) residue in transmembrane helix 3 (TM3), which is well-conserved among biogenic amine receptors.  The Asp residue is one of the most crucial amino acids for ligand binding.  The tested histamine H1 receptor antagonists with tri- and tetracyclic structures were not selective for histamine H1 receptors and showed affinity for several other biogenic amine receptors.  In contrast, KW-4679 ((Z)-11-[3-(dimethylamino)propylidene]-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid-HCl), a tricyclic compd., was a selective histamine H1 receptor antagonist.  [3H]KW-4679 had high affinity (Kd value of 2.5 nM) for wild-type human histamine H receptors.  In the [3H]KW-4679 binding assay, replacement of Asp107 by alanine by site-directed mutagenesis greatly reduced the affinities (280-2100-fold) of tri- and tetracyclic compds., whereas this mutation led to a comparatively small redn. (14-fold) in KW-4679 affinity.  These results demonstrate that the tested tri- and tetracyclic histamine H1 receptor antagonists which have a tight interaction with the Asp residue are not selective for the histamine H1 receptor.  Furthermore, the high selectivity of KW-4679 might be explained by a unique binding pocket, which consists of the Asp residue and other acceptor sites, in the histamine H1 receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBNMM_S2KXtrVg90H21EOLACvtfcHk0lgYu1c8otA65g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXitVKis7k%253D&md5=383232ccc6640311241b59ed226331c8</span></div><a href="/servlet/linkout?suffix=cit20b&amp;dbid=16384&amp;doi=10.1016%2FS0014-2999%2897%2901620-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-2999%252897%252901620-8%26sid%3Dliteratum%253Aachs%26aulast%3DNonaka%26aufirst%3DH.%26aulast%3DOtaki%26aufirst%3DS.%26aulast%3DOhshima%26aufirst%3DE.%26aulast%3DKono%26aufirst%3DM.%26aulast%3DKase%26aufirst%3DH.%26aulast%3DOhta%26aufirst%3DK.%26aulast%3DFukui%26aufirst%3DH.%26aulast%3DIchimura%26aufirst%3DM.%26atitle%3DUnique%2520binding%2520pocket%2520for%2520KW-4679%2520in%2520the%2520histamine%2520H1%2520receptor%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D1998%26volume%3D345%26spage%3D111%26epage%3D117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Kehne, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baron, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carr, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaney, S. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elands, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feldman, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frank, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Giersbergen, P. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCloskey, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCarty, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poirot, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senyah, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siegel, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Widmaier, C.</span><span> </span><span class="NLM_article-title">Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT<sub>2A</sub> antagonist with a favorable CNS safety profile</span> <span class="citation_source-journal">J. Pharmacol Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">277</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">968</span><span class="NLM_x">–</span> <span class="NLM_lpage">981</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Fjm100856p&amp;key=8627580" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm100856p&amp;key=1%3ACAS%3A528%3ADyaK28XivFeht7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=1996&pages=968-981&issue=2&author=J.+H.+Kehneauthor=B.+M.+Baronauthor=A.+A.+Carrauthor=S.+F.+Chaneyauthor=J.+Elandsauthor=D.+J.+Feldmanauthor=R.+A.+Frankauthor=P.+L.+van+Giersbergenauthor=T.+C.+McCloskeyauthor=M.+P.+Johnsonauthor=D.+R.+McCartyauthor=M.+Poirotauthor=Y.+Senyahauthor=B.+W.+Siegelauthor=C.+Widmaier&title=Preclinical+characterization+of+the+potential+of+the+putative+atypical+antipsychotic+MDL+100%2C907+as+a+potent+5-HT2A+antagonist+with+a+favorable+CNS+safety+profile"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile</span></div><div class="casAuthors">Kehne, John H.; Baron, Bruce M.; Carr, Albert A.; Chaney, Stephen F.; Elands, Jack; Feldman, Daniel J.; Frank, Robert A.; Van Giersbergen, Paul L. M.; McCloskey, Timothy C.; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">277</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">968-981</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">In preclin. studies, [R-(+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol] (MDL 100,907), a putative atypical antipsychotic, was characterized in vitro as a potent and selective ligand for the serotonin2A (5-HT2A) receptor and was evaluated in vitro and in vivo as a potent 5-HT2A receptor antagonist.  Furthermore, MDL 100,907's potential CNS safety profile and selectivity as a potential antipsychotic agent were evaluated and compared with benchmark compds.  MDL 100,907 demonstrated low nanomolar or subnanomolar binding in vitro at the 5-HT2A receptor and showed a > 100-fold sepn. from all other receptors measured.  MDL 100,907 has subnanomolar potency as a 5-HT2A antagonist in vitro in reversing 5-HT-stimulated inositol phosphate accumulation in NIH 3T3 cells transfected with the rat 5-HT2A receptor.  In vivo, MDL 100,907 potently inhibited 5-methoxy-N,N-dimethyltryptamine-induced head twitches in mice or 5-hydroxytrypophan-induced head twitched in rats.  In vivo functional tests in mice revealed a > 500-fold sepn. between doses that produced 5-HT2A antagonism and doses that produced α1-adrenergic or striatal D2 antagonism.  Using inhibition of D-amphetamine-stimulated locomotion in mice as a measure of potential antipsychotic efficacy, MDL 100,907 showed a superior CNS safety index relative to the ref. compds., haloperidol, clozapine, risperidone,ritanserin, and amperozide, in each of five tests for side effect potential, including measures of ataxia, general depressant effects, α1-adrenergic antagonism, striatal D2 receptor antagonism, and muscle relaxation.  MDL 100,907 did not antagonize apomorphine-induced stereotypies in rats, suggesting that it potentially lacks extrapyramidal side effect liability.  MDL 100,907 showed selectivity as a potential antipsychotic in that it lacked consistent activity in selected rodent models of anticonvulsant, anti-depressant, analgesic, or anxiolytic activity.  In summary, these preclin. data indicate that MDL 100,907 is a potent and selective ligand at the 5-HT2A receptor.  MDL 100,907's potent 5-HT2A antagonist activity might account for its activity in preclin. models of antipsychotic potential.  Ongoing clin. evaluation with MDL 100,907 will test the hypothesis that 5-HT2A receptor antagonism is sufficient for antipsychotic activity in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqravKtRD4ZLbVg90H21EOLACvtfcHk0lgYu1c8otA65g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XivFeht7s%253D&md5=01a7031bf3ef86ac47fe60ac14493a64</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKehne%26aufirst%3DJ.%2BH.%26aulast%3DBaron%26aufirst%3DB.%2BM.%26aulast%3DCarr%26aufirst%3DA.%2BA.%26aulast%3DChaney%26aufirst%3DS.%2BF.%26aulast%3DElands%26aufirst%3DJ.%26aulast%3DFeldman%26aufirst%3DD.%2BJ.%26aulast%3DFrank%26aufirst%3DR.%2BA.%26aulast%3Dvan%2BGiersbergen%26aufirst%3DP.%2BL.%26aulast%3DMcCloskey%26aufirst%3DT.%2BC.%26aulast%3DJohnson%26aufirst%3DM.%2BP.%26aulast%3DMcCarty%26aufirst%3DD.%2BR.%26aulast%3DPoirot%26aufirst%3DM.%26aulast%3DSenyah%26aufirst%3DY.%26aulast%3DSiegel%26aufirst%3DB.%2BW.%26aulast%3DWidmaier%26aufirst%3DC.%26atitle%3DPreclinical%2520characterization%2520of%2520the%2520potential%2520of%2520the%2520putative%2520atypical%2520antipsychotic%2520MDL%2520100%252C907%2520as%2520a%2520potent%25205-HT2A%2520antagonist%2520with%2520a%2520favorable%2520CNS%2520safety%2520profile%26jtitle%3DJ.%2520Pharmacol%2520Exp.%2520Ther.%26date%3D1996%26volume%3D277%26issue%3D2%26spage%3D968%26epage%3D981" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="note"><p class="first last">Parent spiroketone of compound <b>43</b> is <b>8a</b>(<i>R</i>). This is the only example where the <i>R</i> isomer is more active then the <i>S</i> isomer, for the spiroketone <b>8a</b>. The activity of corresponding compound obtained from <b>8a</b>(<i>S</i>) is <i>f</i>-p<i>K</i><sub>i</sub> hH<sub>1</sub> = 7.2 (FLIPR)/<i>f</i>-p<i>K</i><sub>i</sub> h5-HT<sub>2A</sub> = 5.7 (aequorin).</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Fernandez, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alonso, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andre′s, J. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cid, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dıaz, A</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iturrino, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gil, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Megens, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sipido, V. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trabanco, A. A.</span><span> </span><span class="NLM_article-title">Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">48</span><span class="NLM_x">, </span> <span class="NLM_fpage">1709</span><span class="NLM_x">–</span> <span class="NLM_lpage">1712</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm049632c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=1709-1712&author=J.+Fernandezauthor=J.+M.+Alonsoauthor=J.+I.+Andre%E2%80%B2sauthor=J.+M.+Cidauthor=A+D%C4%B1azauthor=L.+Iturrinoauthor=P.+Gilauthor=A.+Megensauthor=V.+K.+Sipidoauthor=A.+A.+Trabanco&title=Discovery+of+new+tetracyclic+tetrahydrofuran+derivatives+as+potential+broad-spectrum+psychotropic+agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fjm049632c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm049632c%26sid%3Dliteratum%253Aachs%26aulast%3DFernandez%26aufirst%3DJ.%26aulast%3DAlonso%26aufirst%3DJ.%2BM.%26aulast%3DAndre%25E2%2580%25B2s%26aufirst%3DJ.%2BI.%26aulast%3DCid%26aufirst%3DJ.%2BM.%26aulast%3DD%25C4%25B1az%26aufirst%3DA%26aulast%3DIturrino%26aufirst%3DL.%26aulast%3DGil%26aufirst%3DP.%26aulast%3DMegens%26aufirst%3DA.%26aulast%3DSipido%26aufirst%3DV.%2BK.%26aulast%3DTrabanco%26aufirst%3DA.%2BA.%26atitle%3DDiscovery%2520of%2520new%2520tetracyclic%2520tetrahydrofuran%2520derivatives%2520as%2520potential%2520broad-spectrum%2520psychotropic%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D1709%26epage%3D1712" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Kalgutgar, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardner, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott Obach, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaffer, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Callegari, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henne, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mutlib, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalvie, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Donnel, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harriman, S. P.</span><span> </span><span class="NLM_article-title">A comprehensive listing of bioactivation pathways of organic fuctional groups</span> <span class="citation_source-journal">Curr. Drug Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">161</span><span class="NLM_x">–</span> <span class="NLM_lpage">225</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Fjm100856p&amp;key=10.2174%2F1389200054021799" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Fjm100856p&amp;key=15975040" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2005&pages=161-225&author=A.+S.+Kalgutgarauthor=I.+Gardnerauthor=R.+Scott+Obachauthor=C.+L.+Shafferauthor=E.+Callegariauthor=K.+R.+Henneauthor=A.+E.+Mutlibauthor=D.+K.+Dalvieauthor=J.+S.+Leeauthor=Y.+Nakaiauthor=J.+P.+O%E2%80%99Donnelauthor=J.+Boerauthor=S.+P.+Harriman&title=A+comprehensive+listing+of+bioactivation+pathways+of+organic+fuctional+groups"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.2174%2F1389200054021799&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389200054021799%26sid%3Dliteratum%253Aachs%26aulast%3DKalgutgar%26aufirst%3DA.%2BS.%26aulast%3DGardner%26aufirst%3DI.%26aulast%3DScott%2BObach%26aufirst%3DR.%26aulast%3DShaffer%26aufirst%3DC.%2BL.%26aulast%3DCallegari%26aufirst%3DE.%26aulast%3DHenne%26aufirst%3DK.%2BR.%26aulast%3DMutlib%26aufirst%3DA.%2BE.%26aulast%3DDalvie%26aufirst%3DD.%2BK.%26aulast%3DLee%26aufirst%3DJ.%2BS.%26aulast%3DNakai%26aufirst%3DY.%26aulast%3DO%25E2%2580%2599Donnel%26aufirst%3DJ.%2BP.%26aulast%3DBoer%26aufirst%3DJ.%26aulast%3DHarriman%26aufirst%3DS.%2BP.%26atitle%3DA%2520comprehensive%2520listing%2520of%2520bioactivation%2520pathways%2520of%2520organic%2520fuctional%2520groups%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2005%26volume%3D6%26spage%3D161%26epage%3D225" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Tokunaga, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeda, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shinomiya, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirase, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamei, C.</span><span> </span><span class="NLM_article-title">Effects of some H<sub>1</sub>-antagonists on the sleep−wake cycle in sleep-disturbed rats</span> <span class="citation_source-journal">J. Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">201</span><span class="NLM_x">–</span> <span class="NLM_lpage">206</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Fjm100856p&amp;key=10.1254%2Fjphs.FP0061173" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Fjm100856p&amp;key=17287588" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm100856p&amp;key=1%3ACAS%3A528%3ADC%252BD2sXisFGnsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2007&pages=201-206&author=S.+Tokunagaauthor=Y.+Takedaauthor=K.+Shinomiyaauthor=M.+Hiraseauthor=C.+Kamei&title=Effects+of+some+H1-antagonists+on+the+sleep%E2%88%92wake+cycle+in+sleep-disturbed+rats"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Effects of some H1-antagonists on the sleep-wake cycle in sleep-disturbed rats</span></div><div class="casAuthors">Tokunaga, Shin; Takeda, Yasuhiro; Shinomiya, Kazuaki; Hirase, Masahiro; Kamei, Chiaki</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacological Sciences (Tokyo, Japan)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">201-206</span>CODEN:
                <span class="NLM_cas:coden">JPSTGJ</span>;
        ISSN:<span class="NLM_cas:issn">1347-8613</span>.
    
            (<span class="NLM_cas:orgname">Japanese Pharmacological Society</span>)
        </div><div class="casAbstract">The present study was undertaken to investigate the effects of some H1-antagonists on the sleep-wake cycle in sleep-disturbed rats in comparison with those of nitrazepam.  Electrodes were chronically implanted into the frontal cortex and the dorsal neck muscle of rats for the EEG and electromyogram (EMG), resp.  EEG and EMG were recorded with an electroencephalograph.  SleepSign ver.2.0 was used for EEG and EMG anal.  The total times of waking, non-rapid eye movement (non-REM), and rapid eye movement (REM) sleep were measured from 10:00 to 16:00.  Nitrazepam showed a significant decrease in sleep latency, total waking time, and delta activity and an increase in the total non-REM sleep time.  A significant decrease in the sleep latency was obsd. with diphenhydramine, chlorpheniramine, and cyproheptadine.  Cyproheptadine also caused a significant decrease in the total waking time and increases in total non-REM sleep time, REM sleep time, slow wave sleep, and delta activity, although no remarkable effects were obsd. with diphenhydramine and chlorpheniramine.  In conclusion, cyproheptadine can be useful as a hypnotic, having not only sleep inducing-effects, but also sleep quantity- and quality-increasing effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQmVwKtvLJd7Vg90H21EOLACvtfcHk0lh62PUQAuHAwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXisFGnsr0%253D&md5=2a0a95848f78eb2e57aaa95d2eb58e0f</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1254%2Fjphs.FP0061173&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1254%252Fjphs.FP0061173%26sid%3Dliteratum%253Aachs%26aulast%3DTokunaga%26aufirst%3DS.%26aulast%3DTakeda%26aufirst%3DY.%26aulast%3DShinomiya%26aufirst%3DK.%26aulast%3DHirase%26aufirst%3DM.%26aulast%3DKamei%26aufirst%3DC.%26atitle%3DEffects%2520of%2520some%2520H1-antagonists%2520on%2520the%2520sleep%25E2%2588%2592wake%2520cycle%2520in%2520sleep-disturbed%2520rats%26jtitle%3DJ.%2520Pharmacol.%2520Sci.%26date%3D2007%26volume%3D103%26spage%3D201%26epage%3D206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Wigglesworth, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lawless, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Standing, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mackenzie, E. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitchen, V. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mckay, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brough, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stylianou, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jewitt, F. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mclaren-Douglas, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jowet, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tamayama, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finnigan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wise, A.</span><span> </span><span class="NLM_article-title">Use of cryopreserved cells for enabling greater flexibility in compound profiling</span> <span class="citation_source-journal">J. Biomol. Screening</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">354</span><span class="NLM_x">–</span> <span class="NLM_lpage">362</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Fjm100856p&amp;key=10.1177%2F1087057108317768" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Fjm100856p&amp;key=18467669" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Fjm100856p&amp;key=1%3ACAS%3A528%3ADC%252BD1cXotlCms7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2008&pages=354-362&author=M.+J.+Wigglesworthauthor=K.+J.+Lawlessauthor=D.+J.+Standingauthor=E.+K.+Mackenzieauthor=V.+R.+Kitchenauthor=F.+Mckayauthor=E.+Wardauthor=S.+J.+Broughauthor=M.+Stylianouauthor=F.+R.+Jewittauthor=A.+M.+Mclaren-Douglasauthor=M.+I.+Jowetauthor=N.+Tamayamaauthor=D.+Finniganauthor=J.+Dingauthor=A.+Wise&title=Use+of+cryopreserved+cells+for+enabling+greater+flexibility+in+compound+profiling"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Use of cryopreserved cells for enabling greater flexibility in compound profiling</span></div><div class="casAuthors">Wigglesworth, M. J.; Lawless, K. J.; Standing, D. J.; Mackenzie, E. K.; Kitchen, V. R.; McKay, F.; Ward, E.; Brough, S. J.; Stylianou, M.; Jewitt, F. R.; McLaren-Douglas, A. M.; Jowet, M. I.; Tamayama, N.; Finnigan, D.; Ding, J.; Wise, A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biomolecular Screening</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">354-362</span>CODEN:
                <span class="NLM_cas:coden">JBISF3</span>;
        ISSN:<span class="NLM_cas:issn">1087-0571</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Measurement of intracellular calcium release following agonist challenge within cells expressing the relevant membrane protein is a commonly used format to derive structure-activity relationship (SAR) data within a compd. profiling assay.  The Fluorometric Imaging Plate Reader (FLIPR) has become the gold std. for this purpose.  FLIPR traditionally uses cells that are maintained in continuous culture for compd. profiling of iterative chem. campaigns.  This supply dictates that assays can only be run on 4 of 5 weekdays, or alternative cell culture machinery is required such that plating can occur remotely at the weekend.  The data reported here demonstrate that high-quality compd. profiling data can be generated from the use of cryopreserved cells and that these cells can also be plated at various densities to generate equiv. data between 24 and 72 h post-plating.  Hence, the authors report a method that allows data generation throughout the week and without the requirement of highly automated cell culture or continuous culture.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGou2A9-oUY2m7Vg90H21EOLACvtfcHk0lh62PUQAuHAwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXotlCms7g%253D&md5=e8767082b55d7d687534eebe5871eb04</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1177%2F1087057108317768&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1087057108317768%26sid%3Dliteratum%253Aachs%26aulast%3DWigglesworth%26aufirst%3DM.%2BJ.%26aulast%3DLawless%26aufirst%3DK.%2BJ.%26aulast%3DStanding%26aufirst%3DD.%2BJ.%26aulast%3DMackenzie%26aufirst%3DE.%2BK.%26aulast%3DKitchen%26aufirst%3DV.%2BR.%26aulast%3DMckay%26aufirst%3DF.%26aulast%3DWard%26aufirst%3DE.%26aulast%3DBrough%26aufirst%3DS.%2BJ.%26aulast%3DStylianou%26aufirst%3DM.%26aulast%3DJewitt%26aufirst%3DF.%2BR.%26aulast%3DMclaren-Douglas%26aufirst%3DA.%2BM.%26aulast%3DJowet%26aufirst%3DM.%2BI.%26aulast%3DTamayama%26aufirst%3DN.%26aulast%3DFinnigan%26aufirst%3DD.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DWise%26aufirst%3DA.%26atitle%3DUse%2520of%2520cryopreserved%2520cells%2520for%2520enabling%2520greater%2520flexibility%2520in%2520compound%2520profiling%26jtitle%3DJ.%2520Biomol.%2520Screening%26date%3D2008%26volume%3D13%26spage%3D354%26epage%3D362" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Brough, S. J.; Shah, P.</span><span> </span><span class="NLM_article-title">Use of Aequorin for G-Protein Coupled Receptor Hit Identification and Compound Profiling</span>. In  <span class="citation_source-book">G Protein-Coupled Receptors in Drug Discovery</span>, <span class="NLM_edition">5</span>th ed.; <span class="NLM_contrib-group">Leifert, W.</span>, Ed.; Methods in Molecular Biology, Vol. 552; <span class="NLM_publisher-name">Humana Press</span>: <span class="NLM_publisher-loc">New York</span>,<span class="NLM_x"> </span><span class="NLM_year">2009</span><span class="NLM_x">; </span>pp  <span class="NLM_fpage">181</span>− <span class="NLM_lpage">198</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Fjm100856p&amp;key=10.1007%2F978-1-60327-317-6_13" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2009&pages=181-198&author=S.+J.+Brough&author=P.+Shahauthor=W.+Leifert&title=G+Protein-Coupled+Receptors+in+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1007%2F978-1-60327-317-6_13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-1-60327-317-6_13%26sid%3Dliteratum%253Aachs%26aulast%3DBrough%26aufirst%3DS.%2BJ.%26atitle%3DUse%2520of%2520Aequorin%2520for%2520G-Protein%2520Coupled%2520Receptor%2520Hit%2520Identification%2520and%2520Compound%2520Profiling%26btitle%3DG%2520Protein-Coupled%2520Receptors%2520in%2520Drug%2520Discovery%26aulast%3DLeifert%26aufirst%3DW.%26pub%3DHumana%2520Press%26date%3D2009%26spage%3D181%26epage%3D198" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Aslanian, R. G.; Shih, N.-Y.; Ting, P. C.; Berlin, M. Y.; Rosenblum, S. B.; McCormick, K. D.; Tom, W. C.; Boyce, C. W.; Mangiaracina, P.; Mutahi, M. W.; Piwinski, J. J.</span><span> </span><span class="NLM_article-title">Piperidine Compounds as Anti-Allergic</span>. WO/2002/032893,<span class="NLM_x"> </span><span class="NLM_year">2002</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2002&author=R.+G.+Aslanian&author=N.-Y.+Shih&author=P.+C.+Ting&author=M.+Y.+Berlin&author=S.+B.+Rosenblum&author=K.+D.+McCormick&author=W.+C.+Tom&author=C.+W.+Boyce&author=P.+Mangiaracina&author=M.+W.+Mutahi&author=J.+J.+Piwinski&title=Piperidine+Compounds+as+Anti-Allergic"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAslanian%26aufirst%3DR.%2BG.%26atitle%3DPiperidine%2520Compounds%2520as%2520Anti-Allergic%26date%3D2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Sugita, K.; Otsuka, M.; Oki, H.; Haginoya, N.; Ichikawa, M.; Itoh, M.</span><span> </span><span class="NLM_article-title">Tricyclic Compound</span>. WO/2007/055093,<span class="NLM_x"> </span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=K.+Sugita&author=M.+Otsuka&author=H.+Oki&author=N.+Haginoya&author=M.+Ichikawa&author=M.+Itoh&title=Tricyclic+Compound"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSugita%26aufirst%3DK.%26atitle%3DTricyclic%2520Compound%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i79"><a href="/doi/suppl/10.1021/jm100856p">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_56786"></div></div></div></div></div><hr /></hr><p class="last">Experimental procedures and supporting data for compounds <b>43</b>, <b>44</b>, <b>49</b>, <b>50</b>, <b>52</b>, <b>53</b>, <b>55</b>−<b>63</b>, <b>66</b>−<b>68</b>, and <b>70</b>−<b>72</b>. This material is available free of charge via the Internet at <a class="extLink" href="http://pubs.acs.org">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm100856p/suppl_file/jm100856p_si_001.pdf">jm100856p_si_001.pdf (297.32 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm100856p&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2010.53.issue-21%3Barticle%3Aarticle%3A10.1021%2Fjm100856p%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm100856p" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                1MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799e9fcb9af3cbe","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
